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Wir können den Wind nicht ändern, aber die Segel anders setzen. 
Aristoteles, griechischer Philosoph und Schüler Platons.[A]
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1. Zusammenfassung 
Die Herstellung gut löslicher Peptide mit Hilfe der Fmoc-basierten Festphasenpeptidsynthese 
(Fmoc-SPPS) und nativen chemischen Ligation (NCL) ist ein Routineverfahren. Die Ligation 
größerer Transmembranproteine ist jedoch, aufgrund der geringen Löslichkeit hydrophober 
Peptidfragmente, schwierig. In konventionellen (wässrigen) Ligationspuffern neigen solch 
hydrophobe Peptidfragmente zum aggregieren und ausfallen. Es besteht dennoch ein großer 
Bedarf an effizienten Synthesestrategien für hydrophobe membranassoziierte Peptide und 
Proteine mit Hilfe chemischer Verfahren. Im Gegensatz zur Proteinexpression ermöglicht die 
Festphasenpeptidsynthese schnelle und gezielte Modifikationen der Peptidkette, wie den 
Einbau unnatürlicher Aminosäuren, die Verwendung von Schutzgruppen oder eine präzise 
Isotopenmarkierung. Daher konzentriert sich diese Arbeit auf die Entwicklung neuer 
Strategien und Reaktionsbedingungen zur Herstellung hydrophober Transmembranpeptide 
mittels Fmoc-basierter Festphasenpeptidsynthese und nativer chemischer Ligation. Die 
Einleitung dieser Dissertation bietet einen Überblick über zahlreiche Synthesestrategien, die in 
den letzten Jahrzehnten speziell für die Herstellung hydrophober Peptide entwickelt wurden. 
Im ersten Teil werden Fmoc-kompatible Methoden für die Synthese C-terminaler Thioester 
präsentiert welche für die native chemische Ligation mit N-terminalen Cysteinpeptiden 
Verwendung finden (Kapitel 3.2). In den darauf folgenden Kapiteln sind zahlreiche interne 
Modifikationen und externe Konditionen beschrieben, die die Löslichkeit hydrophober Peptide 
erhöhen. Die vorgestellten internen Modifikationen basieren auf dem Einbau temporär 
gebundener Löslichkeits-Tags, welche nach der Ligation oder Aufreinigung wieder entfernt 
werden können (Kapitel 3.4). Die beschriebenen externen Konditionen beruhen auf der 
Zugabe löslichkeitsverbessernder Additive für Ligationspuffer. Diese Additive umfassen 
verschiedenste organische Lösemittel, Tenside oder ionische Flüssigkeiten (Kapitel 3.5). Ein 
besonders wichtiger Punkt dieses Kapitels ist die Untersuchung der ionischen Flüssigkeit,  
1-Ethyl-3-methylimidazoliumacetat [C2mim][OAc] als alternatives Medium für die native 
chemische Ligation. Im darauf folgenden Kapitel werden Post-Ligationsstrategien wie die 
Cystein Desulfurierung und Acetamidomethyl (Acm) Abspaltung vorgestellt (Kapitel 3.6). 
Die während dieser Arbeit entwickelten und untersuchten Methoden zielen darauf ab, die 
Löslichkeit chemisch hergestellter Peptidfragmente während der Aufreinigung, nativen 
chemischen Ligation (NCL) und Desulfurierung, zu verbessern. Dafür wurden interne 
Modifikationsstrategien und unterschiedliche externe Bedingungen getestet (Kapitel 5). Als 
Modellpeptid für diese Studien wurde die Influenza B Virus Protonenkanalsequenz BM2(1-51) 
verwendet (Kapitel 3.7). Diese Proteinsequenz spielt bei der Vermehrung des Influenza B 
Virus eine bedeutende Rolle und ist daher für die Entwicklung eines antigrippalen 
Arzneimittels von hoher Relevanz. Alle vorherigen Versuche BM2(1-51) mit Hilfe der Fmoc-
basierten Festphasenpeptidsynthese herzustellen schlugen jedoch fehl.[3] Die im Rahmen 
dieser Arbeit entwickelten Strategien zur Synthese von BM2(1-51) sind im Folgenden 
zusammengefasst. 
Erhöhung der Löslichkeit durch interne Modifikationen (Chem. Sci., 2018)[2]: 
Die neu entwickelte interne Modifikationsstrategie beruht auf dem Einbau temporär 
gebundener Löslichkeits-Tags am C-Terminus von 2-Hydroxy-3-mercaptopropanamid (Hmp) 
Peptiden. Hmp ist ein trifunktionaler Linker, der über eine O-zu-S Acyl-Umlagerungsreaktion 
aktive Thioester bilden kann. Dadurch können funktionelle Gruppen oder Löslichkeits-Tags an 
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den C-Terminus des Peptids gebunden und während der Ligation wieder entfernt werden 
(temporärer Tag). In Kapitel 5.1 ist die Herstellung kurzer Model Hmp-Peptide und 
vollständiger BM2 Hmp-Peptide mit unterschiedlichen Löslichkeits-Tags (ADO, ADO2, ADO-
Lys5) beschrieben. In einer ersten Studie wurden die Stereochemie und optimale 
Synthesebedingungen für Hmp-Peptide getestet. Dabei ist ein Kopplungsprotokoll an Hmp 
weiterentwickelt worden, welches auf der Mitsunobu-Reaktion basiert. Die Synthese der 
Modell Hmp-Peptide gelang nach diesem modifizierten Protokoll mittels manueller Fmoc-
basierter Festphasenpeptidsynthese (Kapitel 5.1.5). Für die Herstellung der vollständigen 
BM2 Hmp-Peptidfragmente wurde eine Kombination aus manueller und automatisierter, 
Fmoc-basierter Festphasenpeptidsynthese angewendet (Kapitel 5.1.6). Nach der erfolgreichen 
Herstellung der kurzen und langen Hmp-Peptide, mit verschiedenen Löslichkeits-Tags, 
wurden Ligationsstudien in konventionellen (wässrigen) Ligationspuffern durchgeführt 
(Kapitel 5.1.9). Dabei konnte gezeigt werden, dass C-terminal gebundene Löslichkeits-Tags 
wie ADO oder Polylysin keinen negativen Einfluss auf die Ligationseffizienz und Ausbeute 
haben. Die interne Löslichkeits-Tag Strategie erwies sich als effiziente Methode für die native 
chemische Ligation von Transmembranpeptiden was durch die Herstellung von 
[Cys22]BM2(17-35) mit Ausbeuten von über 85% gezeigt werden konnte. Als effizientester 
Löslichkeits-Tag für lange, hydrophobe BM2 Hmp-Peptidfragmente erwies sich eine 
Kombination von Pentalysin und einer ADO-Gruppe. Dieser Löslichkeits-Tag wurde für die 
Ligation der hydrophoben Peptidsequenz [Cys(Acm)11][Leu21][Cys22]BM2(1-51), mit einer 
Ausbeute von 71%, verwendet.[2]
Externe Konditionen (J. Org. Chem., 2017)[1], (Chem. Sci., 2018)[2]:  
Die in dieser Arbeit untersuchten externen Bedingungen zur Verbesserung der Löslichkeit 
beinhalten die Zugabe von Additiven zu konventionellen (wässrigen) Ligationspuffern 
(Kapitel 5.2). Als vielversprechende Additive für Ligationsstudien mit langen, hydrophoben 
Hmp-Peptiden wurden zuerst fluorierte Alkohole wie Trifluorethanol (TFE) oder 
Hexafluorisopropanol (HFIP) getestet (Kapitel 5.2.1). Die Ligation mit dem TFE basierten 
Puffer führte zu einem überraschenden Befund, der auf eine unerwartete TFE vermittelte 
Carbamylierung von N-terminalen Cysteinresten in Gegenwart von Harnstoff hinwies. Diese 
durch TFE vermittelte Nebenreaktion wurde in der Literatur nie zuvor beschrieben und führte 
zu einer deutlichen Reduktion der Ligationsausbeute (Kapitel 5.2.2). Als effizientestes 
Ligationsmedium für hydrophobe BM2 Peptide wurde eine Phosphatpuffer/HFIP-basierte 
Emulsion entwickelt, welche nahezu quantitative Ligationsausbeuten ermöglichte  
(Kapitel 5.2.3). Durch Zugabe von HFIP konnten keine Nebenreaktionen des N-terminalen 
Cysteinrestes beobachtet werden, was ein großer Vorteil im Vergleich zum TFE-basierten 
Ligationsmedium war. Diese HFIP-basierte Ligationsstrategie wurde erfolgreich für die native 
chemische Ligation der hydrophoben Peptide [Cys(Acm)11][Leu21][Cys22]BM2(1-51) und 
[Leu10]BM2(1-51) verwendet.[2]
Als weiteres vielversprechendes Ligationsmedium für hydrophobe Hmp-Peptide wurde die 
ionische Flüssigkeit 1-Ethyl-3-methylimidazoliumacetat ([C2mim][OAc]) untersucht. In einer 
ersten Reihe von Experimenten konnte gezeigt werden, dass die reine ionische Flüssigkeit 
[C2mim][OAc] mit Thiol- und Disulfid-haltigen Verbindungen wie Thiophenol (PhSH), 
Benzylmercaptan (BzlSH), Diphenyldisulfid (PhSSPh) und Dibenzyldisulfid (BzlSSBzl) 
reagieren kann (Kapitel 5.2.5 und 5.2.6). Die aus NMR-, RP-HPLC- und ESI-MS-Studien 
gewonnenen Daten stützten einen Reaktionsmechanismus, bei dem Thiole zunächst zu den 
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entsprechenden Disulfiden oxidiert werden, bevor sie mit in situ gebildeten  
N-heterocyclischen Carbenen (NHCs) reagieren können. Untersuchungen des N-terminalen 
Cysteinpeptids [Cys22]BM2(1-51) in der ionischen Flüssigkeit [C2mim][OAc] resultierten in 
der gleichen Modifizierung der Thiolgruppe wie bei den organischen Modellverbindungen 
(PhSH, BzlSH, PhSSPh, BzlSSBzl). Darüber hinaus wurden mit Hilfe von ESI-MS weitere 
Peptidmodifikationen an [Cys22]BM2(22-35) gefunden, die durch die reinen ionischen 
Flüssigkeit gebildet wurden (Kapitel 5.2.7). Im weiteren Verlauf dieser Untersuchungen 
konnte gezeigt werden, dass eine Zugabe von mindestens 30% Wasser ausreichend ist, um 
NHC-induzierte Peptidmodifikationen vollständig zu unterdrücken (Kapitel 5.2.8).[1]
Basierend auf diesen Erkenntnissen gelang die Entwicklung eines IL-basierten 
Ligationspuffers, welcher höhere Ausbeuten für hydrophobe Hmp-Peptide erzielte als 
konventionelle Ligationspuffer. Der optimale Wasseranteil wurde durch eine Serie von 
Ligationsexperimenten mit kurzen Hmp-Peptiden ermittelt in dem der Wassergehalt für jede 
Ligation schrittweise um jeweils 10% erhöht wurde (Kapitel 5.2.9). Als effizientestes 
Ligationsmedium wurde eine Mischung bestehend aus 60% [C2mim][OAc], 40% Wasser, 
150 mM TCEP HCl und 150 mM Thiophenol ausgemacht. Dieses Mischungsverhältnis zeigte 
einen pH-Wert von 7.5, welcher sich bereits bei den HFIP-basierten Ligationsexperimenten in 
Kapitel 5.2.3 als optimal für Hmp-Peptide erwies. Im Vergleich zur nativen chemischen 
Ligation im HFIP-basierten Puffer war die IL-basierte Ligation jedoch schneller und 
ermöglichte das Lösen größerer Peptidmengen in kleineren Puffervolumina. Die Vorteile 
dieses IL-basierten Ligationspuffers konnte durch die Herstellung des finalen Zielpeptids 
[Leu10]BM2(1-51), mit einer Ausbeute von 76%, demonstriert werden (Kapitel 5.2.10). 
Post-Ligationsmethoden: Desulfurierung und Abspaltung von Acm (Chem. Sci., 2018)[2]: 
Obwohl die Desulfurierung löslicher Peptide in der Literatur umfassend beschrieben ist, 
bleiben schwerlösliche Peptide und Proteine eine Herausforderung. Wie in Kapitel 5.3.1
gezeigt, eignen sich herkömmliche Desulfurierungspuffer im Allgemeinen nicht dafür 
hydrophobe Transmembranpeptide in Lösung zu bringen und zu desulfurieren. In dieser 
Arbeit wird ein effizientes Desulfurierungsprotokoll für schwer lösliche Transmembranpeptide 
vorgestellt, welches für die Desulfurierung des Peptids [Cys(Acm)11][Leu21][Cys22]BM2(1-51) 
Verwendung fand. Dabei gelang die Desulfurierung mittels einer Phosphatpuffer/HFIP 
Emulsion in Gegenwart von Glutathion, dem Reduktionsmittel TCEP (Tris(2-
carboxyethyl)phosphin) und dem Radikalstarter VA-044 (2,2'-Azobis[2-(2-Imidazolin-2-
yl)propan] dihydrochlorid) (Kapitel 11.1.2). Diese HFIP Emulsion war in der Lage die 
hydrophoben BM2 Peptide vollständig in Lösung zu bringen und ermöglichte eine nahezu 
quantitative Umwandlung der Cys22 Ligationstelle zum entsprechenden Ala22. 
Eine weitere Post-Ligationsmethode, welche für die Synthese des finalen BM2 Peptids 
[Leu21]BM2(1-51) Verwendung fand, war die Acm Abspaltung. Dazu wurden zwei 
unterschiedliche Methoden getestet und miteinander verglichen. Die oxidative Acm 
Abspaltung mit elementarem Iod sowie die Verwendung von Silbertrifluormethansulfonat 
(AgOTf) in konzentrierter Trifluoressigsäure. Beide Strategien ermöglichten die Herstellung 
von [Leu21]BM2(1-51), jedoch mit großen Unterschieden in der Ausbeute. Durch elementares 
Iod wurde nur eine sehr schlechte Ausbeute von etwa 16% erzielt, während der größte Teil 
des Peptids oxidiert wurde. Durch die Verwendung von AgOTf gelang jedoch die Synthese des 
finalen Peptids [Leu21]BM2(1-51) mit einer Ausbeute von 66% (Kapitel 5.3.2). 
 4                                                                                                                                                                     Zusammenfassung
Analyse der bevorzugten Faltung mittels CD-Spektroskopie (Chem. Sci., 2018)[2]: 
Die bevorzugte Faltung der hergestellten BM2 Peptide wurde mit Hilfe der CD Spektroskopie 
ermittelt (Kapitel 5.4). Diese Untersuchungen bestätigten eine bevorzugt alpha-helikale 
Faltung aller hergestellten BM2 Peptide. Die Analyse der beiden finalen Zielpeptide 
[Leu10]BM2(1-51) und [Leu21]BM2(1-51) in TFE und POPC Liposomen enthüllte einen alpha-
helikalen Anteil von über 60% in der Influenza B Virus Peptidsequenz BM2(1-51). Dieses 
Ergebnis deutet auf mögliche helikale Strukturen innerhalb der Peptidsequenz 36-44 hin, 
welche in früheren Studien als unstrukturiert betrachtet wurden.[4]
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2. Summary 
The chemical production of well soluble peptides by Fmoc-based solid phase peptide synthesis 
(Fmoc-SPPS) and native chemical ligation (NCL) is a routine procedure. However, native 
chemical ligation of extended transmembrane proteins is usually hampered by the poor 
solubility of hydrophobic peptide fragments which tend to aggregate and precipitate in 
conventional (aqueous) ligation buffers. Nevertheless, there is a great demand for the efficient 
production of transmembrane peptides/proteins by chemical methods. In contrast to protein 
expression, chemical peptide synthesis allows a fast incorporation of specific modifications 
including unnatural amino acids, protecting groups or precise isotopic labelling. Therefore, 
this thesis is focused on the development of novel strategies and reaction conditions for the 
synthesis of hydrophobic transmembrane peptides by Fmoc-based solid phase peptide 
synthesis and native chemical ligation.  
This thesis provides an overview of various synthetic strategies for hydrophobic peptides and 
proteins which were published over the last decades. In the first part, Fmoc-chemistry 
compatible methods for the synthesis of C-terminal peptide thioesters are presented which can 
be used for native chemical ligation with N-terminal cysteine peptides (chapter 3.2). In the 
following chapters various internal modifications and external conditions are presented which 
were developed to enhance peptide solubility for purification or native chemical ligation 
(chapter 3.3). The internal modification strategies, introduced in this thesis, are based on the 
incorporation of temporarily bound solubilizing tags (chapter 3.4). The external conditions, 
presented in this work, describe the addition of solubility enhancing additives to ligation 
buffers (chapter 3.5). These additives comprise different organic solvents, surfactants or ionic 
liquids. One main focus of this chapter lies in the investigation of ionic liquid 1-ethyl-3-
methylimidazolium acetate [C2mim][OAc] as an alternative ligation media. In the following 
chapter post-ligation strategies such as cysteine desulfurization and Acm deprotection are 
presented (chapter 3.6). 
The newly-developed strategies investigated during this work are focused on increasing the 
solubility of transmembrane peptides during purification, native chemical ligation (NCL) and 
cysteine desulfurization. Therefore, internal modification strategies and external conditions 
were tested (chapter 5). As a model peptide for these studies, the influenza B proton channel 
sequence BM2(1-51) was chosen (chapter 3.7). This protein sequence plays an important role 
in the multiplication of the influenza B virus and is therefore of great relevance for the 
development of an anti-flu drug. However, all previous attempts to obtain BM2(1-51) by 
Fmoc-based SPPS failed.[3] The strategies for the synthesis of BM2(1-51) which were 
developed during this thesis are summarized below. 
Solubility enhancement by internal modifications (Chem. Sci., 2018)[2]:
The newly-developed internal modification strategy relies on the attachment of temporary 
bound solubilizing tags at the C-terminus of 2-hydroxy-3-mercaptopropanamide (Hmp) 
peptides. Hmp is as trifunctional linker which is capable of forming active peptide-thioesters 
via rearrangement over an O-to-S acyl shift reaction. This allows an attachment of functional 
groups or solubilizing tags at the C-terminus of peptides which are removed during ligation 
(temporary tag). In chapter 5.1 the synthesis of model Hmp-peptides and complete BM2 
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Hmp-peptide fragments, with various solubilizing tags (ADO, ADO2, ADO-Lys5), is presented. 
In the first studies the stereochemistry and optimal synthetic conditions for  
Hmp-peptides were investigated. Thereby, a coupling protocol at the Hmp moiety was further 
developed which is based on the Mitsunobu reaction. The synthesis of the model  
Hmp-peptides succeeded with this modified protocol using manual Fmoc-SPPS  
(chapter 5.1.5). For the synthesis of complete BM2 Hmp-peptide fragments a combination of 
manual Fmoc-SPPS (preloading of the resin) and automated, microwave assisted Fmoc-SPPS 
was applied (chapter 5.1.6). After successful production of Hmp-peptides with different 
solubilizing tags, ligation studies in a conventional (aqueous) ligation buffer were performed 
(chapter 5.1.9). Thereby, it could be shown that C-terminal bound solubilizing tags such as 
ADO or polylysine have no negative effect on the ligation efficiency or yield. The internal 
solubilizing tag strategy in combination with Hmp-peptides turned out to be an efficient 
method for native chemical ligation (NCL) of transmembrane peptides as demonstrated by the 
successful NCL of the influenza B proton channel fragment [Cys22]BM2(17-35) with ligation 
yields of over 85%. The most powerful solubilizing tag for complete, hydrophobic BM2  
Hmp-peptides was a combination of pentalysine with an ADO group which was applied for 
the NCL of the sequence [Cys(Acm)11][Leu21][Cys22]BM2(1-51) with a yield of 71%.[2]
Solubility enhancement by external conditions (J. Org. Chem., 2017)[1] (Chem. Sci., 2018)[2]:
The investigation of external conditions includes the addition of solubility improving additives 
to conventional (aqueous) ligation buffers (chapter 5.2). At first fluorinated alcohols such as 
2,2,2-trifluoroethanol (TFE) or hexafluoro-2-propanol (HFIP) were tested as promising 
additives for ligation studies with hydrophobic Hmp-peptide fragments (chapter 5.2.1). The 
ligation in the presence of TFE led to a surprising finding indicating an unexpected, TFE-
promoted, carbamylation of N-terminal cysteine residues by urea. This side reaction in the 
presence of TFE was never described in literature and led to a dramatic decrease of ligation 
yield (chapter 5.2.2). The most efficient medium for the NCL of the hydrophobic BM2 peptide 
fragments was a phosphate buffer/HFIP-based emulsion which achieved nearly quantitative 
ligation yields (chapter 5.2.3). By addition of HFIP no side reactions of N-terminal Cys 
residues were detectable which was a great advantage compared to the TFE based buffer 
solution. The HFIP-based strategy was successfully applied for the NCL of the sequence 
[Cys(Acm)11][Leu21][Cys22]BM2(1-51) and the target peptide [Leu10]BM2(1-51).[2]
The second promising media, the ionic liquid 1-ethyl-3-methylimidazolium acetate 
([C2mim][OAc]), was investigated for the ligation of hydrophobic Hmp-peptides. In a first set 
of experiments it was demonstrated that the neat ionic liquid [C2mim][OAc] is capable of 
reacting with thiol- and disulfide-containing compounds such as thiophenol (PhSH), benzyl 
mercaptan (BzlSH), diphenyl disulfide (PhSSPh) and dibenzyl disulfide (BzlSSBzl) (chapters 
5.2.5 and 5.2.6). The acquired data from NMR, RP-HPLC and ESI-MS studies supported a 
reaction mechanism in which thiols are first oxidized to the corresponding disulfides before 
reacting with in situ formed N-heterocyclic carbenes (NHCs). Investigations of the Cys 
containing model peptide [Cys22]BM2(22-35) into the neat [C2mim][OAc] resulted in the 
same modifications of the thiol group as observed for the organic model compounds (PhSH, 
BzlSH, PhSSPh, BzlSSBzl). Moreover, several different peptide modifications of 
[Cys22]BM2(22-35) were found by ESI-MS which were formed in neat [C2mim][OAc] 
(chapter 5.2.7). In the further course of these studies it could be demonstrated that the 
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addition of at least 30% of water was sufficient to supress NHC-induced peptide modifications 
entirely (chapter 5.2.8).[1] Based on these results the development of an IL-based ligation 
buffer succeeded which showed better ligation yields for hydrophobic Hmp-peptides than 
conventional ligation buffers. The optimal water content of the IL-based ligation buffer was 
found by a series of ligation studies using short model Hmp-peptides in which the water 
content was gradually increased by 10% for each ligation (chapter 5.2.9). The most efficient 
ligation buffer was a mixture of 60% [C2mim][OAc], 40% water, 150 mM TCEP HCl and 
150  mM thiophenol. This mixture showed a pH of 7.5 which was already found as optimal 
for the NCL of Hmp-peptides in the HFIP-based ligation buffer of chapter 5.2.3. However, in 
comparison with the NCL in the HFIP-based buffer, the IL-based NCL was much faster and 
allowed the dissolution of more peptide in small buffer volumes. The benefits of the IL-based 
ligation buffer could be impressively demonstrated by the native chemical ligation of the final 
target peptide [Leu10]BM2(1-51) with a ligation yield of 76%. This peptide sequence 
represents a large fragment of the BM2 proton channel (5.2.10). 
Post-ligation methods: Desulfurization and Acm deprotection (Chem. Sci., 2018)[2]:
Although Cys desulfurization of soluble peptides is well described in literature, poorly-soluble 
peptides/proteins still remain a challenge. Conventional desulfurization buffers are in general 
unsuitable to dissolve and desulfurate hydrophobic transmembrane domains as demonstrated 
in chapter 5.3.1. In this thesis an efficient desulfurization protocol for poorly-soluble 
transmembrane peptides is presented which was developed for the desulfurization of the BM2 
sequence [Cys(Acm)11][Leu21][Cys22]BM2(1-51). The desulfurization could be accomplished 
using a buffer/HFIP emulsion in the presence of glutathione, the reducing agent TCEP (tris(2-
carboxyethyl)phosphine) and the radical initiator VA-044 (2,2'-azobis[2-(2-imidazolin-2-
yl)propane] dihydrochloride). This HFIP emulsion was capable of dissolving hydrophobic 
BM2 peptides entirely and allowed a nearly quantitative conversion of the Cys22 ligation site 
to the corresponding Ala22 residue.  
The second post-ligation method used for the synthesis of the final BM2 peptides was the Acm 
cleavage from the Cys11 side chain. For the synthesis of the final target peptide 
[Leu21]BM2(1-51), two different methods were tested and compared including the oxidative 
cleavage of Acm by elemental iodine or the use of silver trifluoromethanesulfonate (AgOTf). 
Both strategies showed product formation of the final target peptide [Leu21]BM2(1-51), yet 
with dramatic differences in the yield. With elemental iodine only very poor yields of approx. 
16% were obtained while most of the peptide was oxidized. However, the synthesis of the 
final peptide [Leu21]BM2(1-51) succeeded by AgOTf with a yield of 66% (chapter 5.3.2). 
Predominate fold analysis of BM2 peptides by CD spectroscopy (Chem. Sci., 2018)[2]: 
The predominant fold of the synthesised BM2 peptides were investigated by circular 
dichroism (CD) spectroscopy (chapter 5.4). These studies confirmed a predominate alpha-
helical folding for all investigated BM2 peptides. Analysis of the final target peptides 
[Leu10]BM2(1-51) and [Leu21]BM2(1-51) in TFE and POPC liposomes revealed an alpha-
helical content of about 60% in the influenza B virus proton channel sequence 1-51 indicating 
possible helical structures between residues 36-44 which were considered structurally 
disordered in previous studies.[4]
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3. State of the Art 
3.1. Chemical peptide synthesis – A brief historical overview 
Since the first steps of peptide chemistry by T. Curtius and E. Fischer at the beginning of the 
last century, numerous scientists have constantly searched for new synthetic methods to 
produce peptides and peptide analogues by total chemical methods.[5] Already in 1904,  
T. Curtius published the first useful synthetic pathway for benzoylglycines, using the azide-
coupling method. This two-step coupling strategy relied on the reaction of an acyl azide with 
the nucleophile amino group of amino acids.[6] Despite this first practical coupling method, 
the application was limited to short peptide sequences and unprotected amino acids.  
This changed in 1931 with the introduction of the carbobenzoxy (Cbz) group by  
M. Bergmann.[7] The Cbz-group was stable under basic conditions and could be removed by 
strong acids or under reductive conditions using hydrogen and palladium catalysts. 
Bergmanns invention allowed the synthesis of more complex peptides and led to the first total 
chemical synthesis of the peptide hormones vasopressin and oxytocin. In 1955, Vigneaud was 
rewarded with the Noble Prize for this work.[8] Shortly after the first successful synthesis of 
bioactive peptides, the discovery of the tert-butyloxycarbonyl (Boc) group was published by 
Carpino and colleagues.[9] The Boc group was stable under strong basic conditions but could 
be easily removed by acidic treatment. One decade later Carpino presented the 
fluorenylmethyloxycarbonyl (Fmoc) group which was stable under acidic conditions but could 
be removed by strong bases.[10] Together, both protecting groups enabled an orthogonal 
protection strategy for chemical peptide synthesis. Nowadays Boc- and Fmoc-protected amino 
acids are the fundament of the chemical solid-phase peptide synthesis (SPPS). 
Simultaneously, new activation agents for carboxyl groups were developed. Usually activation 
of carboxyl groups can be achieved by introduction of an electron-withdrawing group. This 
activated intermediate must possess an intrinsic self-stability to prevent premature hydrolysis, 
enolisation or cyclisation. At the beginning of the last century acyl azides, halides or mixed 
anhydrides were used as electrophile reactants for aminolysis with unprotected amino 
acids.[11] Although all these precursors worked well for short sequences, more reliable 
activation agents were constantly developed. Especially, the development of carbodiimide-
based coupling agents by Sheehan and Khorana in the middle of the last century simplified 
peptide synthesis significantly.[6b, 12] Famous examples for these important activation agents 
are N,N'-diisopropylcarbodiimide (DIC) and N,N'-dicyclohexylcarbodiimide (DCC). 
Although efficient coupling agents and orthogonal protecting groups were already available in 
the middle of the last century, chemical peptide synthesis in liquid phase was the standard 
procedure until the end of the 50s. However, chemical synthesis of highly hydrophobic 
peptides was impractical or even impossible in liquid phase.[13] In 1963, almost 60 years after 
T. Curtius and E. Fischer, the American chemist Robert Bruce Merrifield solved this problem 
by the first practical peptide synthesis on a solid resin support. These solid supports are 
composed of small polymer beads covered with a functional surface.[14] The strategy consists 
of the stepwise coupling of orthogonal protected amino acids on the resin support followed by 
deprotection steps.[15] The major advantage of this method is a simple purification after each 
coupling and deprotection step by filtration. Thereby, peptide chains remain covalently bound 
to the resin beads. The possibility of automating this process is a further important advantage 
of this method, allowing a fast chemical peptide synthesis within a few hours.[16]
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Depending on the N-terminal protection group and the type of the solid support there are two 
different strategies which have been developed over time. The first approach that was already 
introduced by Merrifield relied on the usage of Boc-protected amino acids. In this strategy 
concentrated TFA is used after every coupling step to remove the N-terminal Boc group from 
the growing peptide chain. However, the greatest disadvantage of this method is the need for 
strong and toxic acids such as hydrofluoric acid (HF) in order to cleave the final peptide from 
the solid support. A more convenient approach is the Fmoc-based SPPS. In this strategy basic 
conditions are used to remove Fmoc from the N-terminal peptide chain. After synthesis the 
final peptide sequence can be cleaved and deprotected by a mixture of concentrated TFA, 
water and scavengers (e.g. anisole, TIPS). In this work all peptides were synthesized with the 
Fmoc approach. 
Scheme 3.1: Procedure of the Fmoc-solid phase peptide synthesis (Fmoc-SPPS). The final peptide can be cleaved 
from the solid support by acidic treatment using a mixture of concentrated TFA and scavengers. 
Despite the possibility to automate the procedure, the synthesis of peptides with more than 50 
amino acids is usually unprofitable.[17] Fmoc-SPPS of transmembrane related proteins remain 
an especially complicated challenge. Hydrophobic sequences tend to aggregate on the resin 
support and minimize access to the N-terminal amino group of the peptide chain. As a result 
the coupling efficiency decreases with rising chain length.[18]
The limitation of the solid phase peptide synthesis has promoted the development of ligation 
strategies which can be used to conjugate two or more peptide segments. Today, a large 
number of ligation/conjugation methods are described in the literature such as the Staudinger 
ligation, click chemistry or the thiazolidine-forming ligation.[19] However, most of these 
conjugation strategies lead to non-native peptide bonds between peptide segments. In 1994, 
Dawson and Kent published a native chemical ligation (NCL) strategy which involved the 
reaction of an N-terminal cysteine peptide and a C-terminal peptide-α-thioester.[20] The NCL 
enables a regiospecific conjugation of two or more unprotected peptide fragments under 
neutral or slightly basic conditions. This reaction is usually performed in aqueous phosphate 
buffers. The final ligation product is thereby obtained with a native peptide bond. Especially 
important is the preservation of stereochemistry at the ligation site. During the reaction the 
nucleophile thiol group of the cysteine peptide attacks the electrophile thioester site. The 
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generated thioester-peptide intermediate undergoes an N-to-S acyl shift reaction over a five-
membered ring transition state.[21] During this rearrangement, the stereochemistry of the  
C-terminal amino acids is retained. Different studies were able to demonstrate that the final 
ligation product carries less than 1% D-amino acids after NCL.[22]
Scheme 3.2: Mechanism of the native chemical ligation (NCL) between the C-terminal peptide-α-thioester and the 
N-terminal cysteine peptide. The reaction involves an N-to-S acyl shift reaction resulting in a native peptide bond.[21]
After this discovery, NCL became the most popular method for the ligation of peptide 
fragments and was applied for the synthesis of numerous medium-sized proteins.[23] Several 
studies were able to demonstrate the value of the ligation strategy with synthesis of peptides 
with up to 15 kDa.[24] Over time, the strategy was constantly improved by investigation of 
different ligation buffers, catalysts or reducing agents.[21, 25] Today, dozens of different ligation 
variations are known such as the thioacid capture, oxo-ester or acyl azide mediated 
ligation.[26] Through the development of N-terminal cysteine surrogates and efficient 
desulfurization protocols for different amino acid residues (chapter 3.6) even ligations in 
absence of natural cysteine residues are possible.[27]
However, a major drawback of the “classical” ligation method is its restriction to good or at 
least moderately soluble peptide fragments. Hydrophobic, transmembrane peptides are still 
especially challenging to ligate in conventional ligation solutions such as guanidinium 
chloride or urea based phosphate buffers. To counter this issue, a variety of different 
solubilisation strategies for poorly soluble peptide fragments were developed which will be 
presented and discussed in chapter 3.3. 
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3.2. Synthesis of peptide thioesters – Precursors for the native chemical ligation 
Peptide thioesters have become indispensable for chemical synthesis of medium-size proteins 
by NCL. Nevertheless, their synthetic access can still be difficult in many cases. Especially the 
production of long and hydrophobic transmembrane domains is often associated with poor 
yields. Since thioesters are sensitive to aminolysis under basic deprotection conditions,  
Boc-SPPS was long considered as most efficient method for the synthesis of peptide thioesters. 
However, the major drawback of the Boc strategy includes the requirement of strong, toxic 
acids like triflic acid or concentrated hydrofluoric acid (HF). Only in recent years good 
alternative approaches of HF-free protocols were published.[28] The deprotection of the  
N-terminal Boc-group by concentrated TFA though, still remains a main disadvantage. Over 
decades plenty approaches for the Fmoc-based SPPS of peptide thioesters have been 
investigated. These investigations led to many different methods for the preparation of 
peptide thioesters which can be classified into five different types, (i) direct, on resin-bound 
thioester synthesis, (ii) thioesterification of the C-terminus on the solid support, (iii) 
thioesterification by thiolysis from the solid support, (iv) post-cleavage thioesterification and 
(v) thioesterification via intramolecular O-to-S or N-to-S acyl migration. In following chapters 
the most promising Fmoc-based strategies for the synthesis of peptide thioesters are 
summarized. 
3.2.1. Direct synthesis of peptide thioesters 
The direct synthesis of peptide thioesters by Fmoc-SPPS is usually hampered since labile 
thioester are not stable under exposure to basic conditions during repetitive deprotection 
steps using piperidine. However, several groups were able to demonstrate that direct thioester 
preparation can be achieved if non-nucleophilic bases are used for Fmoc-group deprotection 
steps. Already in 1998, Aimoto and co-workers synthesised the 15 amino acid (aa) long 
thioester peptide Verotoxin(11-25)-SR with 24% yield using a conventional Fmoc-SPPS 
protocol. As a mild deprotection mixture for Fmoc cleavage 25% 1-methylpyrrolidine, 2% 
hexamethyleneimine, 2% HOBt in NMP/DMSO (1:1, v/v) were applied. This discovery led to 
the search for mild but more efficient bases for Fmoc deprotection.[29] Two years later, Wade 
et al. described a mixture of 1% 1,8-diazabicyclo[5.4.0]undec-7ene (DBU), 1%  
1-hydroxynezotriazole (HOBt) and DMF as useful solution for Fmoc cleavage. The 
deprotection was performed under continuous flow conditions for 10 min. Although DBU was 
known as a stronger base compared to piperidine, it showed a lower nucleophilicity.[30] The 
application of DBU as non-nucleophilic base for thioester peptide synthesis was later further 
optimised by X. Bu and Z. Guo.[31] During their studies a ratio of 0.88:1 DBU/HOBt showed 
the best results for Fmoc-group removal while the thioester stayed intact. However, even 
under these optimized conditions, aminolysis of the thioester bond could not be prevented 
entirely. Despite this progress, Fmoc-SPPS of thioester peptides longer than 20 amino acids 
remained problematic.[32]
3.2.2. Thioesterification of the C-terminus on the solid support 
An alternative approach to direct thioester synthesis is the thioesterification of the  
C-terminus while the peptide is linked through the side chain or the backbone on the resin 
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support. In all these methods the peptide C-terminus is either protected or in an unreactive 
state during the amino acid coupling and Fmoc deprotection cycles. After Fmoc-SPPS, the  
C-terminus must be converted to a thioester or thioester precursor (e.g. thioimide) before the 
final peptide can be cleaved from the resin.[32] In the approach of Crich et al. a 
thioglycinamdie linker was used to connect the peptide chain to the resin support. After Fmoc-
SPPS the thioamide group was converted into a thioimide group by a simple S-alkylation with 
benzyl bromide. After cleavage from the solid support the final peptide was obtained as  
C-terminal benzyl thioester (scheme 3.3 a).[33]
a)
b) 
Scheme 3.3: a) Thioester production by Crich et al., b) Production by Nakahara et al. (X=CH2O, CH2N, CH2S).
Another example for the side-chain anchored strategy was published by Nakahara and co-
workers. In this approach the C-terminal carboxyl group was protected as allyl ester. After 
Fmoc-SPPS, the C-terminus was deprotected by deallylation using an Pd(0) catalyst followed 
by thioesterification with thiophenol, benzyl mercaptan or ethyl-3-mercaptopropionate. The 
peptides were linked as silyl ether on Wang resin at tyrosine, lysine, cysteine, glutamic or 
aspartic acid (scheme 3.3 b).[32, 34] In 2008, Wong et al. extended this side chain anchored 
strategy with the successful synthesis of the glycoprotein erythropoietin (EPO). The thioester 
peptide EPO(1-28)-SR was obtained with 23% on bromo-(4-methoxyphenyl)methyl resin. 
After deallylation, the free carboxyl acid was coupled with a glycine thioester using HATU as 
activator. The final thioester peptide could be released from the resin support by acidic 
treatment with TFA and scavengers.[32, 35]
3.2.3. Thioesterification by thiolysis 
Although numerous approaches are well described in the literature, safety-catch linker 
strategies remain the most frequently used methods for the synthesis of peptide thioesters. 
Safety-catch linkers were developed to resist harsh basic or acidic conditions even at higher 
temperatures or under microwave radiation. This high stability allows the synthesis of 
thioesters by Fmoc- or Boc-strategies. The peptide cleavage from the resin support requires an 
activation of the linker. This activation is usually achieved by selective alkylation or 
cyclisation of the linker site near the peptide C-terminus. After activation, the peptide can be 
released from the linker by a nucleophile attack of an organic thiol compound  
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(e.g. thiophenol). The crude peptide is thereby obtained as a fully side chain protected  
C-terminal thioester.  A characteristic feature of all these methods is the side chain 
deprotection after peptide cleavage from the resin support. However, this additional 
deprotection step leads to a longer and inconvenient work-up process compared to other 
methods. One of the most used safety catch linker strategies is the sulfonamdie method 
developed by Ingenito and co-workers (scheme 3.4 a).[36] Commercial available resins are 
preloaded with 4-sulfamylbutyryl linkers. After Fmoc-SPPS the linker is activated by alkylation 
of the sulfamyl residue with trimethylsilyl diazomethane or iodoacetonitrile. The alkylated 
linker is then able to release the peptide by thiolysis.[36]
a)
b)
c)
Scheme 3.4: a) Safety catch strategy developed by Ingenito for the synthesis of peptide thioesters on 
sulfamylbutyryl resins,[36] b) Thioester synthesis by Jensen and colleges using glutamic acid as linker.[37] c) Thioester 
peptide synthesis by Raj et al. using a serine linker[38]
In 2009, the Jensen group developed a Fmoc-based approach for the synthesis of peptide 
thioesters on a C-terminal glutamic acid linker (scheme 3.4 b). Although this approach was 
not directly denoted as “safety catch” strategy the required steps were similar to the safety 
catch approach of Ingenito and co-workers. The method relies on the thiolysis of a backbone 
pyroglutamyl imide which is created by cyclisation of C-terminal glutamic acid. After 
activation the thioester peptide can be released from the resin by thiolysis using a free 
thiol.[37] A comparable strategy was published in 2017 by Elasha and Raj using a serine linker 
(scheme 3.4 c). In this strategy the unprotected amino acid serine acts as a linker surrogate. 
After Fmoc-SPPS, the C-terminal serine is activated by selective cyclization to a urethane 
moiety using N,N-disuccinimidyl carbonate. Subsequently, the urethane unit can be displaced 
by thiolysis releasing the side chain protected peptide as thioester from the solid support. As 
well as for the safety catch strategy, the peptide can be deprotected by acidic treatment after 
cleavage from the resin support. Since serine is used as linker, the method can be applied with 
a great variety of resin types.[38]
 14                                                                                                                                                                             Introduction
3.2.4. Post-cleavage thioesterifications 
Thioesterification after cleavage from the solid support is another widely used approach to 
obtain peptide thioesters. This strategy encompasses many different methods which convert 
the C-terminus into an active thioester in solution. The oldest and simplest approach relies on 
the thioesterification of fully side chain protected peptide acids. Usually the Fmoc-SPPS is 
performed on highly acid-sensitive resins such as HMPB or chlorotrityl resin. After peptide 
cleavage using mild acidic conditions, the C-terminal carboxyl group is activated in the 
presence of thiols. As product a fully side chain protected peptide thioester is obtained which 
must be deprotected in a following procedure.[39] However, solubility problems caused by the 
high hydrophobic character of fully side chain protected peptides make this method 
impractical for the synthesis of long membrane peptide domains. 
a)
b)
c)
Scheme 3.5: a) Dbz (first generation) and MeDbz (second generation) strategy developed by Dawson et al.,[40] b)
activation of the ortho-aminoanilide linker developed by Liu and co-workers using NaNO2.
[41], c) Ligation of peptide 
hydrazides by Liu and co-workers. The conversion of the hydrazide group into an azide group can be performed in 
the ligation buffer using sodium nitrite.[42]
An improved strategy that has received much attention in recent years is the synthesis of  
N-acyl-benzimidazolinone (Nbz) peptides originally invented by Dawson and co-workers.[40a]
In this method peptides were synthesized on ortho-aminoanilide linkers. Activation of this 
linker is achieved by acetylation with 4-nitrophenylchloroformate which leads to cyclisation of 
the ortho-amino moiety. The resulting Dbz peptides can be easily cleaved from the resin by 
acidic treatment using TFA. Since Nbz peptides can be rapidly converted into the 
corresponding thioester by thiolysis, the direct use of Nbz peptides for the NCL is possible 
(scheme 3.5 a). Although the Nbz method is compatible with Fmoc-SPPS, over-acetylation of 
the ortho-aminoanilide group can inactivate the linker. To diminish those side reactions more 
carefully Fmoc-SPPS conditions were investigated for the synthesis of Nbz peptides.[43]
Additionally, capping steps with acetic anhydride should be avoided to prevent over-
acetylation of the unprotected amino group. To counter this problem Blanco-Canosa and 
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Dawson improved the strategy by introduction of the ortho-(N-methyl)aminoanilide unit as a 
less sensitive linker. This MeNbz method is more resistant to over-acetylation yet reactive 
enough for activation via 4-nitrophenylchloroformate.[40b] This enhanced MeDbz method was 
used several times for NCL of cysteine-rich proteins such as cyclotides Kalata B1, MCoTI-II, 
cyclic peptides, cyclothiodepsipeptides[44] and many more.[45] An impressive example for this 
method was also made by Sueiras-Diaz et al. by the first total chemical synthesis of the 
Human Growth Hormone consisting of 191 amino acid residues. The synthesis was achieved 
by sequential native chemical ligation with three peptide fragments.[46] Dbz- and MeDbz-
peptides are not only very easily convertible into C-terminal thioesters, these peptides can also 
be stored safely over a long period of time. Furthermore, the Dbz carboxyl group can be 
applied for the attachment of C-terminal tags. To date, the Dbz method has been constantly 
further developed and is therefore one of the most used synthetic pathways for peptide 
thioesters. Recently, Pala-Pujadas and Blanco-Canosa presented a kinetically controlled NCL 
on the base of MeDbz-peptides using p-cyano-phenylcarbamate as an activation agent. This 
strategy was recently used for the chemical synthesis of a 175 amino acid long Sonic 
Hedgehog protein.[47] Inspired by that work, Tsuda and co-workers further enhanced this 
protocol using 4-fluorophenyl chloroformate activated MeDbz precursors.[48] This approach 
was successfully used for the one-pot NCL of three peptide segments which can be controlled 
over the pH of the ligation solution.[33a]
A further modification of this method is the conversion of the ortho-aminoanilide linker into a 
benzotriazole leaving group (scheme 3.5 b). Several works already demonstrated that 
benzotriazole peptides can be applied for peptide ligation but their synthesis was rather 
uncomfortable and not suitable for long peptides.[49] In 2015 Liu et al. published an improved 
modification of the Dbz method using sodium nitrite (NaNO2) to convert the ortho-
aminoanilide unit into a benzotriazole moiety.[41] These C-terminal benzotriazole peptides 
reacted similar to Nbz peptides and could be used as thioester precursors directly in the 
ligation buffer. The method was used for the preparation and NCL of histone H2B from five 
peptide segments. Additionally, the method was compatible with C-terminal solubilizing tags 
attached on the aminoanilide moiety which was demonstrated by the preparation of the cyclic 
protein lactocyclicin Q.[33a, 41]
A further post-cleavage thioesterification method which used sodium nitrite as an activation 
agent was presented in 2011 by Liu and colleges.[42] The method relies on C-terminal 
hydrazide peptides which can be easily converted into peptide azides in aqueous ligation 
buffers (scheme 3.5. c). At low temperatures and slightly acidic conditions sodium nitrite is 
capable of reacting chemoselectively with the hydrazide moiety while the rest of the peptide 
chain remains unmodified. The formed azide group is then immediately replaced by a 
nucleophile thiol catalyst such as MPAA or thiophenol. This NaNO2-mediated ligation strategy 
encompasses several advantages, including the simple access of hydrazide peptides trough 
Fmoc-SPPS and their direct usage in the ligation buffer. Even more important, inactivated 
peptide hydrazides remain unreactive in NCL and allow orthogonal ligation strategies in 
combination with peptide thioesters.[33a] Moreover, the stepwise activation of the hydrazide 
group allows the one-pot ligation of multiple peptide segments from the N- to the C-terminus 
without the need of cysteine protecting groups.[50] To date, this versatile hydrazide strategy 
has been applied with the successful ligation of multiple medium-sized proteins such as 
human α-synuclein[50a], the M2 influenza A proton channel[51], histone H2A[52], Mambalgin-
1[50b] and many more.[53]
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3.2.5. Thioesterification by O/N-to-S acyl shift reactions 
The discovery of Fmoc-compatible thioester generating rearrangement groups was a 
tremendous progress for the synthesis of peptide thioesters. In this strategy peptides were not 
directly obtained as thioester after Fmoc-SPPS. Instead, rearrangement units with thiol 
containing side chains are linked over amide or oxo-ester bonds at the C-terminus. Under 
slightly basic conditions the free thiol group acts as internal nucleophile which attacks the  
C-terminal carbonyl unit over a cyclic intramolecular O-to-S or N-to-S acyl shift reaction. The 
rearrangement relies on an equilibrium that is dependent on temperature, pH and possible 
substituents next to the carbonyl group. Surprisingly, a similar mechanism was discovered 
during intein-mediated protein splicing that can be found in eukaryotes, bacteria and 
archaea.[54] The principle of the O-to-S or N-to-S acyl shift reaction is shown in scheme 3.6. 
Scheme 3.6: Left: Intramolecular thioesterification by the N-to-S acyl transfer reaction over a cyclic transition state, 
Right: Intramolecular thioesterification over an O-to-S acyl transfer reaction. 
In recent years this revolutionary approach attracted much attention due to constant 
developments of new rearrangement groups. In 2004, the first discovery of a thioester 
forming rearrangement group was published by Danishefsky and co-workers. As a 
rearrangement unit, 2-mercaptophenol was successfully applied reaching ligation yields up to 
78%. Encouraged by this success, side chain protected peptide fragments were converted into 
disulfide-protected 2-mercaptophenyl esters[32] and then used for the NCL of glycopeptides.[55]
However, the main drawback of this strategy was the rather complicated synthesis of the 
peptide thioesters in solution.  
In 2006, Bang and Kent published a “kinetically controlled native chemical ligation” which 
allowed chemical ligation of multiple peptide segments in one reaction vessel. This strategy 
relied on different ligation rates of peptide-α-thioarylesters and peptide-α-thioalkylesters. In 
absence of thiophenol were thioalkylesters considered as effectively unreactive while 
thioarylesters remain reactive.[56] Inspired from that kinetically controlled approach, Zheng  
et al. investigated different thiol-containing oxo-esters which can rearrange to a C-terminal 
thioester (table 3.1). For that study, glycine derivatives of oxo esters 1-4 were ligated with 
free cysteine in a phosphate-buffered saline (PBS) solution. The study was primarily focused 
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on the relationship between the structure of the oxo-ester and the ligation efficiency with 
cysteine. The conversion, hydrolysis and ligation amounts were determined after 48 h using 
RP-HPLC analysis (table 3.1).[57]
Table 3.1: Results of the ligation experiments using oxo-esters 1-4, after 48 h reaction time, at room temperature. 
Ligation buffer: 0.2 M PBS, 2% PhSH, 30 mM TCEP, pH=6.5.[57]
Structure Substituents 
Hydrolysis
[%] 
Ligation
[%] 
Conversion
[%] 
1 
1 to 5 acyl shift 
(fast conversion) 
R1=H, R2=H 90 10 100
R1=Me, R2=Me 86 11 97
R1=COR, R2=H 6 93 99
R1=CONHR, R2=H 16 84 100
2
1 to 6 acyl shift 
(slow conversion)
R3=H, R4=H 3 8 11
R3=OR, R4=H 2 8 10
R3=Me, R4=Me 2 12 14
3
1 to 6 acyl shift 
(fast conversion)
aromatic substituent 100 0 100 
4
1 to 7 acyl shift 
(fast conversion) 
aromatic substituent 31 38 69 
The conversion rate was highly dependent on the number of carbon atoms between the 
oxygen and sulfur atom. After 48h, rearrangements over 1 to 5 acyl migration (structure 1) 
showed nearly 100% conversion, while 1 to 6 acyl shift reactions (structure 2) reached only 
about 10%. Furthermore, in the case of a five-membered ring intermediate (structure 1) 
substituent R1= H, Me showed a massive amount of hydrolysis while R1= COR, CONHR 
resulted in high ligation yields. These results suggest that the presence of a sterically hindered 
group near the ligation site seemed to improve the ligation efficiency.  
The incorporation of an aryl group (structure 3 and 4) accelerated the reaction rate 
significantly. The internal thioesterification over a six-membered ring intermediate was slow 
for thioalkylesters (structure 2) but noticeably faster for thioarylesters (structure 3). After 
48 h, oxo-ester 3 showed 100% conversion. However, no ligation product was found. The 
rearrangement over a seven-membered ring intermediate (structure 4) showed 69% 
conversion with a hydrolysis/ligation ratio of approximately 1:1.  
Since intramolecular thioesterifications via an O-to-S acyl transfer attracted more attention at 
the beginning of this decade [55, 58] an understanding of the mechanism was required. In 
theoretical calculations of the O-to-S acyl transfer reaction by the Qing-Xiang group, more 
detailed information about the hydrolysis and the reactivity-structure relationship were 
analyzed.[59] It was found that the O-to-S rearrangement, as well as hydrolysis, proceeds over 
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an anionic stepwise mechanism in which the cleavage of the C-O bond is the rate-limiting 
step. Surprisingly, the calculated energy barriers of the oxo-ester hydrolysis  
(+24.3 kcal/mol) and the thioester hydrolysis (+25.5 kcal/mol) for model compound  
2-mercaptoethyl acetate led to the assumption that hydrolysis occurs preferably over the  
oxo-ester.  
The O-to-S acyl migration by the anionic stepwise mechanism is initiated by deprotonation of 
the thiol group followed by a rearrangement over the five-membered ring intermediate 
(figure 3.1). The relative free energy of transition state 1 (TS1) is independent from R1 or R2
and was calculated for model compound 2-mercaptoethyl acetate (R1, R2=H) with  
12.5 kcal/mol. Substitution of R1 and R2 by bigger groups showed almost no changes for the 
relative free energy of TS1 (table 3.2). However, the free energy barrier of transition state 2 
(TS2), decreased with rising steric hindrance of R1 and R2 (table 3.2, TS2). Since the energy 
barrier of the oxo-ester hydrolysis (+24.3 kcal/mol) is also considered as independent from 
substituents, big space claiming groups for R1 and R2 should favour the O-to-S acyl 
migration.[59]
Figure 3.1: The energy barriers of both transition states TS1 and TS2 during the O-to-S acyl migration. The 
rearrangement occurs over a five-membered ring intermediate (INT).[59]
Especially 2-hydroxy-3-mercaptopropanamide (Hmp) (entry 1.3, table 3.2), with a relative 
free energy barrier of +16.3 kcal/mol (TS2) and 2-hydroxy-2-methyl-3-sulfanylpropanoic acid 
(HMSP) (entry 1.4) with +13.6 kcal/mol (TS2) were calculated as the most efficient 
rearrangement groups for thioester formation.[59] These theoretical calculations confirm the 
experimental results of Zheng and co-workers which are depicted in table 3.1.[57]
Table 3.2: Calculated free energy barriers (in kcal/mol) of TS1 and TS2 with respect to R1 and R2.[59]
Entry Rests ΔG(TS1) ΔG(TS2) Rearrangement group
1.1 R1=H, R2=H 12.5 25.1 2-Mercaptoethanol
1.2 R1=COMe, R2=H 10.0 23.7 MMPA
1.3 R1=CONHR, R2=H 9.5 16.3 Hmp
1.4 R1=CONHR, R2=Me 9.9 13.6 HMSP
Although HMSP 1.4 can be easily made from the commercially available precursor methyl  
2-methylglycidate using the method of Liu and Maier,[60] no practical applications of this 
promising rearrangement group have been published so far. However, in contrast to the 
theoretical model group 1.4, the Hmp unit 1.3 was used several times to produce peptide 
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thioesters. Already in 2004, Botti and co-workers published the first method for the 
preparation of disulfide protected Hmp-peptides. Therefore the resin support was prepared by 
the coupling of disulfide protected Fmoc-Cys-OH. After deprotection of the Fmoc group, the 
free amino group was converted into a hydroxyl function using sodium nitrite and slightly 
acidic conditions (scheme 3.7 a). The following peptide sequence of NNY-Rantes-(2-33)-Hmp 
was synthesized using a standard Fmoc-based protocol. According to the authors, the coupling 
of the first amino acid at Hmp succeeded quantitative by Steglich esterification using 
HBTU/DIEA with DMAP as a catalyst. However, these quantitative coupling yields through 
Steglich esterification were not reproducible by other groups. Indeed, later studies 
demonstrated that Steglich esterification is rather inefficient for the coupling of most amino 
acids at the Hmp moiety.[2, 60] Nevertheless Botti et al. showed that Hmp-peptides can be 
directly applied for ligations in conventional phosphate buffers. In these ligation experiments, 
Hmp hydrolysis was observed as a single side reaction with an amount of 12.6%.[61] These 
results confirmed the findings of Zheng et al. who determined Hmp hydrolysis to 16% in 
0.2 M PBS buffer (table 3.1).  
The main drawback of Bottis approach was a rather complicated on-resin preparation of Hmp 
which resulted in low loading capacities. In the following years several groups tried to avoid 
this disadvantage via a complex synthesis of t-butyldimethylsilyl (TBS) protected Hmp.[62]
Nevertheless, this rather complicated procedure relied on five synthetic steps which prevented 
a breakthrough of this method. 
a)
b)
c)
Scheme 3.7: a) Synthesis of disulfide protected Hmp on the resin support by Botti et al.,[61] b) Production of trityl 
protected Hmp by Liu and Maier,[60] c) Synthesis of the trityl protected Hmp by Wisniewski.[63]
In 2013, Liu and Maier introduced an Fmoc compatible, trityl-protected Hmp(Trt) building 
block which was compatible with Fmoc-SPPS. In contrast to previous approaches, the 
synthesis of Hmp(Trt) succeeded quickly and simply starting from oxirane-2-carboxylate and 
triphenylmethyl thiol (scheme 3.7 b). Additionally, this study presented an efficient method 
for the coupling of the first amino acid at Hmp(Trt) using the Mitsunobu reaction. Liu et al.
were also able to increase the yield of the SPPS by using 2-methylpiperidine instead of 
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piperidine for Fmoc deprotection steps. All these improvements allowed an efficient synthesis 
of Hmp-peptides with enhanced yields.[60] In their study, Liu and Maier used Hmp-peptides 
successfully as precursors for the preparation of peptide thioesters. Furthermore they 
confirmed the results of the ligation experiments from Botti et al. using Hmp-peptides directly 
in NCL.  
A very efficient synthetic route for trityl-protected, enantiomerically pure Hmp ((R)-3-chloro-
2-hydroxypropanoic acid) was published by K. Wisniewski who applied Hmp(Trt) as a 
precursor for the synthesis of the oxytocin agonist [L-Hmp1, Thr4]OT. In this two-step strategy 
3-chloro-1,2-propanediol was first oxidized by 68% nitric acid to 3-chloro-2-hydroxypropanoic 
acid. Treatment with triphenylmethyl thiol resulted in trityl protected Hmp (scheme 3.7 c). 
The main advantage of this method was the simple procedure starting with inexpensive and 
easily available compounds.[63]
For peptide thioester preparation by O-to-S acyl shift reactions Hmp is a promising 
rearrangement group. Nevertheless, an alternative and widely investigated approach is the 
usage of N-to-S acyl shift rearrangement units. In 2002, Vizzavona et al. observed an N-to-S 
acyl transfer at 2-mercapto-4,5-dimethoxybenzyl (Dmmb)-modified peptides during the 
search for a suitable auxiliary group at the X-Gly ligation site. This unsuspected side reaction 
occurred under acidic treatment with concentrated TFA.[64] Three years later, this finding was 
adopted and further expanded by Kawakami and co-workers who developed a Fmoc-based 
SPPS approach for the preparation of peptide thioesters based on the Dmmb-group. In this 
method the thioester was generated during peptide cleavage with concentrated TFA resulting 
from an acid-induced N-to-S acyl transfer.[65] Soon after this discovery it was realized that the 
intramolecular thioesterification via N-to-S acyl shift reactions was a powerful method for 
thioester peptide preparation. In the following years, the numbers of new developed N-to-S 
acyl rearrangement units exploded. Nowadays, thioesterification by the N-to-S acyl transfer 
reaction is a widely used “gold standard” technique for the preparation of peptide 
thioesters.[66] Most of these rearrangement groups are compatible with Fmoc-SPPS and can be 
directly used in NCL. The main advantage of N-to-S acyl rearrangement groups is the stable 
amide bond which is less prone to hydrolysis than the oxo-ester bond. However, this higher 
stability causes lower reaction rates for the N-to-S acyl shift reaction.[66c, 67]
a)
b) 
Scheme 3.8: a) N-to-S-acyl transfer reaction of SEA modified peptides to the activated thioester[68], b)
Rearrangement of α-methylcysteine to a C-terminal peptide thioester.[69]
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A widely applied strategy using N-to-S shift reactions is the SEA ligation with  
bis(2-sulfanylethy-l)amino (SEA) modified peptides (scheme 3.8 a).[70] This method was 
introduced and published by the O. Melnyk and C. Liu group.[68] The enhanced reactivity of 
the SEA motif relies on the presence of two β-mercaptoethyl groups which are bound to the  
N-atom. In this motif one thiol group is always aligned for an intramolecular attack at the 
peptide C-terminus. This SEA mediated thioesterification occurs via a five-membered ring 
intermediate.[71] Since its discovery, the SEA strategy was successfully applied for the total 
chemical synthesis of multiple medium-sized proteins such as cyclic O‑acyl isopeptides, small 
ubiquitin-like modifier (SUMO) proteins and 15 kDa polypeptides.[24b, 72]
In 2014, another promising N-to-S acyl shift reaction was introduced by the Offer group 
(scheme 3.8 b). The strategy was successfully used for the synthesis of the bovine pancreatic 
trypsin inhibitor (BPTI) and murine KC (mKC), the mouse functional homologue of 
interleukin 8.[69] In this study two Cα-substituted cysteine analogues AMP (2-amino-2-
methylpropane-1-thiol) and α-methylcysteine were investigated as potential thioester-
producing rearrangement groups (figure 3.2). The activation of the amide bond was achieved 
by the additional methyl group at the Cα-carbon atom which caused a dramatic acceleration of 
the acyl shift reaction. The additional methyl group at the Cα-atom reduced the free energy 
barrier of the cyclic transition state and facilitated the cleavage of the amide bond. This so 
called gem-dimetyl effect, which can be observed at α-methylcysteine, was thoroughly 
investigated and summarized by M. Jung and G. Piizzi and is also kwon for a number of 
different organic reactions and cyclizations.[73]
The main advantage of this promising method was the high stability of the thioester peptide 
in conventional ligation buffers. In contrast to the O-to-S acyl shift reaction α-methylcysteine 
showed no signs of hydrolysis during NCL. A second advantage of α-methylcysteine was its 
compatibility with the widely used Fmoc-SPPS. However, the main disadvantage of this 
method was the minor reaction rate. Although the usage of α-methylcysteine peptides turned 
out to be an efficient method for the ligation of membrane peptides, α-methylcysteine is not 
commercially available and its precursors are prohibitively expensive.  
a) HMSP b) AMP c) α-methylcysteine
Figure 3.2: a) structure of 2-hydroxy-2-methyl-3-sulfanylpropanoic acid, b) 2-amino-2-methylpropane-1-thiol, c)
structure of α-methylcysteine.[59, 69]
Interestingly, α-methylcysteine resembles the theoretically designed rearrangement group 
HMSP (2-hydroxy-2-methyl-3-sulfanylpropanoic acid) which was proposed by the Qing-Xiang 
group and discussed above in table 3.2.[59] Similar to AMP and α-methylcysteine, HMSP 
carries an additional methyl group at the Cα-atom (figure 3.2). However, HMSP is not deeply 
investigated so far as rearrangement group for ligation studies. In further studies, HMSP could 
be a promising rearrangement unit for the synthesis of peptide thioesters. 
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3.3. Synthetic strategies for hydrophobic peptides 
Figure 3.3: Internal modifications and external conditions used as strategies to improve the solubility of 
hydrophobic peptides during NCL or peptide purification.[74]
The synthesis of hydrophobic proteins by NCL is a recurring challenge in modern peptide 
science. Especially transmembrane peptide/protein domains, which are naturally located in 
cell membranes, often precipitate/aggregate in all known aqueous ligation buffers. Strong 
intra- and intermolecular interactions of hydrophobic sequences tend to form secondary 
structures like β-sheets which further decrease the solubility of peptides/proteins. Over 
decades, different methods have been developed to counter solubility problems of 
transmembrane proteins. These methods can be divided into two different groups.[74]
The first group of solubility-improving strategies include external conditions which use 
detergents, organic solvents or fluorinated alcohols as additives in aqueous buffer solutions. A 
less studied method is the usage of ionic liquids as media for oxidative folding or NCL. 
The second group of solubility-improving strategies include internal modifications of the 
peptide chain. These modifications encompass the incorporation of depsi-motifs  
(O-acyl isopeptides) or the attachment of permanent and temporarily bound solubilizing tags, 
respectively. Of special interest are temporarily bound solubilizing tags, since they can be 
removed from the final target peptide. This requires a cleavable linker, which must be 
tracelessly cleaved from the peptide chain under defined conditions. In contrast to 
temporarily bound tags, permanently bound tags are mostly applied for recombinant protein 
expression since cleavable linkers are usually difficult to incorporate by recombinant methods. 
Famous examples for recombinant solubilizing tags are solubility enhancing ubiquitous 
(SNUT), aggregation-resistant proteins, glutathione-S-transferase (GST) and polyionic amino 
acid sequences with chargeable side chains (Asp-, Lys-, Arg-, Glu-, His-tags).[75] The following 
chapters give a precise insight into temporarily bound tags which can be incorporated by 
chemical methods. 
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3.4. Internal modifications as solubilization strategies 
3.4.1. Synthesis of O-acly isopeptides 
A well-studied method to increase peptide solubility by internal modifications of hydrophobic 
peptides is the synthesis of O-acly isopeptides (depsipeptides) which contain oxo-ester bonds 
within the primary sequence.[76] These oxo-esters are located at threonine or serine residues 
and can be incorporated by Fmoc-SPPS. The depsi-motif prevents the formation of 
unfavourable secondary structures (e.g. β-sheets) which tend to aggregate and participate in 
aqueous ligation buffers. After ligation, the natural peptide sequence can be obtained under 
slightly basic conditions, since the depsipeptides tend to rearrange over an O-to-N acyl shift 
reaction to from the native peptide bond. An important example of the power of this strategy 
is the successful ligation of the highly hydrophobic β-amyloid peptide Aβ42 which is related to 
Alzheimer's disease (scheme 3.9).[77]
Scheme 3.9: Rearrangement of O-acyl isopeptides to the natural peptide sequence under slightly basic conditions. 
The irreversible O-to-N acyl transfer reaction occurs over a five-membered ring intermediate.[77b]
3.4.2. Side chain and backbone attached solubilizing tags 
Despite the great variety of possible recombinant solubilizing tags, non-native solubilizing 
tags can hardly be incorporated by protein expression. The chemical peptide synthesis, 
however, can be performed using native or non-native building blocks. Frequently used 
examples for non-native solubilizing tags are hydrophilic polymers such as 
poly(ethyleneglycol)polyamide (PPO) or poly-8-amino-3,6-dioxaoctanoic acid (ADO).[2, 78]
Nevertheless, natural amino acids represent the most used building blocks for solubilizing 
tags. Especially basic amino acids such as histidine, lysine or arginine are frequently 
incorporated in solubility enhancing sequences.
Kato et al. compared the differences between polylysine and polyarginine tags with the help of 
the model peptide bovine pancreatic trypsin inhibitor (BPTI-22). They found that the 
solubility-improving effect was not only dependent on the number of basic amino acids but 
also the location of the tag was an important factor. Attachment on the C-terminus seemed to 
increase peptide solubility more than N-terminal-bound tags. Furthermore, polyarginine tags 
showed a slightly higher solubility potential as their polylysine counterparts. However, the 
differences between polyarginine and polylysine tags were negligible for sequences shorter 
than 5 amino acids.[79] Surprisingly, Albericio and co-workers came to opposite results. In 
their HPLC studies, peptides with linear polylysine tags showed a greater increase in polarity 
than their polyarginine counterparts.[80] Due to this controversial finding, polylysine and 
polyarginine tags were considered similarly efficient.  
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The attachment of solubility enhancing tags at the side chain or backbone is one of the most 
favored methods to increase peptide solubility.[35] Side chain or backbone linked tags provide 
several advantages over C-terminal or N-terminal tags. The attachment of large groups or 
tags, far away from the C-terminus, reduces steric hindrance at the ligation site. Additionally, 
the high number of functional groups alongside the side chain offers various anchor points for 
solubility tags. Despite these benefits, the synthesis of thioester peptides with side chain or 
backbone modifications is challenging. Due to lower safety risks, Fmoc-SPPS is the most 
applied method for production of those peptide thioesters (chapter 3.2). Last decade, a 
remarkable number of new linker types and backbone modifications were developed which 
enabled the attachment of permanent or temporarily bound polyionic tags at the peptide 
chain. Especially important are temporarily bound tags, since they can be removed from the 
final target peptide after native chemical ligation or purification. 
Temporarily bound solubilizing tags:
Table 3.3 shows a comprehensive selection of temporary linker types and solubilizing tags 
which were successfully applied for the synthesis or purification of hydrophobic peptides. 
Table 3.3: Backbone and side chain modification strategy to attach solubilization tags on hydrophobic peptides. 
Peptide SPPS Modifi. site Solubility tag Reference
AYVLWYA Fmoc Tyr Nmec taga Wahlström et al., 2008 [81]
ACP(65-74) Fmoc Tyr, Asp TEGBz tag L. Kocsis et al., 2008 [82]
KWLPFLA Fmoc Trp Nmbu taga Wahlström et al., 2009 [83]
hEPO(43-77) Fmoc Glu, Lys polyarginine Z. Tan et al., 2011 [84]
LC31(1-114) Fmoc Gln polyargininec Y. Huang et al., 2013 [85]
AM2(1-97) Fmoc Gly backbone polyarginineb J. Zheng et al., 2014 [51]
H4(1-102) Fmoc Cys tri-arginineb S. Maity et al., 2016 [86]
Aβ(1-48) Fmoc backbone polyarginineb C. Zuo et al., 2016 [87]
HCV p7 Fmoc backbone polyarginineb J. Zheng et al., 2016 [43]
GroES(1-97)
L31(1-70) 
Fmoc Lys 
polylysineb
PEG2b
M. Kay et al., 2016 [88]
Aβ(1-42) Fmoc Lys oNb-OEG3b,c J. Karas et al., 2017 [89]
AM2(1-97) Fmoc backbone polyarginineb S. Tang et al., 2017 [90]
Model peptide Fmoc Lys KKK, RRRb S. Tsuda et al., 2018 [48]
hepatitis B
Cp (1-149) 
Fmoc Cys deka-lysine S. Tsuda et al., 2018 [91]
PYY(3-36) Fmoc Lys PEG22 Castelletto et al., 2018 [78b]
BM2(1-51) Fmoc Cys polylysineb S. Tsuda et al., 2019 [92]
a: used for purification via HPLC.
b: used for purification and native chemical ligation.
c: photocleavable tag.
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Solubilizing tags attached to a side chain of peptides: 
One of the first attempts to incorporate temporarily bound solubilizing tags at the side chain 
of peptides was made by K. Wahlström and co-workers.[81] Wahlström introduced two side 
chain protecting groups (Nmec and Nmbu) with solubility improving properties, for tyrosine 
(Tyr) and tryptophan (Trp) residues. Both protected building blocks Fmoc-Tyr(Boc-Nmec) 
and Fmoc-Trp(Boc-Nmbu) were compatible with Fmoc-based SPPS and could be easily 
incorporated by standard coupling conditions (figure 3.4).  
The strategy was developed and tested by the synthesis of short model peptides (table 3.3). 
During peptide cleavage using a TFA cleavage cocktail, the Boc group was removed releasing 
Nmec or Nmbu carrying peptides. The resulting deprotected peptide chain was positively 
charged at Nmec or Nmbu residues and showed a greatly improved solubility. Although this 
strategy was only used to improve the solubility of peptides during purification via RP-HPLC, 
this approach is also applicable for ligation studies with hydrophobic transmembrane peptides 
containing Tyr and Trp residues. After purification, the Nmec and Nmbu tags can be traceless 
removed from the peptide chain under basic conditions (pH ~9.5).[81, 83]
a) b)
Figure 3.4: Solubility improving amino acid building blocks a) Fmoc-Tyr(Boc-Nmec) and b) Fmoc-Trp(Boc-Nmbu) 
suitable for Fmoc-SPPS. Boc protecting groups are removed during peptide cleavage from the solid support.[81, 83]
Despite this interesting approach, the method of Wahlström et al. is limited to tyrosine and 
tryptophan residues. However, numerous solubility improving tags were published over the 
last decades (table 3.3). Most of these developed linker types and solubilizing units are 
compatible with Fmoc-based SPPS. For instance, Tan et al. used the side chains of Glu and Lys 
for the synthesis of glycosylated human erythropoietin (hEPO). Here, arginine subunits were 
attached over 6-hydroxyhexanoic acid linkers at Glu and Lys residues.[84] Huang et al. coupled 
polyarginine tags at Gln using a photo cleavable nitrobenzyl linkers for the synthesis of the 
autophagosomal marker protein LC3-II.[85] Maity and co-workers used the side chain of Cys to 
attach tri-arginine tags at Phacm (phenylactamidomethyl) linker. The strategy was applied for 
the NCL of the histone protein H4.[86] The Kay group coupled a combination of PEG2 and 
polylysine tags at a Ddae (4,4-dimethyl-2,6-dioxocyclohexylidene-3-[2-(2-aminoethoxy) 
ethoxyl]-propan-1-ol) linker to modify the side chain of lysine. This method was also 
successfully applied for the NCL of an Ebola virus C20 peptide and the 70-residue ribosomal 
protein L31.[88]
In 2018, Tsuda and Yoshiya presented a polyionic tag that was composed of several lysine 
residues, attached on a trityl anchor.[93] This trityl-polylysine tag was able to react selectively 
with thiol groups and was therefore considered a promising tool to attach solubilizing tags on 
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cysteine residues of fully deprotected peptides. Ingeniously, this reaction could be performed 
in HFIP which has long been known as a superb solvent for hydrophobic membrane 
peptides.[94] Already in 2014, Mochizuki et al. described that tritylation of unprotected  
Cys-containing peptides can be efficiently achieved in neat HFIP.[95] Shortly after this 
invention, the advantage of this method was impressively demonstrated by the successful 
synthesis of a 149-amino acid capsid protein from hepatitis B.[91] However, a major drawback 
of this method was a very low yield after attachment of the trityl tag at cysteine. Furthermore, 
this trityl tag strategy was not compatible with thioester-forming rearrangement groups which 
produce thioester via O-to-S- or N-to-S-acyl shift (chapter 3.2.5). 
Solubilizing tags attached to the backbone of peptides: 
A completely different approach that does not require a suitable peptide side chain is the 
attachment of solubility enhancing groups at a backbone of a peptide. Temporarily attached 
linkers along the backbone are not only anchor points for tags, but also prevent the formation 
of unfavorable secondary structures like β-sheets which are considered as possible reason for 
peptide aggregation. 
a) b)
Figure 3.5: a) First generation of linkers for the removable backbone modification (RBM) strategy. b) second 
generation of linkers. 
One of the strategies using backbone-attached solubilizing tags is the removable backbone 
modification (RBM) strategy developed by the Liu group. Initially, the method was invented 
to increase the solubility of medium-sized transmembrane proteins during NCL. The feasibility 
of this strategy was impressively demonstrated by the total chemical synthesis of the 
membrane-embedded domain of the potassium channel Kir5.1.[51]
The first generation of RBM linkers used modified glycine derivatives to attach a polyarginine 
tag to the backbone of hydrophobic peptides (figure 3.5a). However, the synthesis of this 
glycine derivative was rather tedious. Additionally, the strategy could only be used for 
peptides with glycine residues in the natural sequence. These disadvantages encouraged the 
Liu group to develop a second generation of RBM linkers which were compatible with all 
natural amino acids (figure 3.5b). This second generation of linkers was much easier to 
synthesize and is one of the most promising approaches for the synthesis of highly 
hydrophobic peptide thioesters.[74] The strategy was adopted for the total chemical synthesis 
of various difficult peptides using Fmoc-based SPPS and NCL.[43] One of the examples was 
published by Tang and co-workers who achieved the synthesis of the influenza A virus proton 
channel sequence AM2(1-97) using the RBM strategy.[90] Another example was reported by 
Zuo and Zheng who applied the second generation RBM strategy for the NCL of β-amyloid 
peptides which are linked to Alzheimer’s disease.[87]
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3.4.3. Solubilizing tags at the N-terminus 
The temporary attachment of hydrophilic tags to a peptide N-terminus is another possible 
strategy to enhance peptide solubility. The nucleophilic character of the amino group and the 
low steric hindrance are two main reasons why the N-terminus is an ideal anchor point for 
solubility-improving tags. Since decades, this idea is used supporting the native chemical 
ligation or purification of poorly soluble, recombinant proteins.[75, 96] However, examples for 
total chemical synthesis of peptides with N-terminal attached solubilizing tags are sparely 
represented in the literature. One main reason for the restricted application of the N-terminal 
tag strategy is their limitation to the thioester fragment. Highly hydrophobic N-terminal 
cysteine peptides are not suitable for this method since a free N-terminus in form of cysteine 
is required for the ligation. Therefore, most N-terminal solubilizing tags published were used 
for purification purposes by preparative HPLC or affinity chromatography. Table 3.4 shows 
examples of N-terminal attached solubilizing tags and linkers which were developed over the 
last two decades.  
Table 3.4: Summary of N-terminal solubilization tag strategies for poorly soluble peptides. 
Peptide SPPS Linker Solubility tags Reference
PQFVQNINIENLFR Boc Ntl Poly-(RGG)a Robillard et al., 1999 [97]
ALFCYRANGCSPKGYS Fmoc Canaline KKK, RRRb S. Tsuda et al., 2018 [48]
Insulin A chain Fmoc Ddae KKKc Disotuar et al., 2019 [98]
a: used for purification via HPLC.
b: used for purification and native chemical ligation.
c: disulfide ligation with B chain.
Englebretse and Robillard first described an approach by attachment of a polyarginine-di-
glycine tag through a base-labile urethane linker at the peptide N-terminus. After purification, 
the linker was removed by treatment with a mild aqueous base. However, the method was 
only compatible with the Boc-based SPPS, because the prepared Ntl-linker  
2-[(2-Aminoethyl)sulfonyl]ethanol was highly base-labile.[97]
Recently, Disotuar et al. presented a cleavable N-terminal tri-lysine tag to improve the 
solubility of the insulin A chain. This tag was coupled over a PEG spacer at a Ddae  
(4,4-dimethyl-2,6-dioxocyclohexylidene-3-[2-(2-aminoethoxy) ethoxyl]-propan-1-ol) linker. 
The Ddae linker could be removed using a hydrazine-based buffer at a pH of 7.5. Although 
this strategy was not thought to improve the solubility during NCL, this approach can be 
applied for hydrophobic peptide thioesters.[98]
A promising strategy for NCL-mediated synthesis of hydrophobic peptides was presented by 
Tsuda and colleagues who applied the non-proteinogenic amino acid canaline as an  
N-terminal linker between a polyarginine tag and the poorly soluble part of the sequence. In 
contrast to previous methods, canaline-containing peptides can be synthesised by standard 
Fmoc-SPPS. Interestingly, canaline can be attached at both the N-terminus and the side chain 
of lysine, which makes the method especially versatile. In combination with the kinetically 
controlled ligation (KCL), the canaline strategy can also be applied for N-to-C assembling of 
peptides. After ligation, the linker could be removed with a slightly acidic treatment in an 
ammonium acetate buffer.[48]
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3.4.4. Solubilizing tags at the C-terminus 
So far the most published solubilizing tag strategy for hydrophobic peptides is the attachment 
to the C-terminus. This approach is usually accompanied by less steric hindrance compared to 
backbone modification methods, thus facilitating the incorporation of solubilizing tags into 
the peptide sequence during the SPPS. Table 3.5 present a comprehensive selection of  
C-terminal solubilizing tags investigated over recent years. 
Table 3.5: Summary of C-terminal solubilizing tag strategies for chemical synthesis of hydrophobic peptides.  
Peptide SPPS Linker Sol. tags Reference
CP10(42-55) Boc glycolamide ester tetra-argininea Alewood et al., 1996 [99]
TMPs Fmoc 4-Hmb-oxo-ester (GK)nb Choma et al., 1998 [100]
Vpu(2-31) Boc thioester PPO2h Becker et al., 2004 [78a]
ORL1(288–370) Boc MPA-thioester penta-argininee Sato et al., 2005 [101]
DGK, KcsA Boc MPA-thioester hexa-argininee Kent et al., 2007 [102]
[D83A]RNase Boc MPA-thioester hexa-argininee Boerema et al., 2007 [103]
HIV 1 protease  Boc MPA-thioester deka-argininee Johnson et al., 2007 [104]
IGF1(1-70) Boc MPA-thioester tetra-argininee Sohma et al., 2008 [105]
Insulin glargine Fmoc 4-Hmb-oxo-ester penta-lysinea Hossain et al., 2009 [106]
NY-ESO-1  Fmoc HMBA-oxo-ester hexa-argininea Harr. et al., 2009 [107]
mouse INSL5, B Fmoc 4-Hmb-oxo-ester penta-lysinea Belgi et al., 2011[108]
DAGK (46-121) Boc MPA-thioester hexa-argininee Lahiri et al., 2011[109]
C1q (68-134) Boc MPA-thioester penta-lysine e Yang et al., 2013 [110]
DEN2C (21-100) Boc MPA-thioester hexa-argininee Zhan et al., 2013 [111]
α-Conotoxins Fmoc PAM-oxo-ester tetra-lysinea Peigneur et al., 2014 [112]
Q11 Fmoc Mmsb-oxo-ester polylysinec Albericio et al., 2014 [113]
Aβ40 Fmoc Amide ester polylysinea,d Wetzel et al., 2014 [114]
Lactocyclicin Q Fmoc Dbz-amide hexa-argininef Wang et al., 2015 [41]
IFITM3 Fmoc No linker hepta-arginineg Bode et al., 2017 [115]
SUMO-2, Ub Fmoc Dbz-amide hexa-argininef Brik et al., 2017 [116]
BM2(1-51) Fmoc Hmp-thioester penta-lysinee Baumruck et al., 2018 [2]
Model peptides Fmoc Dbz-amide tri-argininee Tsuda et al., 2018 [48]
a: used for purification via HPLC. e: used to improve the solubility of the C-terminal thioester peptide for NCL.
b: used for purification and thioether coupling. f: used to improve the solubility of the N-terminal Cys peptide during NCL.
c: used for fragment condensation. g: used to improve the solubility of the N-terminal peptide for KAHA ligation.
d: removed by Carboxypeptidase B (CPB). h: used to improve the solubility of the N-terminal peptide for oxime ligation.
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The C-terminal tag strategy was first described in 1996 by Englebretsen and Alewood who 
coupled a poly-glycine-arginine tag to a base labile glycolamide ester.[99] However, this 
approach was only compatible with Boc-based SPPS and was used to dissolve peptides for 
purification by preparative RP-HPLC. Two years later, Choma and Englebretsen published a 
Fmoc-SPPS compatible strategy using 4-Hmb (4-hydroxymethyl benzoic acid) oxo-ester as a 
linker. This approach was additionally applied for the coupling of two transmembrane protein 
segments by thioether ligation.[100] Over the course of time oxo-ester linkers were applied in 
combination with polyarginine or polylysine tags to improve handling and purification of 
poorly soluble peptides such as Q11,[113] insulin glargine[106] or NY-ESO-1.[107b]
a) b) c)
Figure 3.6: a) 4-(Hydroxymethyl)benzoic acid (4-Hmb) linker by Englebretsen, b) 2-Methoxy-4-methylsulfinylbenzyl 
alcohol (Mmsb) linker by Albericio,[80] c) 3-Mercaptopropionic acid (3-MPA) linker by Sato and Aimoto.[101]
In 2004, Becker et al. suggested the use of a PPO (polyethylene glycol-polyamide) auxiliary in 
the thioester moiety to improve the solubility of the HIV (human immunodeficiency virus) 
protein sequence Vpu(2-31). The strategy was used to couple the Vpu (viral protein u) 
domain to a small peptide template via oxime ligation.[78a] In the same year, Sato and  
co-workers proposed a similar approach for the NCL of the hydrophobic transmembrane 
peptide ORL1 (opioid receptor like 1). The strategy relied on a good soluble penta-arginine 
tag with 3-MPA (3-mercaptopropionic acid) as a linker.[101] In the following years this idea 
was adopted by several groups for the synthesis of different poorly soluble peptides such as 
KcsA,[102] IGF1(1-70),[105] DAGK(46-121)[109] and DEN2C(21-100).[111] However, the main 
drawback of this method was the need of Boc chemistry for the synthesis of the thioester 
segment.  
Fmoc-based synthetic routes for the synthesis of peptide thioesters with C-terminal solubility 
tags are barely reported in the literature. One main reason is that thioesters are base-labile 
during the Fmoc-deprotection step. Less basic deprotection agents as described by Wade et 
al.[30] or Guo and co-workers[31], allow only the synthesis of short thioester peptides. The most 
promising approach so far is the Dbz or MeDbz strategy by Blanco-Canosa and Dawson 
(chapter 3.2.4).[40] Indeed, this approach was used to improve the solubility of hydrophobic 
peptides during the ligation of lactocyclicin Q,[41] SUMO-2 or ubiquitin(1-93).[116]
Nevertheless, the Dbz linker is prone to inactivation and uncontrollable side reactions through 
over-acetylation. Capping steps using acetic anhydride should also be avoided which makes it 
difficult to obtain clean products for longer sequences. Furthermore, an additional activation 
step must be introduced for the synthesis of Dbz peptides using toxic chemicals such as  
4-nitrophenylchloroformate.[40b] Another but more convenient Fmoc-SPPS compatible strategy 
for the synthesis of thioester peptides with C-terminal solubility tags is the usage of thioester-
forming rearrangement groups such as Hmp or α-methylcysteine (chapter 3.2.5). In contrast 
to Dbz- or MeDbz-peptides are Hmp-peptides compatible with capping steps and independent 
from activation steps with toxic chemicals. Surprisingly, this strategy has never been widely 
used in the peptide chemistry community so far.  
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3.5. External conditions as solubilization strategies 
3.5.1. Detergents and organic solvents as additives for NCL 
Conventional ligation buffers like urea or guanidinium chloride based solutions with good 
water soluble compounds such as disodium phosphate, TCEP and MPAA are unfortunately 
only applicable for the ligation of soluble peptide fragments. Hydrophobic or poorly water 
soluble peptides precipitate under these conditions. For this reason, solubility-improving 
additives were searched or developed for decades. 
The solubility of hydrophobic peptides during ligation can be enhanced by the addition of 
detergents or organic solvents.[74] Multiple short to medium-size peptides have been 
successfully ligated in the presence of detergents or bilayer forming surfactants.[117] Fujii and 
co-workers introduced the lipid bilayer-assisted NCL of membrane-embedded chemokine 
receptors (CXCR4) in the presence of 1-palmitoyl-2-oleoylphosphatidylcholine  (POPC) or 
sodium dodecyl sulfate (SDS).[118] Kochendoerfer and colleges used 1-monooleoyl-rac-glycerol 
(MO) bilayers to ligate transmembrane domains of bacteriorhodopsin (Halobacterium 
salinarium) [119] and Becker et al. applied dodecylphosphocholine (DPC) or octylglycoside 
(OG) as solubilizing detergents for the ligation of Escherichia coli diacylglycerol kinase 
(DAGK).[109] Despite this success, detergents and surfactants often led to problems during 
purification via RP-HPLC which is a disadvantage of these methods. 
A further method is the addition of organic solvents such as dimethylformamide (DMF), 
dimethyl sulfoxide (DMSO) or N-methyl-2-pyrrolidone (NMP) to the ligation buffer. This 
approach was deeply investigated by Dittmann and co-workers.[120] Especially the usage of 
DMF as an organic ligation media was used for NCL of transmembrane peptides such as small 
chromopeptides or even the entire sensory rhodopsin II/transducer complex containing two 
transmembrane helices.[120-121] Of particular importance is the use of fluorine-containing 
organic solvents or ionic liquids as potential additive in phosphate buffers. Both strategies will 
be presented and discussed in the following sections. 
3.5.2. Fluorinated alcohols as co-solvents 
The use of fluorinated alcohols as powerful solvents for the synthesis of organic compounds 
(e.g. imidazoles, quinolones, Hantzsch esters etc.) has been discussed for a long time.[122]
Soon after their first descriptions as superior solvents, they also found applications in peptide 
synthesis. Especially trifluoroethanol (TFE) and hexafluoroisopropanol (HFIP) attracted much 
attention as effective media for both solution phase[123] and solid phase peptide synthesis of 
difficult or poorly soluble peptides.[124] Both solvents also gained wide use in the field of 
peptide analysis.[125] Several NMR- and CD-studies were able to demonstrate that TFE 
promote the formation of secondary structures (α-helices, β-sheets) in proteins.[126] Urry et al.
concluded that fluorine-containing solvents mimic the natural environment of membrane 
proteins.[126b] Molecular dynamic simulations, by Roccatano et al. suggest that these structure-
stabilizing effects are induced by the accumulation of TFE molecules around the peptide 
chain. This TFE layer represents a dielectric environment in which intramolecular peptide 
hydrogen bonds are favored.[127] Competing hydrophobic interactions in contrast were 
considered as rather low, so that stabilizing effects of secondary structures were preferred.[128]
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In 1988, Narita and Obana conducted profound solubility experiments with poorly soluble 
model peptides in a variety of different organic solvents. They found that HFIP has the highest 
solubilizing potential for hydrophobic peptides followed by HMPA and DMSO.[129] Today, 
multiple studies describe TFE or HFIP as highly effective co-solvents for the ligation of 
transmembrane peptides. DeGrado et al.[130] as well as Mei Hong et al.[131] used TFE 
containing phosphate buffers for the ligation of the M2 proton channel of influenza A. Liu  
et al. investigated HFIP as an potent additive for the chemical ligation of membrane proteins 
and hydrophobic antibiotics such as trifolitoxin.[94] In contrast to other solvent improving 
additives such as SDS, DMF or DMSO, fluorinated alcohols possess a low boiling point and 
minor viscosity which allows simple peptide purification by preparative RP-HPLC.  
Although fluorinated alcohols like HFIP and TFE are known to promote or accelerate some 
organic reactions, possible peptide modifications have not been reported so far.[132]
Nevertheless, in combination with TCEP, MPAA or urea are TFE or HFIP-induced peptide 
modifications possible.[2] Until now, ligation experiments with Hmp-peptides in TFE or HFIP 
containing phosphate buffers were never investigated. Especially interesting is therefore the 
effect of fluorinated alcohols on the ligation yield of Hmp-peptides.  
An alternative approach to the addition of fluorinated alcohols to conventional ligation 
buffers is the use of ionic liquids (ILs) as ligation media. Ionic liquids gathered much attention 
in recent years due to their unique solvent properties for peptides. The following section will 
discuss the advantages and disadvantages of ILs as additives or ligation media for 
hydrophobic peptides. 
3.5.3. Ionic liquids as co-solvents 
During recent decades, interest in more environmentally friendly solvents has increased 
tremendously. Promising alternative solvents are ionic liquids (ILs), which can be considered 
as organic salts with melting points near room temperature.[133] Although ILs were known for 
over a century, very little research on their unique properties were performed for a long 
period of time.[134] Nevertheless, ILs provide countless advantages over more traditional 
organic solvents such as negligible vapour pressure, high thermal stability and low 
flammability.[135] Additionally, ILs offer the possibility to tailor their physical and chemical 
properties for the purpose of interest primarily by structural modifications of the cation or by 
exchange of the anion. Since several years, ILs attract more attention in the scientific 
community as solvents for classical organic reactions such as the Knoevenagel 
condensation[136], Robinson annulation[137] or Diels-Alder reactions.[138] The great number of 
possible applications  and different ILs led to an explosion of publications in this area.[134, 139]
Especially interesting is the application of ILs as media for biomolecules such as DNA,[140]
RNA,[141] enzymes[142] and proteins.[143] Some ILs simultaneously show excellent solvation 
properties for hydrophilic and hydrophobic biomolecules which is primarily useful for 
hydrophobic peptides and proteins. In particular imidazolium-based ionic liquids such as  
1-ethyl-3-methylimidazolium acetate ([C2mim][OAc]) seem to be a favourable reaction media 
for hydrophobic proteins like conotoxins or transmembrane peptides.[144] Different studies 
underline the structure stabilizing effects of imidazolium cations to the native protein 
structure.[145] Although the underlying molecular interactions are not fully understood so far, 
it is thought that imidazolium cations minimize the formation of non-native protein isoforms 
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and stabilize the energetic ground state of secondary and tertiary structures.[146] Additionally, 
imidazolium based ionic liquids supply optimal conditions for the oxidation of cysteine 
residues in the presence of air.[144b, 147] In several studies Tietze, Imhof and co-workers 
demonstrated that [C2mim][OAc] is a highly efficient, biocompatible media for the oxidative 
folding of cysteine-rich conopeptides. The newly developed method showed multiple 
advantages over conventional buffer solutions such as a reduced reaction time, no need for 
redox-active reagents and an increase in peptide concentration by three orders of 
magnitude.[144, 148]
Another possible application for ILs is their usage as ligation media for poorly soluble peptides 
such as transmembrane domains of ion or proton channels. Thioester hydrolysis in aqueous 
ligation buffers is the most important side reaction of the NCL. A reduction of the water 
content by addition of ILs is one possible approach to increase the final ligation yield. Due to 
their special solvent properties, ionic liquids are particularly promising as media for 
membrane associated peptides. Already in 2010, Braga et al. showed that organic thioesters 
are stable in the imidazolium based ionic liquid 1-butyl-3-methylimidazolium 
hexafluorophosphate (BMIM-PF6). However, they never examined the liquid as a media for 
ligation experiments.[149] In the following years, the usage of ionic liquids as solvents for NCL 
has been reported several times.[135, 150] In 2012, Imhof and colleagues tested a variety of 
different imidazolium based ionic liquids for the NCL of tridegin, a 66-mer peptide inhibitor of 
the coagulation factor XIIIa. This study demonstrated that acetate is the most effective anion 
for NCLs in imidazolium based ionic liquids.[151] Two years later, Kühl et al. investigated the 
influence of different C-terminal amino acids by NCL of multiple model peptides in 
[C2mim][OAc].[152] For these studies C-terminal 3-mercaptopropionate thioester were applied 
which could be obtained on 4-sulfamylbutyryl resins using the safety catch linker strategy by 
Ingenito and co-workers (chapter 3.2.3).[36] However, these ligation studies were 
accompanied by severe side reactions involving alkylation, cyclisation and disulfide formation 
of the cysteine residue.[152] Some publications reported the existence of N-heterocyclic 
carbenes in [C2mim][OAc].[153] Nevertheless, carbene involved peptide modifications caused 
by ILs were never investigated thoroughly. Of particular interest are these investigations for 
ligation studies with thioester forming rearrangement groups such as SEA or Hmp peptides, 
since the thiol group must be unprotected during the ligation. 
3.5.4. Carbene formation in imidazolium based ILs 
Already in 1964, NMR studies by Olofson and co-workers gave the first pieces of evidence that 
positively charged, heterocyclic compounds such as 1,3-dimethylimidazolium iodide react like 
carbenes.[154] Three decades later Arduengo and Kline confirmed these observations by the 
isolation and characterisation of the first kinetic and thermodynamic stable imidazolium-
based carbene.[155] In the following years, multiple studies proved that imidazolium-based 
ionic liquids such as [C2mim][OAc] contain traces of highly reactive N-heterocyclic carbenes 
(NHCs).[155-156] In 2010, Nyulaszi and colleagues found that the amount of NHCs formation in 
ILs is dependent on the strength of the basic anion.[157]
Different chemical reactions were applied as indirect indicators for the existence of NHCs in 
[C2mim][OAc]. Aggarwal and Mereu observed unexpected side reactions of imidazolium-
based ionic liquids with aldehydes.[158] Cooks and co-workers achieved the first experimental 
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measurements of the proton affinity of N-heterocyclic carbenes in the gas phase[159] and 
Gurau et al. were able to identify the [C2mim][H(OAc)2][C2mim+-COO-] complex after 
chemisorption of carbon dioxide in concentrated [C2mim][OAc]. Moreover, the authors 
reported on the fast release of carbon dioxide after the addition of water, leading to the 
formation of [C2mim][HCO3].[160]
Sulfur and sulfur-containing amino acids like cysteine seem to be especially sensitive towards 
NHC-related modifications in [C2mim][OAc]. Previous studies by Rodriguez et al. were able to 
detect 1-ethyl-3-methylimidazole-2-thione as a reaction product of neat [C2mim][OAc] with 
elemental sulfur.[161] Although [C2mim][OAc] was frequently described as a superior solvent 
for hydrophobic, cysteine-rich peptides, possible carbene related modifications of the peptide 
chain have never been investigated thoroughly. Such unpredictable side reactions can severely 
limit the application of ionic liquids as possible ligation media. 
3.6. Post-ligation methods: Desulfurization and Acm deprotection 
The selective desulfurization of cysteine provides the possibility to ligate peptides and proteins 
next to an alanine residue. Since alanine is a common amino acid in proteins, this strategy 
allows access to sequences without naturally occurring cysteine residues. The first description 
of protein desulfurization was made in 1951 by Cooley and Wood who applied Raney nickel 
catalysts for the desulfurization of casein and albumin.[162] However, this method was not 
restricted to cysteine alone, it also showed heavy amounts of methionine desulfurization. 
Twenty years later, Cheng et al. tested various temperatures and pH conditions to determine 
the mildest conditions for a specific cysteine desulfurization. These efforts led to the first 
selective desulfurization of the proteins hemoglobin, lysozyme and α-lactalbumin.[163] Since 
then the usage of Raney nickel was for a long time the only reliable method for a selective 
desulfurization of cysteine in proteins. In 2001, Yan and Dawson achieved a breakthrough by 
the combination of NCL and cysteine desulfurization. This study expanded the NCL-
desulfurization strategy by the introduction of Pd/Al2O3 catalysts.[164]
However, the selective desulfurization of the ligation site in the presence of multiple free thiol 
groups was a major problem at that time. This was solved by Pentelute and Kent who 
introduced the acetaminomethyl (Acm) group for the protection of multiple cysteine residues 
within the peptide chain. In this study, Raney nickel induced conversion of cysteine to alanine 
could be successfully applied for the total chemical synthesis of the peptide hormone amylin 
and the small trypsin inhibitor protein EETI-II.[165] These pioneering works encouraged several 
groups to extend the NCL-desulfurization strategy to other desulfurization agents and amino 
acid surrogates.[166] Meanwhile the “alanine ligation” strategy has been expanded to the usage 
of unnatural β- or γ-mercapto amino acids derivatives, which enable the NCL at almost each 
amino acid.[167] A significant step was also made by the development of the metal-free, 
radical-based desulfurization which is described in the following section and was a basis of 
the strategy development within this thesis. 
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3.6.1. Metal-free desulfurization of peptides 
The metal-related desulfurization using Ni or Pd catalysts is often associated with low yields 
of peptide recovery. The large surface of the sponged metal catalyst frequently leads to 
adsorption and aggregation of denatured peptides. In addition unexpected modifications such 
as hydrogenation of tryptophan or demethylthiolization of methionine have been 
observed.[164] A major disadvantage is also the instability of the thiazolidine (Thz) protecting 
group during the metal-related desulfurization, which is frequently applied for N-terminal 
protection during multiple segment ligations.[168]
In 1956, F. Hoffmann et al. reported on desulfurization of organic mercaptans using 
trialkylphophites under thermal or photochemical conditions.[169] Later, this work was 
continued by C. Walling and co-workers who initiated the reaction by catalytic amounts of 
azobisisobutyronitrile (AIBN).[170] Four decades later A. González and G. Valencia were the 
first who proposed the specific desulfurization of cysteine and cysteine derivatives in peptides 
and proteins by means of photochemical initiated desulfurization with triethylphosphite. 
However, this study was only conducted with simple amino acids and allowed no deeper 
conclusions about possible side reactions or peptide modifications.[171] This was changed in 
2007 by Q. Wan and S. Danishefsky who introduced the first selective free-radical 
desulfurization of glycopolypeptides in the presence of TCEP, the radical initiator  
2,2'-azobis[2-(2-imidazolin-2-yl)propane] dihydrochloride (VA-044) and a free thiol as a 
proton donator (scheme 3.10).[172]
Scheme 3.10: Proposed reaction mechanism of the radical-based desulfurization of cysteine using TCEP and the 
radical initiator VA-044.  
The reaction is compatible with conditions used for the native chemical ligation and can be 
performed as a one-pot ligation and desulfurization procedure.[173] Today, the free radical-
based desulfurization by Danishefsky is one of the easiest and most efficient strategies to 
convert cysteine or other unnatural mercapto amino acids into their desulfurated 
counterparts. This radical-based desulfurization relies on the reaction of the thiol group with 
trisubstituted organic phosphines. In the presence of a radical initiator, the thiol function of 
cysteine is deprotonated under formation of the thiyl radical. This radical intermediate reacts 
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with TCEP to create a phosphoranyl radical which is decomposed in the further course of the 
reaction, creating an alkyl radical. The final alanine residue is created after abstraction of a 
hydrogen atom from a proton donating thiol compound such as glutathione. This hydrogen 
exchange creates a new thiyl radical which can restart the radical cycle or react with another 
thiyl radical.[168, 174] In combination with the native chemical ligation this desulfurization 
strategy was chosen for the synthesis of multiple proteins.[175]
Very recently, the P-B desulfurization method was reported from the X. Li group who 
described TCEP activation by boron compounds (e.g. NaBH4, LiEt3BH) as a particularly mild 
alternative to the metal-based or radical-initiated desulfurization. In contrast to the radical 
initiation, the P-B desulfurization proceeds via a ylide like phosphine–borane complex. 
Possible radical based side reactions like the cleavage of sensible photochemical amino acid 
derivatives could be prevented by this approach. In addition, the authors describe this strategy 
as a reliable and robust method with high yields. So far this method has been successfully 
applied for the synthesis of ubiquitin, γ-synuclein, and histone H2A.[176] Due to solubility 
problems, desulfurization of hydrophobic transmembrane peptides using the mentioned above 
methods is frequently incomplete or even impossible, which clearly represents an urgent need 
for the development of desulfurization strategies for highly hydrophobic peptides. 
3.6.2. Cleavage of the Acm-protection group 
The sulfhydryl function of cysteine is by far the most reactive group within the sequence of 
native proteins. In nature, thiol groups play a crucial role for maintaining the active 
conformation of proteins over disulfide bonds or as a splicing site for inteins.[177] From the 
chemical point of view, cysteine represents a possible ligation site for the native chemical 
ligation.[20a] The high reactivity of cysteine makes the search for reliable and efficient 
protecting groups necessary. A protecting group that has gained particular importance 
alongside the trityl and MeBzl[178] group is the acetaminomethyl (Acm) group. Since its first 
description Acm-protected cysteine has been used multiple times for the total chemical 
synthesis of medium-sized proteins by NCL and desulfurisation.[179]
Figure 3.7: Acm deprotection of peptides by different deprotection agents described in literature. 
In general Acm is stable under basic, acidic or reductive conditions which allow its use for 
Fmoc- and Boc-chemistry as well as a protecting group for reductive desulfurizations. 
Challenging is the mild removal of Acm in the presence of an unprotected peptide chain with 
a variety of functional groups. Over the course of time several deprotection strategies for Acm 
have been published. The first removal strategy was proposed by Veber and co-workers using 
mercury (Hg) ions under release of H2S.[180] Nevertheless, due to the high toxicity of mercury, 
this method is rather unpopular. Another strategy relies on the oxidative removal of Acm by 
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elemental iodine. This method is particularly useful for Acm removal of two adjacent Acm 
protected cysteine residues resulting in disulfide formation.[181] However, some sources 
describe Acm deprotection with iodine also for peptides with only one Acm protected thiol 
group within the peptide sequence.[182] Other strategies, that were investigated thoroughly, 
involve the usage of sulfur containing organic compounds such as 2-pyridine sulfenyl 
chloride[183] or 2,2′-dithiobis(5-nitropyridine) (DTNP).[184] However, most of these methods 
suffer from unexpected side reactions and peptide modifications.  
The most practical method is the usage of silver salts such as silver tetrafluoroborate 
(AgBF4)
[185] or silver acetate (AgOAc).[186] Fujii and colleges discovered that especially silver 
trifluoromethanesulfonate (AgOTf) in the presence of 2% anisole, dissolved in concentrated 
TFA, is one of the most efficient mixtures for Acm cleavage.[187] Since then, AgOTf mediated 
Acm cleavage has been used in multiple publications after NCL and cysteine 
desulfurization.[188]
3.7. The influenza B proton channel sequence BM2(1-51) 
Every year more than 3-5 million people worldwide suffer from an infection with influenza A, 
B or C with 250.000-500.000 deaths.[189] The consistently high number of new infections and 
yearly death toll surpasses even the cases of breast cancer-related deaths in the united states 
and places influenza in the top ten causes of premature death.[190] Despite the existence of 
vaccines, patients who suffer from immunodeficiency or show allergies against vaccine 
components are unsuitable for immunization. The investigation and development of antiviral 
drugs for a complementary therapy is therefore an essential aim of medical research. As 
potential target for antiviral drug treatment M2 proton channels were identified which belong 
to the smallest known bona fide ion channels with exceptionally high ion selectivity.[191] M2 
proton channels are embedded in the virus particle membrane and function as pH gated 
proton channels. At the beginning of the infection the virus particle enters the cell by 
receptor-mediated endocytosis. The low pH in the endosome causes a selective transport of 
protons through the M2 channel pore that increases the pH in the virus capsule.[192] This 
acidification leads to dissociation of the matrix protein 1 (M1) from the ribonucleoprotein 
(RNP) allowing the release of viral ribonucleoproteins (vRNPs) into the cytoplasm of the host 
cell. This process is essential to the replication of all influenza virus subtypes.[193]
It is thought that over 20% of all influenza infections in recent years are related to the 
influenza B variant.[194] While some antiviral drugs like M2 proton channel inhibitors  
(e.g. amantadine, rimantadine) are available for the influenza A treatment, no effective M2 
inhibitors for influenza B exist.[195] Several groups investigated structural properties of BM2 to 
understand the function of the proton channel.[189a, 190, 196] BM2 is a 109 amino acid long, left-
handed, integral type III protein which is embedded as a homotetramer in the membrane of 
the virus capsid. The coiled-coil arrangement of the four TM domains form a stable channel 
pore by itself, which conducts protons highly selectively and unidirectionally from the N- to 
the C-terminus.[197] The BM2 proton channel of influenza B is functional similar to its 
influenza A counterpart but shares only 24% sequence homology with AM2.[195] Despite the 
minor sequence homology between BM2 and AM2, both channel variants possess the 
important HXXXW sequence motif. In BM2 this motif is located inside the channel pore 
including the residues His19 and Trp23 (figure 3.8).[4]
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Figure 3.8: a) HXXXW motif (His19, Trp23) within the open BM2 channel pore. Amino acid Ile21 in the WT is 
directed to the hydrophobic membrane. b) BM2 homotetramer side view.[B] c) BM2 channel pore formed by the 
stable arrangement of the four TM domains.[B]
Mutation studies in which one of these amino acids are replaced proved that both amino acids 
are essential for the function of the channel.[198] In recent years, further important core-lining 
residues were identified by NMR studies in lipid bilayers. Mei Hong and co-workers were able 
to investigate the proton conduction and hydration of the BM2 channel pore. They also 
provided further evidence for the contribution of His27 to the proton-dissociation rate of 
His19, which regulates the channel activity.[196a] As a result the pKa value of His19 in BM2 is 
significant lower than that of His37 in AM2. Based on multiscale computer simulations, Zheng 
et al. even proposed the existence of a second, reversed WxxxH motif within the BM2 channel 
pore due to the interaction of His29 and Trp23.[189a] In addition, the channel interior of BM2 
is also lined with a number of polar residues which accelerate the proton flux rate across the 
channel pore. It is thought that several Ser, Gln and Asn residues create a hydrophilic 
pathway that relays protons to the WxxxH gating element. In fact, mutation studies of one of 
these polar residues showed significantly decreases in channel activity.[4, 197]
Figure 3.9: Peptide sequence of the 109 amino acid long influenza B M2 proton channel (PDB database: 2KIX). The 
dark letters show the peptide sequence BM2(1-51) which was synthesized during this thesis.[4, 195]
Previous studies obtained BM2 by expression in Escherichia coli or Xenopus oocytes fused with 
a polyhistidine or glutathione S-transferase tag (GST).[199] Very recently, Mei Hong et al. 
expressed uniformly 13C- and 15N-labelled His6-TEV-BM2(1-51) for NMR studies in  
POPC/POPG bilayers. This domain was chosen since BM2(1-51) includes the proton 
conduction channel pore as well as the cytoplasmic section for membrane targeting.[195] They 
found that residues 6-28 form a well-ordered α-helix, which represent the trans membrane 
domain (TMD) of the BM2 channel, while residues 1-5 and 29-35 showed chemical shifts of a 
random coil.[195] However, residues 36-44 remained structurally unknown. 
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4. Motivation and Aims of the Thesis 
The total chemical synthesis of membrane-associated peptides and medium-sized proteins 
offers many advantages over alternative strategies, such as protein expression. Synthetic 
peptides can be synthesised faster, customized depending on the purpose of research or 
isotopically labelled (e.g. 13C, 15N).[2] Moreover, the combination of SPPS and NCL is by far 
the shortest and fastest route to obtain the peptide of interest in a multi-milligram scale. 
Although preparation of good water soluble proteins by NCL is a routine procedure, chemical 
synthesis of medium-sized, hydrophobic peptides is often accompanied by poor solubility, 
aggregation and inefficient ligation yields.[200] Synthetic access by “classical” ligation 
strategies is usually limited due to solubility problems of hydrophobic peptide fragments in 
the ligation buffer. 
An especially important class of hydrophobic peptides and proteins include membrane 
proteins which make up more than 23% of the human proteome.[201] Today, membrane 
proteins are targets for more than 60% of all available pharmaceutical drugs as they are 
involved in essential biochemical processes inside and outside of the cell membrane.[201a, 202]
In the past, structure-based drug design with the help of membrane proteins led to the 
development of new and improved pharmaceutical ingredient as for G protein-coupled 
receptors (GPCRs)[203], proton channels[204], voltage gated-ion channels[205] and many 
more.[206] Reliable synthetic routes for transmembrane peptides, which allow the production 
of hydrophobic peptides in multi-milligram amounts, are therefore essential for the molecular 
characterisation and function studies of transmembrane peptides. Over the last decades, the 
development of new synthetic approaches for hydrophobic peptides and transmembrane 
proteins turned into a “booming” field in modern peptide chemistry (chapter 3.3). 
This thesis is focused on the development of an oxo-ester based ligation strategy, employing 
internal modifications and external conditions, in order to facilitate chemical production of 
highly hydrophobic peptides and protein domains at a multi-milligram scale. For that purpose, 
temporary solubilizing tags (internal modifications) and the addition of fluorinated alcohols 
or ionic liquids (external conditions) were studied and discussed. The results of these 
experiments represented within this thesis contribute and enable the structural and functional 
characterizations of transmembrane proteins (TMP), interaction studies of TMPs potential 
drug leads or development of membrane-based bio-inspired materials.  
Overall, the following five aims can be formulated and represent the content of this thesis 
(Figure 4.1): 
(i) Development of a novel strategy for the synthesis of transmembrane peptides 
by combination of oxo-ester Hmp-peptides and C-terminal solubilizing tags; 
(ii) Exploration of the NCL based on the strategy developed in part (i) and 
comparison of a set of removable solubilizing tags;  
(iii) Exploration of NCL based on the strategy developed in part (i) in terms of 
variation of ligation media: application of fluorinated alcohols as additives; 
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(iv) Exploration of NCL based on the strategy developed in part (i) in terms of 
variation of ligation media: application of ionic liquid [C2mim][OAc] as 
ligation media;  
(v) Development of novel follow-up protocols: desulfurization and Acm-group 
cleavage. 
Figure 4.1: Schematic representation of thesis aims. 
A peptide of interest which represents a promising drug target and gathered much attention 
in recent years is the influenza virus B protein BM2, especially its fragment BM2(1-51), since 
it includes part of the sequence which is not yet structurally characterized. Various attempts 
have been undertaken to chemically synthesize the BM2(1-51) sequence at once,[3] however, 
all attempts failed. These circumstances make BM2(1-51) an ideal model system for the 
development of a new production strategy for highly hydrophobic peptides. The ligation 
strategy developed during this thesis was used for the synthesis of the final target peptides 
[Leu10]BM2(1-51) and [Leu21]BM2(1-51) which are presented in table 4.1. 
Synthesized variants of BM2(1-51)
[Leu21]BM2(1-51) MLEPFQILSI CSFILSALHF LAWTIGHLNQ IKRGINMKIR IKGPNKETIN R
[Leu10]BM2(1-51) MLEPFQILSL CSFILSALHF IAWTIGHLNQ IKRGINMKIR IKGPNKETIN R
Table 4.1: Sequences of [Leu21]BM2(1-51) and [Leu10]BM2(1-51) which represent the final target peptides of this 
thesis.
The synthesized peptide variants [Leu10]BM2(1-51) and [Leu21]BM2(1-51) can be applied for 
structural investigations of the BM2 proton channel sequence of influenza B. Analysis by 
circular dichroism (CD) spectroscopy can be used to determine the alpha-helical content 
within the BM2(1-51) sequence. Since some sections of BM2(1-51) are still structural 
uncharacterised, these studies contribute to the structural elucidation of this promising drug 
target. 
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5. Results and Discussion 
5.1. Investigation of internal modifications 
5.1.1. Synthesis of 2-Hydroxy-3-(triphenylmethyl)thio-propanoic acid 
In recent decades the thioester-forming rearrangement group Hmp was proposed several 
times for the synthesis of C-terminal, thioester-forming, oxo-ester peptides.[62] Already P. Botti  
et al.[61] and F. Liu[60] et al. were able to demonstrate that Hmp-peptides can serve as 
precursors for the production of peptide thioesters. However, no commercial access and 
comparatively high hydrolysis rates limited the interest in Hmp-peptides within the scientific 
community. In order to facilitate the access to Hmp, an economically useful route for 
synthesis was investigated during this thesis. As most valuable economically route, the 
strategy by K. Wisniewski was adopted and modified in the course of this work  
(chapter 3.2.5). In the two-step strategy by K. Wisniewski trityl-protected Hmp(Trt) was 
produced by oxidation of (R)-3-chloro-1,2-propanediole to (R)-3-chloro-2-hydroxypropanoic 
acid using 68% nitric acid followed by substitution of the chlorine leaving group with 
triphenylmethyl thiol (scheme 3.7c). In the literature enantiopure (L)-Hmp(Trt) was obtained 
with an overall yield of 58%.[63] However, the use of the enantiopure precursor (R)-3-chloro-
1, 2-propanediole is expensive compared to the use of inexpensive, racemic 3-chloro-1, 2-
propanediole as a precursor.  
During this thesis a protocol for the production of racemic, trityl-protected Hmp was 
developed based on the previous work of K. Wisniewski et al. (chapter 9.1). As a result an 
improved protocol was created which allowed the production of racemic Hmp(Trt) with an 
overall yield of 66%. The cheaper precursor 3-chloro-1, 2-propanediole and the higher yield 
are the main advantages of the newly developed protocol which represent an economically 
more valuable synthetic route for the production of trityl-protected Hmp.  
After synthesis following protocols 9.1.1 and 9.1.2, the final Hmp(Trt) building block was 
obtained as a white powdered solid which could be applied using a standard coupling 
procedure by Fmoc-based SPPS. The structure and purity of racemic Hmp(Trt) was confirmed 
by NMR spectroscopy and LC-MS. In Figure 5.1 the LC-MS of the synthesized Hmp(Trt) 
building block is depicted. The chromatogram shows one main product peak at 12.9 min. 
Mass spectra of the retention time between 12.72 – 13.17 min shows the negative charged 
molecular ion peak of [Hmp(Trt)-O-]- at 362.9 m/z and the negatively charged fragmentation 
product [Trt-S-]- at 275.2 m/z. 
Figure 5.1: LC-MS measurement of the racemic Hmp building block. Liquid chromatography was performed at 
220 nm wavelength. The main peak at 12.9 min belongs to Hmp(Trt).  
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Intermediate 3-Chloro-2-hydroxypropanoic acid 
Structure of intermediate 
3-Chloro-2-hydroxypropanoic acid
2-Hydroxy-3-(triphenylmethyl)thio-propanoic acid 
Structure of the final product 2-Hydroxy-3-
(triphenylmethyl)thio-propanoic acid (Hmp(Trt)) 
Figure 5.2: Pictures and chemical structures of the synthesized intermediate 3-chloro-2-hydroxypropanoic acid 
(upper picture) and the final product 2-Hydroxy-3-(triphenylmethyl)thio-propanoic acid (lower picture). 
a) 1H-NMR in DMSO-D6 b) 13C-NMR in DMSO-D6
Figure 5.3: 3-Chloro-2-hydroxypropanoic acid in DMSO-D6 at 300 MHz, a) 1H-NMR (DMSO, 300 MHz, 300 K):  
δ (ppm) = 4.32 – 4.29 (t, 2H), 3.77 – 3.76 (d, 1H) 2.52 and b) 13C-NMR (DMSO, 300 MHz, 300 K): δ = 172.40, 70.05, 
47.08, 39.95 – 38.84. 
a) 1H-NMR in CDCl3 b) 13C-NMR in CDCl3
Figure 5.4: 2-Hydroxy-3-(triphenylmethyl)thio-propanoic acid in CDCl3 at 500 MHz, a)
1H-NMR (CDCl3, 500 MHz, 
300 K): δ (ppm) = 2.63 (2H, CH2
β), 3.81 (1H, CHα), 7.12-7.38 (15H, Trt) and b) 13C-NMR (CDCl3, 500 MHz, 300 K):  
δ (ppm) = 36.10 (CH2
β), 67.05 (Ph3, CH
α), 68.96, 126.92, 127.16, 128.06, 129.54, 144.32 (phenyl). 
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5.1.2. Investigation of the stereochemistry of Hmp-peptides 
The production of stereochemically pure peptides is one of the most important issues in 
chemical peptide synthesis. While peptide expression in bacteria or yeasts usually lead to 
stereochemically pure L-amino acid composed peptides, chemical peptide synthesis can cause 
racemisation of amino acid residues. To reduce those unwanted side reactions, additives like 
HOAt (1-hydroxy-7-azabenzotriazol) are commonly utilized for Fmoc-SPPS.  
However, peptides synthesised under novel coupling conditions or with different coupling 
reactants such as DEAD and PPh3 need to be investigated for their stereochemistry. For this 
reason, two peptide variants Phe-(L-Leu)-Hmp and Phe-(D-Leu)-Hmp were synthesized 
according to instruction 9.2. Since Hmp(Trt) was obtained and used as a racemic mixture, 
two peaks for each of both peptide variants were expected in the chromatogram (figure 5.6). 
The first amino acids L-Leu or D-Leu, respectively, were coupled by the Mitsunobu reaction 
using the method of Liu et al.[60] In order to evaluate the amount of racemization, both 
peptides were analysed by RP-HPLC and ESI mass spectrometry. The figures below show the 
structures and stereochemistry of the expected model peptides. 
a) L-Hmp-L-Leu-L-Phe b) D-Hmp-L-Leu-L-Phe
c) L-Hmp-D-Leu-L-Phe d) D-Hmp-D-Leu-L-Phe
Figure 5.5: Structures of obtained peptide diastereomers with three stereogenic centers. 
All four peptide variants a), b), c) and d) are diastereomers with three different stereocenters. 
These diastereomers have the same molecular weight but different retention times in the 
chromatogram. In Figure 5.6 the chromatograms of Hmp-L-Leu-Phe and Hmp-D-Leu-Phe are 
compared. Both upper chromatograms show two peaks with different retention times. 
Although all diastereomers differ only in stereochemistry, retention times with differences of 
more than 1 min can be observed. This experiment impressively shows the effect of 
stereochemistry on the RP-HPLC results. Even more important is that no racemisation 
products can be observed in the chromatogram which makes the used coupling conditions 
practical for the synthesis of Hmp-peptides. 
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Figure 5.6: Stacked RP-HPLC chromatograms of dipeptides L-Phe-L-Leu-Hmp (upper chromatogram) and  
L-Phe-D-Leu-Hmp (middle chromatogram). The lower chromatogram displays the coelution of both peptides.  
RP-HPLC conditions: C18 column (150 x 4 mm, 100 Å pore diameter, 3 µm particle size), gradient 0 – 80% 
acetonitrile in 15 min, flow rate 1 ml/min.  
ESI-MS results of both peptide variants Phe-(L)-Leu-Hmp and Phe-(D)-Leu-Hmp have the 
same isotopic pattern and molecular weight of 382.18 m/z. The experimental isotopic pattern 
of both diastereomers is in perfect line with the simulated isotopic pattern (figure 5.7). 
Figure 5.7: ESI-MS of model peptides L-Phe-L-Leu-Hmp (upper spectrum) and L-Phe-D-Leu-Hmp (lower spectrum).  
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5.1.3. Overview of the synthesised peptides 
As mentioned in chapter 4, the influenza virus B protein was chosen as a model system for 
this thesis mainly because of its important role in the multiplication cycle of influenza B. The 
hydrophobic character makes BM2(1-51) to an ideal model peptide for the development of 
new synthetic strategies for transmembrane peptides. This chapter is focused on the 
development of efficient synthetic routes for transmembrane peptides by combination of  
oxo-ester Hmp-peptides, as thioester-forming precursors, in combination with C-terminal 
solubilizing tags. In order to test this strategy, short model Hmp-peptides were synthesised by 
Fmoc-based SPPS. As a model sequence the first five amino acids of the BM2 ligation site 
were chosen.   
The following tables provide an overview of the N-terminal cysteine peptides (table 5.1), the 
model Hmp-peptides (table 5.2) and the complete Hmp-peptide fragments (table 5.3) which 
were synthesised during this thesis. 
Table 5.1: Synthesized N-terminal Cys peptides, (a) monoisotopic molecular mass and (b) average molecular mass. 
No. N-terminal Cys Peptides Formula MW[Da]
a MW[Da]
b
P1 [Cys22]BM2(22-35) C73H120N24O17S 1636.96 1637.95
P2 [Cys22]BM2(22-51) C154H264N52O39S2 3529.97 3532.20
P3 [Cys11]BM2(11-51) C214H353N65O52S2 4729.64 4732.64
Table 5.2: Synthesized model Hmp-peptides, (a) monoisotopic molecular mass and (b) average molecular mass. 
No. BM2 Model Hmp-Peptides Formula MW[Da]
a MW[Da]
b
P4 [Ile21]BM2(17-21)-Hmp C33H50N8O7S 702.36 702.86
P5 [Ile21]BM2(17-21)-Hmp-ADO C39H61N9O10S 847.43 848.02
P6 [Ile21]BM2(17-21)-Hmp-ADO2 C45H72N10O13S 992.5 993.18
P7 [Leu21]BM2(17-21)-Hmp C33H50N8O7S 702.36 702.86
P8 [Leu21]BM2(17-21)-Hmp-ADO C39H61N9O10S 847.43 848.02
P9 [Leu21]BM2(17-21)-Hmp-ADO2 C45H72N10O13S 992.5 993.18
P10 [Leu21]BM2(17-21)-Hmp-Lys5 C63H109N17O13S 1343.81 1344.71
P11 [Leu21]BM2(17-21)-Hmp-ADO-Lys5 C69H122N19O15S 1488.91 1489.89
P12 [Leu21]BM2(17-21)-Hmp-ADO2-Lys5 C75H131N19O19S 1633.959 1635.02
P13 [Leu21]BM2(17-21)-Hmp-Arg5 C63H109N27O13S 1483.842 1484.78
P14 [Leu21]BM2(17-21)-Hmp-ADO-Arg5 C69H120N28O16S 1628.916 1629.93
P15 [Leu21]BM2(17-21)-Hmp-ADO2-Arg5 C75H131N29O19S 1773.99 1775.09
Table 5.3: Complete Hmp-peptide fragments of BM2, (a) monoisotopic mass and (b) average mass. 
No. Complete BM2 Hmp-Peptide Fragments Formula MW[Da]
a MW[Da]
b
P16 [Leu10]BM2(1-10)-Hmp C59H96N12O16S2 1292.65 1293.59
P17 [Ile21]BM2(1-21) C116H181N25O27S2 2420.30 2421.96
P18 [Cys(Acm)11]BM2(1-21)-Hmp C122H190N26O30S3 2595.33 2597.17
P19 [Cys(Acm)11]BM2(1-21)-Hmp-ADO2 C134H212N28O36S3 2885.47 2887.48
P20 [Cys(Acm)11]BM2(1-21)-Hmp -ADO-Lys5 C158H261N37O38S3 3380.88 3383.19
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5.1.4. Synthesis of N-terminal Cys-peptides 
The N-terminal cysteine peptides P1 [Cys22]BM2(22-35), P2 [Cys22]BM2(22-51) and P3
[Cys11]BM2(11-51) were synthesized by automated, microwave-assisted Fmoc-based SPPS 
according to instruction 9.3. The synthesis of P1 and P2 succeeded by a standard Fmoc-SPPS 
coupling cycle while additional washing steps were necessary to obtain the 41-mer peptide P3
(appendix 15.1.4).[207] The purification of the crude peptides was performed via preparative 
RP-HPLC following instruction 8.1.7. All N-terminal cysteine peptides were analysed by 
analytical RP-HPLC and mass spectrometry. For peptides P1 and P2,  
MALDI-TOF-MS was used while peptide P3 was identified by ESI-MS. All products showed the 
correct molecular weight and isotopic pattern which were in line with the simulated patterns. 
Analytical RP-HPLCs displayed clean products with one main peak at 7.89 min (P1), 8.18 min 
(P2) and 14.60 min (P3), respectively. The yields of the peptides are summarized in table 
5.4. 
Figure 5.8: Analytical RP-HPLC of N-terminal cysteine peptides. P1 [Cys22]BM2(22-35), C18 column (150 x 4 mm, 
100 Å pore diameter, 3 µm particle size), gradient 20 - 80% acetonitrile in 20 min, flow rate 1 ml/min. P2
[Cys22]BM2(22-51), C18 column (150 x 4 mm, 100 Å pore diameter, 3 µm particle size), gradient 20 - 40%, flow rate 
1 ml/min. P3 [Cys11]BM2(11-51), C4 column (125 x 4 mm, 300 Å pore diameter, 5 µm particle size), gradient  
20 - 95% acetonitrile in 30, flow rate 1 ml/min. 
Table 5.4: Results of N-terminal cysteine peptides P1, P2 and P3. 
Entry Peptide Found [m/z] Crude Purified Yield
P1 [Cys22]BM2(22-35) 1637.921+ 192 mg 85.2 mg 26.0%
P2 [Cys22]BM2(22-51) 3529.351+ 528 mg 40.7 mg 6.2%
P3 [Cys11]BM2(11-51) 676.677+ 478.6 mg 63.4 mg 5.3%
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5.1.5. Synthesis of model Hmp-peptides 
The first three isoleucine carrying model Hmp-peptides P4 [Ile21]BM2(17-21)-Hmp, P5 
[Ile21]BM2(17-21)-Hmp-ADO and P6 [Ile21]BM2(17-21)-Hmp-ADO2 were synthesized by 
manual Fmoc-SPPS according to procedure 9.2. In this first study, the most efficient coupling 
and Fmoc-deprotection conditions were tested based on previous experiments by F. Liu and 
co-workers.[60] While Hmp(Trt) could be easily coupled using a standard Fmoc-based 
protocol, the coupling of the next amino acid at Hmp(Trt) turned out to be decisive step for 
the production of Hmp-peptides. The first tested coupling method described by F. Liu et al. 
relied on the Steglich esterification of the amino acid at the Hmp(Trt) moiety.[60] However, 
the coupling of Fmoc-Ile-OH was not possible and completely failed. A second more efficient 
coupling protocol by the F. Liu group relied on the Mitsunobu reaction between Fmoc-Ile-OH 
and the Hmp(Trt) moiety.[60, 208] However, this single coupling protocol resulted in only 34% 
loading capacity of isoleucine on the resin support.[60] The most efficient procedure, a double 
coupling protocol developed during this thesis, resulted in much higher loading capacities of 
over 60% for all tested amino acids (protocol 9.2). All following amino acids in the peptide 
sequence were coupled by standard Fmoc-based SPPS conditions. The final peptides were 
cleaved from the resin support by a standard TFA cleavage protocol. Figure 5.9 shows the RP-
HPLC chromatograms of crude peptides P4, P5 and P6 where both diastereomers can be 
observed as a result of the use of racemic Hmp as discussed in chapter 5.1.2. 
Figure 5.9: Analytical RP-HPLC of crude peptides P4, P5 and P6. HPLC conditions: C18 column (150 x 3.9 mm, 100 Å 
pore diameter, 5 µm particle size), gradient 20 – 50% acetonitrile in 20 min, flow rate 1 ml/min. 
Table 5.5: Results of model Hmp-peptides P4, P5 and P6. 
Entry Peptide Theo. [m/z] Found [m/z] Crude Yield
P4 [Ile21]BM2(17-21)-Hmp 352.182+ 352.192+ 11.0 mg 19.3%
P5 [Ile21]BM2(17-21)-Hmp-ADO 424.722+ 424.722+ 14.0 mg 73.6%
P6 [Ile21]BM2(17-21)-Hmp-ADO2 497.26
2+ 497.262+ 11.2 mg 50.2%
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To confirm the presence of diastereomers, the model peptide P4 was investigated by LC-MS. 
Both peaks in the chromatogram showed the same molecular weight and isotopic pattern in 
the mass spectra (figure 5.10). 
a)
b)
Figure 5.10: a) LC-MS of crude peptide P4. RP-HPLC conditions: C8 column (150 x 4.6 mm, 5 µm particle size), 
gradient 20 - 80% acetonitrile in 25 min, flow rate of 0.5 ml/min, b) MS of the separated diastereomers. The upper 
spectrum shows the retention time at 11.8 min. The lower mass spectrum shows the retention time of 12.2 min. 
Both peaks have the same isotopic pattern. 
Since Hmp is a trifunctional linker, peptides with temporarily attached solubilizing tags can 
be produced. This approach was investigated with the attachment of 8-(9-
Fluorenylmethyloxycarbonyl-amino)-3,6-dioxaoctanoic acid (ADO) and ADO2 tags at the Hmp 
moiety. The ADO chain is composed of alternating carbon and oxygen units which can 
interact with polar protic solvents. This interaction is thought to increase the solubility of 
hydrophobic peptides. Due to minor interactions with the stationary phase of the column, 
retention times to a faster elution can be observed in RP-HPLC if ADO units are attached at 
the C-terminus (figure 5.9). The shorter retention times of model peptides P5 and P6 indicate 
a minor change of the hydrophobicity compared to the non-ADO carrying peptide P4. This 
result showed that the ADO tag can not only be used to increase the distance between the 
ligation site and the solubilizing tag, ADO units can also be applied directly as solubility-
enhancing tags for short hydrophobic peptide sequences. In combination with polyionic tags 
such as polylysine or polyarginine, ADO represents an efficient solubility-improving spacer. 
While the synthesis of the Ile-carrying peptides P4, P5 and P6 succeeded with the newly 
developed double coupling protocol by the Mitsunobu reaction, the C-terminal isoleucine 
moiety represented a potential obstacle for subsequent ligation experiments. It is long known 
that some amino acids such as Ile at the C-terminal ligation site significantly influence the 
ligation efficiency. Already Liu et al. were able to demonstrate that ligation yields at  
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C-terminal Ile moieties dramatically drop.[60] For this reason, amino acid Ile21 was mutated to 
Leu21 for the production of the three leucine carrying model peptides P7 [Leu21]BM2(17-21)-
Hmp, P8 [Leu21]BM2(17-21)-Hmp-ADO and P9 [Leu21]BM2(17-21)-Hmp-ADO2. Similar to 
previous experiments two diastereomers could be detected in each chromatogram of all three 
peptide variants. Again, ADO carrying peptides P8 and P9 displayed shorter retention times in 
HPLC. However, the peak area of the first peak decreased with raising length of the ADO 
spacer. Analysis via ESI-MS revealed the same isotopic pattern for each diastereomer. All 
three crude peptides showed only small amounts of impurities in the chromatogram. Due to 
their high purity, model peptides P7, P8 and P9 were directly used for the following ligation 
experiments without further purification. 
Figure 5.11: Analytical RP-HPLC of crude peptides P7, P8 and P9. HPLC conditions: C18 column (150 x 3.9 mm, 100 Å 
pore diameter, 5 µm particle size), gradient 20 - 50% acetonitrile in 20 min, flow rate 1 ml/min.
The synthesis on ADO preloaded resin caused a drop of resin loading from 0.25 mmol/g for 
peptide P7 to 0.19 mmol/g for peptide P8 and 0.18 mmol/g for peptide P9. Surprisingly, the 
loading capacity of ADO preloaded resins dropped with an increasing spacer length. One 
explanation for this finding is the exceeding of the optimal spacer length, which is more likely 
to form undefined “knot-like” structures, which limiting access to the N-terminus of the 
spacer. 
Table 5.6: Results of model Hmp-peptides P7, P8 and P9. 
Entry Peptide Theo. [m/z] Found [m/z] Crude Yield
P7 [Leu21]BM2(17-21)-Hmp 352.182+ 352.182+ 71.8 mg 61.9%
P8 [Leu21]BM2(17-21)-Hmp-ADO 424.722+ 424.722+ 38.3 mg 54.8%
P9 [Leu21]BM2(17-21)-Hmp-ADO2 497.26
2+ 497.262+ 28.1 mg 34.3%
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Peptides with penta-lysine tags 
In order to develop temporarily-bound solubilizing tags, which are expected to dissolve highly 
hydrophobic peptides, penta-lysine tags were attached at the Hmp moiety. The amino acid 
lysine carries a primary amino group which is chargeable under acidic conditions. The 
protonated form of lysine dramatically raises the solubility of hydrophobic peptides. Previous 
studies indicate that lysine is the most efficient amino acid for the dissolution of poorly water 
soluble peptides.[80] However, the steric hindrance of the bulky 2-methylpropan-2-
yl)oxycarbonyl (Boc) side chain of Fmoc-L-Lys(Boc)-OH can lead to a low resin loading after 
coupling of multiple lysine residues. In order to find optimal synthetic conditions three 
different model peptides P10 [Leu21]BM2(17-21)-Hmp-Lys5, P11 [Leu
21]BM2(17-21)-Hmp-
ADO-Lys5 and P12 [Leu21]BM2(17-21)-Hmp-ADO2-Lys5 were synthesized. All peptides were 
synthesized manually on penta-lysine preloaded resin supports according to instruction 9.2. 
HPLC analysis of the crude peptides revealed several side products. In Figure 5.12 the 
chromatograms of the crude products P10, P11 and P12 are highlighted. 
Peptide P10 was synthesized without any spacer unit between Hmp and the penta-lysine tag. 
However, the synthesis of P10 failed (figure 5.12 upper chromatogram). The HPLC 
chromatogram of crude product P10 showed no main peak that could be assigned to the 
searched peptide. Moreover, MALDI-TOF-MS were not able to identify the calculated mass in 
crude product P10. The big steric hindrance of the penta-lysine tag was considered a reason 
for the unsuccessful synthesis. The second model peptide P11 and the third model peptide 
P12 were variants with one and two ADO spacer units between Hmp and the penta-lysine tag.  
Figure 5.12: Analytical RP-HPLC of peptide P10 (upper chromatogram), P11 (middle chromatogram) and P12 (lower 
chromatogram). RP-HPLC was performed with a C18 column (150 x 4 mm, 100 Å pore diameter, 3 µm particle size). 
Gradient: 0 –50% acetonitrile in 20 min, flow rate 1 ml/min. 
The chromatograms of crude peptides P11 and P12 showed two main products, at 14.32 min 
and 20.12 min for crude peptide P11, and 15.37 min and 20.47 min for crude peptide P12,
respectively. MALDI-TOF MS measurements of these main peaks confirmed the right peptides 
at retention times of 20.12 min and 20.47 min corresponding to P11 and P12. The main side 
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products SP11 and SP12 were identified as (Leu)2-Hmp-ADO-Lys5 and (Leu)2-Hmp-ADO2-
Lys5. To investigate the production of side product SP11, test cleavages after the coupling of 
ADO (1), Hmp (2) and Leu (3) were performed. These results proved that side product SP11
was formed during the Mitsunobu reaction. The mass spectra of these test cleavages are 
shown in the appendix (chapter 15.1.2). 
Table 5.7: Found molecular weights and possible products after the test cleavages (1), (2) and (3). 
Entry Test cleavage Found [m/z] Found product
1 ADO-Lys5 803.66
1+ ADO-Lys5
2 Hmp-ADO-Lys5 907.67
1+ Hmp-ADO-Lys5
3 Leu-Hmp-ADO-Lys5 1132.81
1+ (Leu)2-Hmp-ADO-Lys5
After cleavage from resin and lyophilisation, crude peptides P11 and P12 were purified 
according to instruction 8.1.7 and analysed via analytical RP-HPLC and MAILDI-TOF-MS. 
Both peptides showed the typical double peak for Hmp-peptides, however, the difference in 
the retention time of both diastereomers was too small for baseline separation.  
The chromatograms showed no signs of impurities or oxidised side products. The mass spectra 
and measured isotopic pattern were in accordance with the simulated isotopic pattern of the 
expected chemical formulas for P11 and P12 (figure 5.13). 
Figure 5.13: Analytical RP-HPLC of model peptides P11 and P12. HPLC was performed with a C18 column  
(150 x 4 mm, 100 Å pore diameter, 3 µm particle size), gradient 15 - 45% acetonitrile in 30 min, flow rate 1 ml/min. 
Table 5.8: Results of Hmp-model peptides P11 and P12. 
Entry Peptide Found [m/z] Crude Purified Yield
P11 [Leu21]BM2(17-21)-Hmp-ADO-Lys5 1489.02
1+ 35.7 mg 1.36 mg 1.10%
P12 [Leu21]BM2(17-21)-Hmp-ADO2-Lys5 1633.92
1+ 42.2 mg 2.35 mg 1.74%
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Peptides with penta-arginine tags 
In multiple studies arginine tags were used to enhance peptide solubility for purification or 
NCL.[103-104, 115-116] Similar to polylysine, polyarginine tags can be protonated under acidic 
conditions thus increasing the charge of the peptide. In this study the synthesis of three penta-
arginine carrying model Hmp-peptides was tested. For the synthesis of the model peptides 
P13 [Leu21]BM2(17-21)-Hmp-Arg5, P14 [Leu21]BM2(17-21)-Hmp-ADO-Arg5 and P15
[Leu21]BM2(17-21)-Hmp-ADO2-Arg5 the resin was preloaded with penta-arginine using a 
standard Fmoc-SPPS protocol according to instruction 9.2. 
Model peptide P13 was composed of five BM2-derived amino acids (BM2(17-21)), the Hmp 
group and penta-arginine as a tag. The model peptides P14 and P15 were synthesized with a 
distant increasing ADO or ADO2 spacer between Hmp and the C-terminal solubilizing tag. 
Table 5.9 shows the sequences and chemical formulas of model peptides P13, P14 and P15. 
Table 5.9: Sequences of the penta-arginine carrying model peptides P13, P14 and P15. 
Entry Chemical formula Peptide sequence
P13 C63H109N27O13S ALHFL-Hmp-RRRRR
P14 C69H120N28O16S ALHFL-Hmp-ADO-RRRRR
P15 C75H131N29O19S ALHFL-Hmp-ADO2-RRRRR
Figure 5.14 displays the RP-HPLC chromatograms of the obtained crude products P13, P14
and P15. All chromatograms have one main peak at 14.97 min (P13), 15.87 min (P14) and 
16.48 min (P15). To identify these main products MALDI-TOF mass spectroscopy was used 
(figure 5.15). 
Figure 5.14: Analytical RP-HPLC chromatograms of crude product P13 (upper chromatogram), crude product P14
(middle chromatogram) and crude product P15 (lower chromatogram). HPLC measurements were performed with 
a C18 column (150 x 4 mm, 100 Å pore diameter, 3 µm particle size), gradient 0 - 50% acetonitrile in 20 min, flow 
rate 1 ml/min. 
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After peak separation by RP-HPLC, the samples were prepared for mass spectrometry 
following instruction 8.1.5. In the samples of the crude products P13, P14 and P15 the signal 
and the isotopic pattern of the uncoupled sequences Hmp-Arg5, Hmp-ADO-Arg5 and Hmp-
ADO2-Arg5 were identified. 
a) HO-Hmp-Arg5 b) HO-Hmp-ADO-Arg5 c) HO-Hmp-ADO2-Arg5
Theoretical monoisotopic mass Theoretical monoisotopic mass Theoretical monoisotopic mass
SP 13: C33H67N21O7S SP 14: C39H78N22O10S SP 15: C45H89N23O13S
[M+H]+ = 902.53 m/z [M+H]+ = 1047.60 m/z [M+H]+ = 1192.58 m/z
Figure 5.15: Mass spectrometry of crude products P13, P14 and P15. HCCA was used as matrix for MALDI-TOF-MS.  
Figure 5.16: Mechanism of the Mitsunobu reaction with leucine as nucleophile at a penta-arginine preloaded resin. 
The steric hindrance and bulky Pbf protecting group of arginine prevent an efficient nucleophile attack. 
These results can be explained by the high steric hindrance of the Arg(Pbf) side chain which 
prevents the amino acid coupling in the Mitsunobu reaction. The SN2 mechanism of the 
Mitsunobu reaction, in which the deprotonated carboxyl group of leucine acts as nucleophile, 
relies on accessibility of the Cα-carbon atom of the Hmp group. However, bulky groups in the 
vicinity of Hmp(Trt), reduce or even prevent a successful attack of Fmoc protected amino 
acids. Even with ADO2 as spacer, no product formation could be observed by RP-HPLC and 
MALDI-TOF-MS.  
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5.1.6. Synthesis of complete BM2 Hmp-peptide fragments 
Synthesis of P16 [Leu10]BM2(1-10)-Hmp 
The synthesis of P16 BM2(1-10)-Hmp was performed by automated, microwave-assisted 
Fmoc-SPPS according to instruction 9.3. The Hmp group and the first two amino acids leucine 
and serine were coupled manually following procedure 9.2. In order to protect the basic labile 
oxo-ester bond of Hmp, 2-metylpiperidin (2-MP) was applied for the deprotection of the  
N-terminal Fmoc group. For peptide cleavage and deprotection a standard cleavage protocol 
was applied. The RP-HPLC of crude peptide P16 showed the characteristic double peak that 
belongs to the peptide diastereomers P16a and P16b. For ligation experiments both peaks 
were purified by preparative RP-HPLC. After peak separation diastereomers P16a and P16b
were reinjected and analysed by analytical RP-HPLC and ESI-MS (figure 5.17). The isotopic 
patterns of both diastereomers were in accordance with the simulated isotopic patterns. 
Figure 5.17: Analytical RP-HPLC and ESI-MS of purified peptides P16a and P16b. HPLC conditions: C4 column 
(MultoHigh U C4, 100 x 4 mm), gradient 25 -99% acetonitrile in 20 min, flow rate 1 ml/min. 
Since the Hmp(Trt) building block was used as a racemic mixture, the probability for the 
formation of both diastereomers was equal. Diastereomer P16a was acquired with a yield of 
16.5 mg (5.1%) and diastereomer P16b was obtained with 20.4 mg (6.3%). In table 5.10 the 
theoretical and the real obtained yields of P16a and P16b are listed. 
Table 5.10: Results of Hmp-peptide diastereomers P16a and P16b. 
Entry Dia. Peptide Found [m/z] Crude Purified Yield
P16a 1 [Leu10]BM2(1-10)-Hmp 647.3392+ 99.5 mg 16.5 mg 5.1%
P16b 2 [Leu10]BM2(1-10)-Hmp 647.3392+ 99.5 mg 20.4 mg 6.3%
Because the amino acid sequence of peptide P16 was derived from the N-terminal 
hydrophobic part of BM2(1-51) low solubility was expected. The purified peptide 
diastereomers P16a and P16b could not be dissolved in acetonitrile/water based solvent 
mixtures. However, mixtures of TFE or HFIP with water (1 : 2, v/v) were capable of 
dissolving the purified peptides. The low solubility during the purification and analysis of 
these BM2 fragments showed the advantage associated with the C-terminal solubilizing tag 
strategy. 
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Synthesis of P17 BM2(1-21)-NH2
The 21-mer peptide P17 BM2(1-21)-NH2 was synthesized without a C-terminal Hmp unit and 
was used as a reference peptide for solubility tests and CD spectroscopy. Fmoc-SPPS 
succeeded in using a standard protocol according to instruction 9.3. After peptide cleavage 
and lyophilisation, crude peptide P17 was obtained as white solid which was highly 
hydrophobic and insoluble in several different tested mixtures of acetonitrile and water. 
For preparative RP-HPLC only small amounts (approx. 10 mg) of the crude peptide P17 could 
be dissolved in a mixture containing 2.5 ml TFE and 2.5 ml 0.1% TFA. Therefore, P17 was 
pre-dissolved in the organic liquid and slowly diluted with the same amount of 0.1% TFA. 
After purification, peptide P17 was reinjected in analytical RP-HPLC and analysed via MALDI-
TOF-MS. HPLC analysis displayed a single peak at 12.55 min that could be assigned to the 
desired product. The mass spectrum showed the expected monoisotopic signal at 2421.19 
m/z. Below the analytical RP-HPLC chromatogram, the MALDI-TOF mass spectrum and 
isotopic pattern of the purified peptide P17 is highlighted (figure 5.18). 
Figure 5.18: Analytical RP-HPLC and MALDI-TOF-MS of purified peptide P17. HPLC was performed using a C18 
column (150 x 4 mm, 100 Å pore diameter, 3 µm particle size), gradient 50 - 99% acetonitrile in 15 min, flow rate 1 
ml/min. 
After purification 9.5 mg (4.4%) of peptide P17 was obtained. The purified peptide was used 
as a reference substance for CD spectroscopy and analytical RP-HPLC. Table 5.11 shows the 
obtained amounts and the yield of the purified peptide. 
Table 5.11: Results of peptide P17. 
Entry Peptide Found [m/z] Crude Purified Yield
P17 BM2(1-21)-NH2 2421.19
1+ 89.5 mg 9.5 mg 4.4%
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Synthesis of P18 [Leu21]BM2(1-21)-Hmp 
Hmp-peptide P18 was synthesized according to instruction 9.3. Since the C-terminal oxo-ester 
bond of Hmp turned out to be sensitive against piperidine, the less basic 2-metylpiperidine 
was used for Fmoc deprotection. Crude peptide P18 was cleaved from the solid phase and 
released from side chain protecting groups like described in procedure 9.2. The 
chromatogram of the crude product showed two main peaks which could be assigned to 
peptide diastereomers P18a and P18b. Crude peptide P18 was as poorly soluble as the 
hydrophobic peptide P17. Due to the poor solubility only small amounts of P18 could be 
purified. For preparative RP-HPLC 20 mg were dissolved in 2.5 ml TFE and 2.5 ml water 
(0.1% TFA). After peak separation the purified fraction was reinjected in analytical RP-HPLC 
and further analyzed by MALDI-TOF-MS. The MALDI-TOF-MS measurements of the purified 
peptide P18 were performed according to instruction 8.1.5. The measured mass spectra and 
isotopic pattern of both diastereomers P18a and P18b were in accordance with the theoretical 
isotopic pattern. The results of MALDI-TOF-MS and analytical RP-HPLC are highlighted below 
(figure 5.19). 
Figure 5.19: Analytical RP-HPLC and MALDI-TOF-MS of purified peptides P18a and P18b. HPLC conditions: C4 
column (MultoHigh U C4, 100 x 4 mm), gradient 10 -20% acetonitrile in 5 min followed by a gradient of 20 -70% 
acetonitrile in 20 min, flow rate 2 ml/min. 
Both chromatograms showed purified products with a single peak at 12.34 min and 
12.46 min. After peak separation of both diastereomers, the purified fractions were frozen 
and lyophilised. The final diastereomers P18a and P18b were obtained as a white solid which 
were absolutely insoluble in acetonitrile/water mixtures.  
Table 5.12: Results of Hmp-peptide diastereomers P18a and P18b. 
Entry Dia. Peptide Found [m/z] Crude Purified Yield
P18a 1 [Leu21]BM2(1-21)-Hmp 2596.311+ 160.30 mg 4.9 mg 0.85%
P18b 2 [Leu21]BM2(1-21)-Hmp 2596.371+ 160.30 mg 5.2 mg 0.89%
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Synthesis of P19 [Leu21]BM2(1-21)-Hmp-ADO2
The Hmp-peptide P19 was synthesized with a C-terminal ADO2 tag according to instructions 
9.2 and 9.3. Therefore the ADO2 tag, the Hmp unit and the first two amino acids leucine and 
phenylalanine were coupled manually. Loading determination by UV/Vis spectroscopy 
revealed a loading capacity of 0.23 mmol/g after coupling of leucine by the Mitsunobu 
reaction. After cleavage from the solid support 140.20 mg of crude peptide P19 were 
obtained. This crude product was poorly soluble in water/acetonitrile based mixtures despite 
the C-terminal ADO2 tag. For analytical purposes P19 was dissolved in a mixture of 70% TFE 
and 30% water (0.1% TFA). RP-HPLC of the crude peptide showed the typical diastereomer 
double peak of P19a and P19b. After preparative RP-HPLC, the purified diastereomers were 
lyophilized and reinjected in analytical RP-HPLC. The chromatograms of the reinjections are 
depicted below (figure 5.20). 
Figure 5.20: Analytical RP-HPLC and MALDI-TOF-MS of purified peptides P19a and P19b. HPLC conditions: C4 
column (MultoHigh U C4, 100 x 4 mm), gradient 10 - 20% acetonitrile in 5 min followed by a gradient of 20 - 70% 
acetonitrile in 20 min, flow rate 2 ml/min. 
Both chromatograms of P19a and P19b showed pure product peaks without further 
impurities. For identification of the peaks the reinjected diastereomers P19a and P19b were 
analysed by MALDI-TOF-MS. The measured isotopic pattern displayed the exact theoretical 
mass of the expected peptides. 
Table 5.13: Results of Hmp-peptide diastereomers P19a and P19b. 
Entry Dia. Peptide Found [m/z] Crude Purified Yield
P19a 1 [Leu21]BM2(1-21)-Hmp-ADO2 2886.56
1+ 140.20 mg 4.0 mg 1.5%
P19b 2 [Leu21]BM2(1-21)-Hmp-ADO2 2886.56
1+ 140.20 mg 5.3 mg 2.0%
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Synthesis of P20 [Leu21]BM2(1-21)-Hmp-ADO-Lys5
Because BM2(1-21) turned out to be extremely hydrophobic and poorly soluble in previous 
experiments, the attachment of a C-terminal penta-lysine tag was tested. The resin support 
was prepared following instruction 9.2. After manual coupling of the penta-lysine tag, resin 
loading dropped from 0.33 mmol/g to a final loading capacity of 0.1 mmol/g. The following 
peptide sequence was synthesised by automated, microwave-assisted Fmoc-SPPS according to 
instruction 9.3. 
After cleavage and lyophilisation crude peptide P20 was obtained as good water soluble solid 
which was purified via preparative HPLC. The purified product was reinjected in analytical 
RP-HPLC and analysed by MALDI-TOF-MS. Mass analysis showed the exact calculated 
monoisotopic weight and isotopic pattern of the searched peptide sequence. The HPLC 
chromatogram of the purified peptide P20 displayed a single peak at a retention time of 
10.36 min. Although all previous synthesized Hmp-peptides were obtained as mixtures of two 
diastereomers, the purified product P20 showed no double peak even when a smaller 
acetonitrile gradient was applied (figure 5.21). 
Figure 5.21: Analytical RP-HPLC and MALDI-TOF-MS of peptide P20. RP-HPLC was performed with a C4 column 
(MultoHigh U C4, 100 x 4 mm), gradient 10 - 20% acetonitrile in 5 min followed by 20 - 70% acetonitrile in 20 min, 
flow rate 2 ml/min. 
The solubility of peptide P20 was significantly increased in comparison to previous 
synthesised peptides P18 and P19. In the appendix (chapter 15.1.3) the suspension of 
peptide P18 without a solubilizing tag and the solution of peptide P20 with a C-terminal 
penta-lysine tag are compared. After purification and lyophilisation 4.3 mg (0.56%) of P20
were obtained.  
Table 5.14: Results of Hmp-peptide P20. 
Entry Peptide Found [m/z] Crude Purified Yield
P20 [Leu21]BM2(1-21)-Hmp-ADO-Lys5 3382.15
1+ 266.4 mg 4.3 mg 0.56%
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5.1.7. Summary of resin preparation  
The decisive step in the synthesis of Hmp-peptides is the coupling of the first amino acid at 
the unprotected hydroxyl function of Hmp. The efficiency of the Mitsunobu reaction is not 
only dependent on the type and the properties of the solid support, but also on the length of 
the spacer and the type of amino acid used as a building block for the solubilizing tag. Table 
5.15 shows the resin loadings after the Mitsunobu reaction of peptides P4 - P20. The size of 
the solubilizing tag and the distance to Hmp seem to be the most limiting factors for an 
efficient Mitsunobu reaction.  
Solubilizing tags composed of the amino acid arginine as in the case of model peptides P13, 
P14 and P15 result in tremendously low loading capacities under 0.05 mmol/g. This minor 
resin loading can be explained by steric hindrance caused by the bulky Pbf protecting group of 
arginine. However, pentalysine was found to be a good alternative for the synthesis of 
solubilizing tags. Considering the loading growth starting from peptide P10 (0.09 mmol/g) to 
peptide P12 (0.13 mmol/g), the length of the ADO spacer unit is a second decisive factor for 
an efficient Mitsunobu reaction.  
Table 5.15: Influence of the amino acids and spacers to the resin loading after Mitsunobu reaction. 
No. Peptide Name Tag Spacer Loadinga
P4 [Ile21]BM2(17-35)-Hmp n.s.t. n.s. 0.19c
P5 [Ile21]BM2(17-35)-Hmp-ADO ADO n.s. 0.15d
P6 [Ile21]BM2(17-35)-Hmp-ADO2 ADO2 n.s. 0.14d
P7 [Leu21]BM2(17-35)-Hmp n.s.t. n.s. 0.25b
P8 [Leu21]BM2(17-35)-Hmp-ADO ADO n.s. 0.19b
P9 [Leu21]BM2(17-35)-Hmp-ADO2 ADO2 n.s. 0.18b
P10 [Leu21]BM2(17-35)-Hmp-Lys5 Lys5 n.s. 0.07b
P11 [Leu21]BM2(17-35)-Hmp-ADO-Lys5 Lys5 ADO 0.09b
P12 [Leu21]BM2(17-35)-Hmp-ADO2-Lys5 Lys5 ADO2 0.13b
P13 [Leu21]BM2(17-35)-Hmp-Arg5 Arg5 n.s. 0.048b
P14 [Leu21]BM2(17-35)-Hmp-ADO-Arg5 Arg5 ADO 0.050b
P15 [Leu21]BM2(17-35)-Hmp-ADO2-Arg5 Arg5 ADO2 0.053b
P16 [Leu10]BM2(1-10)-Hmp n.s.t. n.s. 0.23b
P18 [Cys(Acm)11][Leu21]BM2(1-21)-Hmp n.s.t. n.s. 0.25b
P19 [Cys(Acm)11][Leu21]BM2(1-21)-Hmp-ADO2 ADO2 n.s. 0.23b
P20 [Cys(Acm)11][Leu21]BM2(1-21)-Hmp-ADO-Lys5 Lys5 ADO 0.09b
a Loading after solid phase Mitsunobu reaction in [mmol/g].
b AmphiSpheres RAM 40 resin with a start loading of 0.33 mmo/g.
c AmphiSpheres RAM 40 resin with a start loading of 0.27 mmo/g.
d Tentagel resin with a start loading of 0.18 mmol/g.
n.s.t. No solubility tag.
n.s. No spacer.
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5.1.8. Summary of resin weights, scales and obtained yields  
The used scale, resin weights and obtained yields of the synthesized peptides are summarized 
in table 5.16. Short model Hmp-peptides P4 - P9 were used as crude peptides in all the 
following analytic steps and ligation experiments. All other peptides were purified before 
usage by preparative RP-HPLC following instruction 8.1.7. 
The obtained yields of the long Hmp-peptides P16 - P20 were under 5% after purification and 
are only half as high as for the synthesis of the N-terminal cysteine peptides P1, P2 and P3.
These low yields can be explained by the dropping of resin loading through the Mitsunobu 
reaction. 
Table 5.16: Summary of the start resin weights, scales, received peptide amounts and obtained yields after Fmoc-
SPPS of N-terminal cysteine peptides and C-terminal Hmp-peptides. 
No. Resin [g] Scale [mmol] Theo. obtained 
Amount [mg] 
Real obtained 
Amount [mg] 
Yield [%]
P1 0.5f 0.20 327.4 192b/85.2a 58.64b/26.2a
P2 0.68d 0.184 648.10 528b/40.7a 81.46b/6.2a
P3 0.75c 0.250 1183.07 479.0b/63.46a 40.48b/5.36a
P4 0.30c 0.081 56.89 11.0 19.3b
P5 0.125e 0.023 19.0 14.0 73.6b
P6 0.125e 0.023 22.3 11.2 50.2b
P7 0.5c 0.165 115.9 71.8 61.9b
P8 0.25c 0.083 69.9 38.3 54.8b
P9 0.25c 0.083 81.9 28.1 34.3b
P10 0.25c 0.083 110.9 31.0 27.9b
P11 0.25c 0.083 122.8 35.7b/1.36a 29.07b/1.1a
P12 0.25c 0.083 134.8 42.2b/2.35a 31.30b/1.74a
P13 0.25c 0.083 122.4 n.p. n.y.
P14 0.25c 0.083 134.4 n.p. n.y.
P15 0.25c 0.083 146.35 n.p. n.y.
P16 0.758c 0.250 1292.65 100.5b/36.9a 7.77b/2.9a
P17 0.27c 0.089 215.40 89.5b/9.5a 41.5b/4.4a
P18 0.68c 0.225 582.39 160.3b/10.1a 27.5b/1.7a
P19 0.27c 0.089 257.09 140.2b/9.3a 54.5b/3.6a
P20 0.68c 0.225 758.89 266.4b/4.3a 35.1b/0.56a
a Purified product.
b Crude product.
c AmphiSpheres RAM 40 resin with a start loading of 0.33 mmo/g.
d AmphiSpheres RAM 40 resin with a start loading of 0.27 mmo/g.
e Tentagel resin with a start loading of 0.18 mmol/g.
f Rink Amide MBHA resin with a start loading of 0.40 mmol/g.
n.p. No product.
n.y. No yield.
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5.1.9. Solubilizing tag-assisted NCL of Hmp-peptides in conventional buffer A 
The usage of Hmp-peptides for NCL of transmembrane peptides offers several advantages 
over alternative ligation strategies which do not enable the attachment of solubilizing tags. 
The solubilizing tag-assisted Hmp strategy allows an efficient ligation of hydrophobic and 
poorly soluble peptide fragments in conventional (aqueous) ligation buffers as well as a 
simple purification using standard methods such as preparative RP-HPLC.  
In the ligation buffer Hmp rearrange over an O-to-S acyl shift reaction forming an active 
thioester at the peptide C-terminus. In the presence of MPAA a peptide-thioaryl ester is 
formed which is capable of undergoing a ligation with a N-terminal Cys-peptide. Since the 
solubilizing tag is removed together with Hmp during the ligation, final target peptides are 
acquired without any modifications. The scheme below shows the ligation strategy (i) which 
was investigated during this work (figure 5.22).[2]
Figure 5.22: Native chemical ligation of BM2 peptides using Hmp as thioester-forming rearrangement group and 
anchor for a C-terminal solubilizing tag.[2]
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For the investigation of ligation strategy (i), in conventional ligation buffer A, 8 M urea, 0.2 M 
disodium phosphate, 150 mM TCEP HCl and 150 mM MPAA was used. In order to find 
optimal conditions for the NCL in buffer A, a set of six different model Hmp-peptides  
(P4, P7-P9, P11-P12) was employed and ligated with the N-terminal Cys peptide P1
(figure 5.32). The sequence of these model Hmp-peptides was derived from the BM2 ligation 
site, comprising the residues BM2(17-21). The N-terminal Cys peptide P1 was composed of 
the influenza virus BM2 sequence 22-35. [Cys22]BM2(17-35) was acquired as a ligation 
product (appendix chapter 15.1.5).  
In the first ligation experiment, using the model peptides P4 [Ile21]BM2(17-21)-Hmp and P7
[Leu21]BM2(17-21)-Hmp, the difference between C-terminal isoleucine and leucine was 
tested. Hmp-peptides P8 – P12 were used to investigate the influence of different types of 
solubilizing tags to the ligation efficiency. After detailed investigation of yields and hydrolysis 
rates in buffer A, the long proton channel sequence P23 [Cys(Acm)11][Leu21][Cys22]BM2 
(1-51) could be synthesised by the NCL of peptide P20 [Cys(Acm)11][Leu21]BM2(1-21)-Hmp-
ADO-Lys5 with the N-terminal cysteine peptide P2 [Cys22]BM2(22-51). All ligation 
experiments in ligation buffer A were performed at room temperature under a nitrogen 
atmosphere. Ligation yields of the short model peptides were calculated using the relative 
peak areas acquired from RP-HPLC. The yield of the final ligation product P23 was calculated 
using the weight of the purified product.  
1 10            20         30          40      50
MLEPFQILSIC(Acm)SFILSALHFLCWTIGHLNQIKRGINMKIRIKGPNKETINR
Sequences of model peptides:
P1: CWTIGHLNQIKRGI
P4: ALHFI-Hmp
P7: ALHFL-Hmp
P8, P9: ALHFL-Hmp-ADO1-2
P11, P12: ALHFL-Hmp-ADO1-2-Lys5
Sequences of complete BM2 fragments:
P2: CWTIGHLNQIKRGINMKIRIKGPNKETINR
P20: MLEPFQILSIC(Acm)SFILSALHFL-Hmp-ADO-Lys5
Figure 5.23: Amino acid sequences of the final target peptide P23 [Cys(Acm)11][Leu21][Cys22]BM2(1-51) and the 
precursors P1, P2, P4, P7, P8, P9, P11, P12 and P20. 
Table 5.17: Ligation experiments of the solubilizing tag-assisted NCL in buffer A. 
Entry Ligation product Cys-peptide Hmp-peptide Sol. tag
P21 [Ile21]BM2(17-35) P1 P4 n.s.t.
P22 
[Leu21]BM2(17-35) P1 P7 n.s.t.
[Leu21]BM2(17-35) P1 P8 ADO
[Leu21]BM2(17-35) P1 P9 ADO2
[Leu21]BM2(17-35) P1 P11 ADO-Lys5
[Leu21]BM2(17-35) P1 P12 ADO2-Lys5
P23 [Cys(Acm)11][Leu21][Cys22]BM2(1-51) P2 P20 ADO-Lys5
n.s.t. No solubilizing tag.
[Cys(Acm)11][Leu21][Cys22]BM2(1-51)N C
 62                                                                                                                                                                                      Results
NCL of model Hmp-peptides P4 and P7 in conventional ligation buffer A 
In the first ligation experiments the two model Hmp-peptides P4 [Ile21]BM2(17-21)-Hmp and 
P7 [Leu21]BM2(17-21)-Hmp were ligated to product P21 [Ile21]BM2(17-35) and P22 
[Leu21]BM2(17-35), respectively. As N-terminal cysteine peptide P1 [Cys22]BM2(22-35) was 
used. In this experiment, the influence of the C-terminal ligation site on the ligation efficiency 
was tested. Already Liu and Mayer were able to demonstrate that the formation of the MPAA-
thioester intermediate is highly dependent on the C-terminus.[60] Especially the amino acids 
Thr, Val and Ile seem to decrease reaction rates and ligation yields. However, reaction rates 
and ligation yields of C-terminal bound Leu were comparable with less sterically hindered 
amino acids such as Gly or Ala. In order to investigate this finding on Hmp-peptides, P4 and 
P7 were ligated and compared under the same conditions. As ligation media conventional 
urea-based buffer A was applied following ligation protocol 10.1.1. 
Table 5.18: Results for ligation experiments of P4 and P7 in buffer A. 
Ligation No. Product Buffer Time Hydrolysis Yield
a) P21 [Ile21]BM2(17-35) A 6 h 97% 3%
b) P22 [Leu21]BM2(17-35) A 2 h 13% 87%
a) b)
Figure 5.24: Stacked chromatograms of ligation experiments a) and b). HPLC conditions: C18 column (150 x 4 mm, 
100 Å pore diameter, 3 µm particle size). Gradient: 15 – 45% acetonitrile in 30 min using a flow rate of 1 ml/min. 
P4-OH/P7-OH: hydrolysis side product, P4-MPAA/P7-MPAA: thioester intermediate, P21/P22: ligation products. 
The ligation of P4 was accompanied by high hydrolysis rates (97%) and low ligation yields 
(3%). After 1 h, peptide P4 was completely converted into hydrolysis product P4-OH
(12.8 min) and into a small amount of the MPAA thioester intermediate P4-MPAA
(22.5 min). After 6 h, a small peak at a retention time of 23.0 min appeared which could be 
assigned to ligation product P21 [Ile21]BM2(17-35).  
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In contrast to the isoleucine carrying peptide P4 was the ligation of the leucine counterpart P7
successful. Already after 30 min a high peak at 23.50 min was detectable which could be 
identified as ligation product P23 [Leu21]BM2(17-35). In ligation buffer A the reaction was 
completed after 2 h showing only a small amount of peptide hydrolysis (P7-OH) at a 
retention time of 13.8 min. The yield of the ligation reached 87%. Similar to previous studies 
by Liu et al. ligation at C-terminal isoleucine resulted in very low ligation yields of 3% which 
were unprofitable for long BM2 segments.[60] In order to identify all reaction products, all 
appearing peaks were separated by RP-HPLC and analysed via MALDI-TOF-MS.  
P4-OH P4-MPAA P21: [Ile21]BM2(17-35)
Theoretical monoisotopic mass Theoretical monoisotopic mass Theoretical monoisotopic mass
C30H45O6N7 C38H51O7N7S C103H163N31O22S
[M+H]+ = 600.350 m/z [M+H]+ = 750.364 m/z [M+H]+ = 2219.238 m/z
Figure 5.25: MALDI-TOF-MS and isotopic pattern of the ligation experiment a): P4-OH: Hmp hydrolysis side product, 
P4-MPAA: thioester intermediate, P21: ligation product [Ile21]BM2(17-35).  
a) P22: Experimental MALDI-TOF-MS b) Isotopic pattern [M+1H]1+
Theoretical average masses Theoretical monoisotopic mass
C103H163N31O22S C103H163N31O22S
[M+1H]1+ = 2220.670 m/z [M+2H]2+ = 110.838 m/z [M+1H]1+ = 2219.238 m/z
Figure 5.26: MALDI-TOF-MS and isotopic pattern of the ligation experiment b): Mass spectrum of final ligation 
product P22 (left) and the isotopic pattern (right). 
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NCL of model Hmp-peptides P8 and P9 in conventional ligation buffer A 
The NCL of the ADO and ADO2 containing peptides P8 [Leu
21]BM2(17-21)-Hmp-ADO and P9 
[Leu21]BM2(17-21)-Hmp-ADO2 with model peptide P1 [Cys22]BM2(22-35) were performed in 
ligation buffer A using the conditions described in protocol 10.1.1. P22 [Leu21]BM2(17-35) 
was obtained as a product of this reaction. 
These ligation experiments aimed to evaluate the effect of C-terminal ADO groups at the 
ligation yield and the amount of hydrolysis. After 30 min, the ligation product P22 was 
detected at 23.5 min. Both ligations were completed after 2 h reaching a yield between  
85-86%. The amount of Hmp hydrolysis was in line with Hmp-peptides without C-terminal 
ADO tags and was calculated to be 14-15%. The comparison of both ligations confirmed that 
there is no difference in the ligation rate or yield, independent from the length of the  
C-terminal ADO group. The ligation product P22 was identified via MALDI-TOF-MS. In figure 
5.27 the results of both ligation experiments are shown. 
Table 5.19: Results for ligation experiment of P8 and P9 in buffer A. 
Ligation No. Product Buffer Time Hydrolysis Yield
a) P22 [Leu21]BM2(17-35) A 2 h 14% 86%
b) P22 [Leu21]BM2(17-35) A 2 h 15% 85%
a) b)
Figure 5.27: Stacked chromatograms of ligation experiments a) and b). HPLC conditions: C18 column (150 x 4 mm, 
100 Å pore diameter, 3 µm particle size). Gradient: 15 – 45% acetonitrile in 30 min using a flow rate of 1 ml/min. 
P8-OH/P9-OH: hydrolysis side product, P8-MPAA/P9-MPAA: thioester intermediate, P22: ligation product. 
Results   65
NCL of model Hmp-peptides P11 and P12 in conventional ligation buffer A 
One key experiment on the solubilizing tag-assisted ligation strategy was the NCL of the 
penta-lysine carrying model peptides P11 [Leu21]BM2(17-21)-Hmp-ADO-Lys5 and P12 
[Leu21]BM2(17-21)-Hmp-ADO2-Lys5 following instruction 10.1.1. In this ligation experiment 
the influence of the sterically demanding penta-lysine tag on the ligation yield, retention time 
and hydrolysis was tested.  
Figure 5.28 shows the chromatograms of these experiments. Both penta-lysine carrying 
starting peptides gave very broad and small peaks in the HPLC and were detected at 6 min 
(P11) and 7.6 min (P12). After 30 min, product P22 [Leu21]BM2(17-35) was obtained at a 
retention time of 25.1 min. Both ligation experiments reached yields of over 80% and proved 
that the steric demanding penta-lysine tag had only a small negative effect on the ligation 
yield. In comparison with previous ligation experiments, slightly higher hydrolysis amounts 
between 17-19% were observed.  
Table 5.20: Results for ligation experiment of P11 and P12 in buffer A. 
Ligation No. Product Buffer Time Hydrolysis Yield
a) P22 [Leu21]BM2(17-35) A 2 h 19% 81%
b) P22 [Leu21]BM2(17-35) A 2 h 17% 83%
a) b)
Figure 5.28: Stacked chromatograms of ligation experiments a) and b). HPLC conditions: C18 column (150 x 4 mm, 
100 Å pore diameter, 3 µm particle size). Gradient: 20 – 40% acetonitrile in 30 min using a flow rate of 1 ml/min. 
P11-OH/P12-OH: hydrolysis side product, P11-MPAA/P12-MPAA: thioester intermediate, P22: ligation product. 
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NCL of the complete BM2 Hmp-peptide P20 in conventional ligation buffer A 
The main goal of the solubilizing tag-assisted ligation strategy was the production of P23
[Cys(Acm)11][Leu21][Cys22]BM2(1-51) in the conventional ligation buffer A. The good soluble 
Hmp peptide P20 [Cys(Acm)11][Leu21]BM2(1-21)-Hmp-ADO-Lys5 was composed of the 
hydrophobic sequence [Cys(Acm)11]BM2(1-21), the thioester forming Hmp group and the  
C-terminal ADO-Lys5 solubilizing tag. As a counterpart for the ligation, the N-terminal Cys 
peptide P2 [Cys22]BM2(22-51) was applied. Both peptide segments were entirely soluble in 
the aqueous ligation buffer A. In contrast to ligation experiments with short model Hmp-
peptides, ligation of long peptide P20 took 24 h. Reaction progress was thereby followed by 
analytical RP-HPLC. Figure 5.29 shows the stacked RP-HPLC chromatograms of the ligation 
experiment. Initial peptides P2 and P20 were found at 4.7 min and 11.5 min, respectively. 
After 2 h, ligation product P23 [Cys(Acm)11][Leu21][Cys22]BM2(1-51) was detected at 
14.5 min. The final ligation product P23 was obtained with a yield of 71%. Due to the 
insolubility of thioester intermediate P20-MPAA, no complete conversion could be achieved. 
After 24 h, 11% of thioester intermediate P20-MPAA was left. The amount of hydrolysis side 
product P20-OH was calculated to be 18%. 
Table 5.21: Results for ligation experiment of P20 in buffer A.  
No. Product Buffer Time Hydrolysis Yield
P23 [Cys(Acm)11][Leu21][Cys22]BM2(1-51) A 24 h 18% 71%
Amino acid sequence P23:MLEPFQILSIC(Acm)SFILSALHFLCWTIGHLNQIKRGINMKIRIKGPNKETINR
Figure 5.29: Stacked chromatograms for the ligation of Hmp-peptide P20. HPLC conditions: C4 column (100 x 4 
mm, 100 Å pore diameter, 5 µm particle size). Gradient: 10 – 20% acetonitrile in 5 min followed by 70% acetonitrile 
in 20 min, rate of 2 ml/min. P20-OH: hydrolysis side product, P20-MPAA: thioester intermediate, P23: ligation 
product. 
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In order to identify all new appearing peaks in the chromatogram, ESI-MS analysis was 
performed. MS showed the expected isotopic pattern of hydrolysis product P20-OH and 
MPAA thioester intermediate P20-MPAA at 13.2 min and 13.8 min. 
a) P2 b) P20-OH c) P20-MPAA
Theoretical monoisotopic mass Theoretical monoisotopic mass Theoretical monoisotopic mass
C154H264O39N52S2 C119H184N25O29S2 C127H191N25O30S3
[M+6H]6+ = 589.336 m/z [M+3H]3+ = 831.445 m/z [M+3H]3+ = 881.786 m/z
Figure 5.30: ESI-MS and isotopic pattern of the separated peaks from the ligation experiment. a) P2: Cys peptide, 
b): P20-OH: hydrolysis side product, c): P20-MPAA: thioester intermediate. 
Figure 5.31 shows the ESI mass spectrum of ligation product P23 and the experimental 
isotopic pattern of the [M+5H]5+ ion. The experimental isotopic pattern of ligation product 
P23 is in perfect accordance with the simulated pattern of formula C273H447N77O67S4.  
a) P23: ESI-MS b) Isotopic pattern [M+5H]5+
Theoretical average masses Theoretical monoisotopic mass
[M+4H]4+ = 1503.063 m/z [M+6H]6+ = 1002.378 m/z C273H447N77O67S4
[M+5H]5+ = 1202.652 m/z [M+7H]7+ =  859.325  m/z [M+5H]5+ = 1201.864 m/z
Figure 5.31: ESI-MS and isotopic pattern of ligation product P23. The experimental isotopic pattern shows the 
expected monoisotopic molecular weight and isotopic pattern of chemical formula C273H447N77O67S4. 
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5.2. Investigation of external conditions 
5.2.1. Application of fluorinated alcohols as additives for NCL of Hmp-peptides 
As alternative strategy to the solubilizing tag-assisted NCL of poorly soluble Hmp-peptides the 
usage of fluorinated co-solvents was tested. The addition of organic solvents was not only 
tested to enhance peptide solubility but also to reduce the water content of the ligation buffer. 
This reduced water content could reduce Hmp hydrolysis and increase the ligation yield. 
The TFE-based ligation (buffer B) and the HFIP-based ligation (buffer C) were investigated by 
the native chemical ligation of product P23 [Cys(Acm)11][Leu21][Cys22]BM2(1-51). All 
ligation experiments were carried out at room temperature and under a nitrogen atmosphere 
according to instructions 10.1.2 (buffer B) and 10.1.3 (buffer C). 
1 10       20         30          40      50
MLEPFQILSIC(Acm)SFILSALHFLCWTIGHLNQIKRGINMKIRIKGPNKETINR
P2: CWTIGHLNQIKRGINMKIRIKGPNKETINR
P16: MLEPFQILSL-Hmp
P18: MLEPFQILSIC(Acm)SFILSALHFL-Hmp
P19: MLEPFQILSIC(Acm)SFILSALHFL-Hmp-ADO2
Figure 5.32: Amino acid sequences of the final target peptide P23 [Cys(Acm)11][Leu21][Cys22]BM2(1-51) and the 
precursors P2, P16, P18 and P19.  
Table 5.22: Performed ligation experiments with long Hmp-peptides in ligation buffer B and C. 
Entry Ligation product 
Cys-
peptide
Hmp-
peptide 
Ligation 
buffer 
P23
[Cys(Acm)11][Leu21][Cys22]BM2(1-51) P2 P18a B
[Cys(Acm)11][Leu21][Cys22]BM2(1-51) P2 P18a C
[Cys(Acm)11][Leu21][Cys22]BM2(1-51) P2 P18b C
[Cys(Acm)11][Leu21][Cys22]BM2(1-51) P2 P19a C
[Cys(Acm)11][Leu21][Cys22]BM2(1-51) P2 P19b C
P27
[Leu10]BM2(1-51) P3 P16a C
[Leu10]BM2(1-51) P3 P16b C
a Hmp-peptide diastereomer 1.
b Hmp-peptide diastereomer 2.
[Cys(Acm)11] [Leu21][Cys22]BM2(1-51)N C
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5.2.2.  TFE-assisted NCL of Hmp-peptides in buffer B  
TFE is long known as excellent solvent for poorly soluble peptides and was investigated 
multiple times for its folding improving properties (chapter 3.5.2).[126a, 209] Kwon and Tietze 
have already described the ligation of the influenza A proton channel sequence M2(22-71) 
using TFE as co-solvent.[131] However, TFE containing phosphate buffers have never been 
tested as ligation media for Hmp-peptides. In this study, the effect of TFE to the ligation yield 
and Hmp hydrolysis was investigated.  
For the ligation of the poorly soluble Hmp-peptide P19a [Cys(Acm)11][Leu21]BM2(17-21)-
Hmp-ADO2 a mixture of 33% TFE and 67% of ligation buffer A was prepared. As N-terminal 
cysteine fragment peptide P2 [Cys22]BM2(22-51) was chosen. Peptide P23
[Cys(Acm)11][Leu21][Cys22]BM2(1-51) was expected as ligation product. In contrast to the 
conventional phosphate buffer A, peptide P19a was completely soluble in the presence of TFE 
(buffer B). RP-HPLC and ESI-MS indicated the formation of the MPAA-thioester intermediate 
P19-MPAA (14.9 min) and hydrolysis product P19-OH (14.0 min) immediately after the start 
of the ligation. The expected ligation product P23 was detected after 1 h at a retention time of 
15.3 min. After 8 h, 35% of thioester intermediate P19-MPAA was still left while the 
hydrolysis product reached 24%. The hydrophobic ligation product P23
[Cys(Acm)11][Leu21][Cys22]BM2(1-51) was obtained with a yield of 32%. 
Table 5.23: Results for ligation experiment of P19a in buffer B. 
No. Product Buffer Time Hydrolysis Yield
P23 [Cys(Acm)11][Leu21][Cys22]BM2(1-51) B 8 h 24% 32%
Amino acid sequence P23:MLEPFQILSIC(Acm)SFILSALHFLCWTIGHLNQIKRGINMKIRIKGPNKETINR
Figure 5.33: Ligation experiment in buffer B. HPLC conditions: C4 column (MultoHigh U C4, 100 x 4 mm). Gradient: 
10 – 20% acetonitrile in 5 min followed by 20 – 70% acetonitrile in 20 min, flow rate 2 ml/min. 
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Figure 5.34b displays the ESI-MS and isotopic pattern of ligation product P23 with the 
formula C273H447N77O67S4. Interestingly, the formation of an unknown side product SP2 could 
be observed at a retention time of 6.2 min that continuously increased over a period of 8 h. 
Side product SP2 turned out as unreactive during the ligation and led to an interruption after 
4 h. The mass spectrum and isotopic pattern of side product SP2 is in line with formula 
C155H262O40N52S2 and shows an exact mass increase of 26 Da. 
a) SP2:[Cys22]BM2(22-51)carbamylated b) Isotopic pattern of P23
Theoretical average masses Theoretical monoisotopic mass
[M+4H]4+ = 890.558 m/z [M+6H]6+ = 594.041 m/z C273H447N77O67S4
[M+5H]5+ = 712.648 m/z [M+7H]7+ = 509.322 m/z [M+6H]6+ = 1001.721 m/z
Figure 5.34: a) ESI-MS of side product SP2 with the isotopic pattern, b) Isotopic pattern of ligation product P23. For 
exact ESI-MS to the third decimal place the mass spectrometer was recalibrated using a peptide standard. 
The fact that SP2 was unreactive during the native chemical ligation led to the assumption 
that the N-terminal cysteine residue of peptide P2 was modified in ligation buffer B. A 
possible structure that can be assigned to the found mass spectrum and chemical formula 
C155H262O40N52S2 is shown in figure 5.35. The formation of a 2-oxo-4-thiazolidine modification 
at the N-terminus nicely explains the loss of reactivity during the ligation and explains the 
found mass increase of exact 26 Da. 
Figure 5.35: Possible side product SP2 that was formed during the NCL in buffer B. The isotopic pattern of this 
theoretical structure is in perfect line with formula C155H262O40N52S2. 
The formation of SP2 can be explained by carbamylation of the cysteine residue. 
Carbamylation of proteins has been reported in the literature for lysine[210] and cysteine[211]
residues as result of cyanate formation derived from urea.[212] In solution, ammonium cyanate 
and urea are in equilibrium.[213] Stark et al. were able to demonstrate that carbamylation can 
be followed by cyclisation to a five membered ring intermediate.[214] Especially, thiol groups 
were carbamylated more rapidly than any other functional groups within the peptide 
chain.[215] This finding suggest that TFE could promote carbamylation of N-terminal cysteine 
peptides in the presence of urea. As result buffer B turned out as ineligible for the NCL of P23. 
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5.2.3. HFIP-assisted NCL of Hmp-peptides in buffer C 
Ligation of Hmp-peptide P18 with N-terminal Cys peptide P2 
Since the TFE-assisted ligation in buffer B led to an unexpected modification of peptide 
P2[Cys22]BM2(22-51), a different buffer system was tested. As an alternative co-solvent for 
TFE, the secondary alcohol HFIP was tested as an additive for the preparation of ligation 
buffer C. Similar to TFE, HFIP has also long been known as an excellent solvent for 
hydrophobic peptides with folding promoting properties. Previous ligation experiments 
confirmed that a pH over 7 is necessary for a successful ligation in the presence of HFIP.[94]
For Hmp-peptides, the optimal pH was found to be 7.5. Buffer C was composed of 33% HFIP 
and 67% of ligation buffer A following procedure 10.1.3. HPLC analysis of the cysteine-
containing peptide P2 in buffer C showed no signs of N-terminal modifications. Additionally, 
both peptide diastereomers P18a or P18b were completely soluble in buffer C. The ligation 
was started by pre-dissolving the peptides P2 and P18 in HFIP followed by the addition of 
buffer A.  
Table 5.24: Results for ligation experiments of P18a and P18b in buffer C. 
Ligation Dia. Product Buffer Time Hydrolysis Yield
a) 1 [Cys(Acm)11][Leu21][Cys22]BM2(1-51) C 24 h 6% 94%
b) 2 [Cys(Acm)11][Leu21][Cys22]BM2(1-51) C 24 h 5% 95%
Amino acid sequence P23:MLEPFQILSIC(Acm)SFILSALHFLCWTIGHLNQIKRGINMKIRIKGPNKETINR
a) b)
Figure 5.36: Stacked chromatograms of the ligation experiments a) and b). HPLC conditions: C18 column (150 x 4 
mm, 100 Å pore diameter, 3 µm particle size). Gradient: 15 – 45% acetonitrile in 30 min, flow rate of 1 ml/min.  
P18-OH: hydrolysis side product, P23: ligation product. 
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At the beginning of the ligation, peptide P2 (4.8 min), hydrolysis product P18-OH (13.5 min) 
and Hmp-peptide diastereomers P18a/P18b (13.9/13.8 min) were visible in the 
chromatogram. After 2 h, product P23 [Cys(Acm)11][Leu21][Cys22]BM2(1-51) was detectable 
at 14.7 min (figure 5.36). After 24 h, both ligations were completed showing no differences 
between the peptide diastereomers P18a and P18b. Except Hmp hydrolysis no further side 
reaction could be observed in buffer C. An interesting finding during NCL in buffer C was the 
unexpectedly high stability of the Hmp moiety at pH of 7.5. In previous experiments Hmp 
turned out to be extremely prone to hydrolysis at pH values higher than 7.0. Surprisingly, 
HFIP addition was not only able to increase the peptide dissolution it was also able to reduce 
the amount of Hmp hydrolysis considerably. In contrast to ligation experiments in buffer  
A or B, NCL in buffer C reached nearly quantitative ligation yields. At the end of the ligation, 
94% yield for P18a and 95% yield for P18b were obtained. 
To identify and compare both ligation products ESI-MS spectra were recorded from all 
captured peaks in the chromatogram. In figure 5.37 the entire mass spectrum and isotopic 
pattern of both ligation products P23 are illustrated. Both experimental isotopic patterns 
displayed the expected monoisotopic mass of P23 and were in perfect agreement with the 
simulated isotopic pattern of chemical formula C273H447N77O67S4. 
a) P23: ESI-MS b) P23 of ligation a) c) P23 of ligation b)
Theoretical average masses Theoretical monoisotopic mass Theoretical monoisotopic mass
[M+4H]4+ = 1503.063 m/z C273H447N77O67S4 C273H447N77O67S4
[M+5H]5+ = 1202.652 m/z [M+6H]6+ = 1001.721 m/z [M+6H]6+ = 1001.721 m/z
Figure 5.37: Comparison of ESI mass spectrum and isotopic pattern of ligation products P23
[Cys(Acm)11][Leu21][Cys22]BM2(1-51). 
The successful synthesis of product P23 in buffer C was a breakthrough. The reduction of 
water content by HFIP addition especially suppressed Hmp hydrolysis. The experiment 
demonstrated that HFIP is an excellent co-solvent to produce hydrophobic transmembrane 
peptides out of Hmp-peptide fragments. In subsequent experiments, buffer C was also used 
for the ligation of different peptide segments. Moreover, the high dissolution potential makes 
ligation buffer C an excellent media for other peptide modifications such as Cys 
desulfurization, since it did not cause any unwanted modifications at both fragments. In the 
further course of this work buffer C was investigated as a solvent system for Cys 
desulfurization of poorly soluble, hydrophobic transmembrane peptides (chapter 5.3). 
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Ligation of Hmp-peptide P19 with N-terminal Cys peptide P2 
Further evidence for the efficiency of ligation buffer C was the successful ligation of P23
[Cys(Acm)11][Leu21][Cys22]BM2(1-51) using the peptide diastereomers P19a or P19b 
[Leu21]BM2(17-21)-Hmp-ADO2. Both peptides were modified with a C-terminal ADO2 tag. As 
N-terminal Cys peptide P2 [Cys22]BM2(22-51) was applied. Both peptide fragments were 
completely soluble in buffer C. In figure 5.38 the stacked chromatograms of both ligation 
experiments are compared. The N-terminal cysteine peptide P2 was detected at a retention 
time of 4.6 min. After 2 h, the MPAA intermediate P19-MPAA (14.5 min) and ligation product 
P23 (14.5 min) were visible. The ligation was completed after 24 h and showed no 
unexpected side reactions. Peptide P18a reached a yield of 81% which was explained by a 
slightly higher pH adjustment (pH 7.7) during the preparation of the ligation buffer. 
However, P18b resulted in 95% ligation yield at a pH of 7.5 which was in line with previous 
experiments in buffer C at the same pH value.Similar to previous ligation experiments with 
short model Hmp-peptides, P8 and P9 (chapter 5.1.9) the ADO2 tag had no negative effect on 
the ligation yield. 
Table 5.25: Results for ligation experiments of P19a and P19b in buffer C. 
Ligation Dia. Product Buffer Time Hydrolysis Yield
a) 1 [Cys(Acm)11][Leu21][Cys22]BM2(1-51) C 24 h 18% 82%
b) 2 [Cys(Acm)11][Leu21][Cys22]BM2(1-51) C 24 h 5% 95%
Amino acid sequence P23:MLEPFQILSIC(Acm)SFILSALHFLCWTIGHLNQIKRGINMKIRIKGPNKETINR
a) b)
Figure 5.38: Stacked chromatograms of the ligation experiments a) and b). HPLC conditions: C18 column (150 x 4 
mm, 100 Å pore diameter, 3 µm particle size). Gradient: 15 – 45% acetonitrile in 30 min, flow rate of 1 ml/min.  
P19-OH: hydrolysis product, P23: ligation product. 
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The final ligation product P23 [Cys(Acm)11][Leu21][Cys22]BM2(1-51) that was produced by 
NCL in buffers A, B and C was purified via preparative RP-HPLC according to procedure 8.1.7. 
In figure 5.39 the analytical reinjection of product P23 is depicted. The chromatogram 
displays one single peak at 14.47 min and no further impurities. After purification P23 was 
analysed by ESI-MS and SDS-PAGE. 
Figure 5.39: Analytical RP-HPLC chromatogram and ESI-MS of ligation product P23. HPLC conditions: C4 column 
(MultoHigh U C4, 100 x 4 mm). Gradient: 10 - 20% acetonitrile in 5 min followed by 20 - 70% acetonitrile in 20 min, 
flow rate 2 ml/min. 
Figure 5.40 shows the result of the SDS-polyacrylamide gel electrophoresis (SDS-PAGE) in 
ligation buffer A (LB), the diluted ligation buffer A (DLB) and the purified peptide P23. The 
peptides were denaturated in the presence of dithiothreitol (DTT), for 10 min, at 95°C 
according to instruction 8.1.11. Compared to the coloured marker (M), all fractions show a 
protein mass between 5-10 kDa that belongs to ligation product P23 with an average 
molecular weight of 6008.2 Da. 
M LB DLB P23
Figure 5.40: SDS-PAGE of ligation product P23 in the presence of reducing agent DTT, (LB) ligation buffer, (DLB) 
diluted ligation buffer (buffer A/water (1:1, v/v)) and the purified ligation product peptide (P23). SDS page was 
performed using 20% acrylamide gel that was prepared from acrylamide / bisacrylamide solution (29:1). Coomassie 
G-250 was used for staining. 
25 kDA
15 kDA
10 kDA
4.6 kDA
40 kDA
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Ligation of Hmp-peptide P16 with N-terminal Cys peptide P3 
Buffer C was also investigated for the native chemical ligation of P27 [Leu10]BM2(1-51) using 
the Hmp-peptide diastereomer P16a or P16b [Leu10]BM2(1-10)-Hmp and the N-terminal 
cysteine peptide P3 [Cys11]BM2(11-51). Again, all peptide segments were soluble in buffer C. 
Already at the beginning of the reaction, ligation product P27 was detected at 21.49 min. 
Nevertheless, the reaction took 24 h until Hmp-peptides P16a or P16b disappeared entirely. 
At the end of the reaction, hydrolysis product P16-OH was detected at 14.80 min. After 24 h, 
ligation yields of 87% for P16a and 88% for P16b were achieved.  
Table 5.26: Results for ligation experiments of P16a and P16b in buffer C. 
Ligation Dia. Product Buffer Time Hydrolysis Yield
a) 1 [Leu10]BM2(1-51) C 24 h 13% 87%
b) 2 [Leu10]BM2(1-51) C 24 h 12% 88%
Amino acid sequence P23:MLEPFQILSLCSFILSALHFLCWTIGHLNQIKRGINMKIRIKGPNKETINR
a) b)
Figure 5.41: Stacked chromatograms of the ligation experiments a) and b). HPLC conditions: C18 column (150 x 4 
mm, 100 Å pore diameter, 3 µm particle size). Gradient: 10% acetonitrile for 3 min followed by 99% acetonitrile in 
30 min, flow rate: 1 ml/min. P16-OH: hydrolysis product, P16-MPAA: thioester intermediate, P23: ligation product. 
The use of peptide fragments P16 and P3 provided a great advantage compared to the 
ligation of Hmp-peptides P18 [Leu21]BM2(17-21)-Hmp or P19 [Leu21]BM2(17-21)-Hmp-
ADO2 with P2 [Cys22]BM2(22-51). The additional incorporation of Acm protected Cys11 
followed by Cys22 desulfurization and Acm deprotection was unnecessary, since Cys11 occurs 
in the native peptide sequence of BM2(1-51). As final ligation product peptide P27
[Leu10]BM2(1-51) was acquired. After purification following procedure 8.1.7, final ligation 
 76                                                                                                                                                                                      Results
product P27 [Leu10]BM2(1-51) was analyzed via RP-HPLC and ESI-MS (figure 5.42). Analysis 
via RP-HPLC analysis showed the product peak at a retention time of 19.95 min. The 
experimental monoisotopic mass and isotopic pattern of product P27 were in line with the 
simulated isotopic pattern of formula C270H442N76O66S3. 
a) Analytical RP-HPLC of [Leu10]BM2(1-51)
b) ESI-MS of P27 [Leu10]BM2(1-51) c) Isotopic pattern of P27
Theoretical average masses Theoretical monoisotopic mass
[M+5H]5+ = 1182.023 m/z [M+3H]3+ = 1969.367 m/z C270H442N76O66S3
[M+4H]4+ = 1477.277 m/z [M+2H]2+ = 2951.644 m/z [M+3H]3+ = 1968.098 m/z
Figure 5.42: a) Analytical RP-HPLC chromatogram of ligation product P27. HPLC was performed with a C4 column 
(MultoHigh U C4, 100 x 4 mm), gradient: 40–70% acetonitrile in 30 min, flow rate 1 ml/min, b) experimental ESI-MS 
and c) isotopic pattern of peptide P27. 
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5.2.4. Investigation of the ionic liquid [C2mim][OAc] as reaction media 
Study of 1‑Ethyl-3-methyl-imidazolium acetate reactivity towards biomolecules 
The low toxicity, the capability of dissolving highly hydrophobic peptides and the folding-
inducing properties make 1‑ethyl-3-methyl-imidazolium acetate ([C2mim][OAc]) to an ideal 
media for poorly water soluble membrane peptides. However, some publications report about 
the generation of N-heterocyclic carbenes (NHCs) in the neat ionic liquid [C2mim][OAc] 
(chapter 3.5.4).[155-156] Since the amino acid cysteine is the most chemically reactive group 
within the peptide chain, unexpected modifications of cysteine are possible in the presence of 
[C2mim][OAc]. In order to identify those side products and to suppress unwanted side 
reactions, experiments with small sulfur-containing model compounds were performed. In a 
first study the organic compounds thiophenol (PhSH), diphenyl disulfide (PhSSPh), benzyl 
sulfide (BzlSH) and dibenzyl disulfide (BzlSSBzl) were dissolved in the neat ionic liquid 
[C2mim][OAc] and analysed via RP-HPLC, TLC, ESI-MS and NMR spectroscopy. 
Figure 5.43: Analytical and preparative methods for the investigation of NHC-induced modifications of sulfur-
containing model compounds and N-terminal cysteine peptides. 
The simple structure of organic sulfur-containing compounds allowed a fast structure 
determination by NMR. In a follow-up study, using model peptide P1 [Cys22]BM2(22-35), 
possible peptide modifications by the neat ionic liquid [C2mim][OAc] were investigated by 
ESI-MS. Finally, conditions in which NHC formation can be entirely supressed were searched. 
These findings allowed the development of ionic liquid based ligation buffers on the basis 
[C2mim][OAc]. 
Table 5.27: Sulfur containing compounds which were dissolved and analysed in [C2mim][OAc].
Entry Model compound Abbreviation
C1 Thiophenol PhSH
C2 Benzyl sulfide BzlSH
C5 Diphenyl disulfide PhSSPh
C6 Dibenzyl disulfide BzlSSBzl
P1 CWTIGHLNQIKRGI [Cys22]BM2(22-35)
 78                                                                                                                                                                                      Results
5.2.5.  Reaction of thiophenol and diphenyl disulfide in [C2mim][OAc] 
To understand NHC-induced chemical modifications of sulfur-containing substances 
thiophenol C1 and diphenyl disulfide C2 were dissolved and analyzed in the neat 
[C2mim][OAc] according to procedure 8.1.1. Both substances showed good solubility in the 
ionic liquid. The reaction is characterised by two equilibriums which are represented in figure 
5.44. A first equilibrium between the reduced form C1 and the oxidized form C2 and a second 
equilibrium between the positive charged imidazolium cation and the neutral deprotonated 
imidazolium carbene. 
Equilibrium oxidation-
reduction 
Equilibrium deprotonation-
protonation 
Products
found 
Figure 5.44: NHC formation and modification of thiophenol C1 and diphenyl disulfide C2 in neat [C2mim][OAc].
After dissolution and HPLC analysis of C1 in neat [C2mim][OAc], three different peaks 
appeared at 4.49 min, 10.79 min and 19.39 min (figure 5.45). The peak at 10.79 min was 
assigned to educt C1. After 5 min reaction time, significant amounts of oxidation product C2
was detected at 19.39 min. Additionally, a peak at 4.49 min appeared directly at the start of 
the reaction.  According to NMR spectroscopy and ESI-MS, this peak was identified as reaction 
product C3 (figure 5.4.6). After 8 h, starting compound C1 was almost completely 
transformed into product C3. After 12 h reaction time, product C3 was isolated as orange 
liquid by column chromatography applying a mixture of acetonitrile and water (9:1, v/v) as 
mobile phase. 
Approximately 4 h after dissolution of compound C1 in the neat [C2mim][OAc], product C4
was detected at a retention time of 12.39 min. After 72 h reaction time, product C4 was left 
as the main product. However, product C4 was difficult to isolate via column chromatography 
and vacuum evaporation. Therefore, product C4 was directly extracted with cyclohexane-d12 
from the reaction mixture and analyzed by NMR (figure 5.4.7). Surprisingly, reaction product 
C4 could be identified as thioanisole indicating a second possible side-reaction of aromatic 
thiols in the neat ionic liquid. Obviously, [C2mim][OAc] was also capable of methylating the 
thiol group of aromatic thiols such as thiophenol. Interestingly, only the methylated but not 
the ethylated form was obtained in this reaction.  
Results   79
The dissolution and analysis of diphenyl disulfide (C2) in the neat ionic liquid [C2mim][OAc] 
led to the same products as the reaction of thiophenol (C1). However, formation of C3 and 
C4 was distinctly faster when C2 was used as starting compound, indicating that diphenyl 
disulfide is the actual reactant in this reaction. In the case of diphenyl disulfide (C2) as 
starting compound, product C3 was obtained as the main product after 5 min reaction time. 
The methylated product C4 was already detected after 2 h reaction time. Both experiments 
are compared in the RP-HPLC chromatograms in figure 5.45. 
a) PhSH in neat [C2mim][OAc] b) PhSSPh in neat [C2mim][OAc]
Figure 5.45: Analytical HPLCs of C1 thiophenol and C2 diphenyl disulfide in neat [C2mim][OAc] at 240 nm. HPLC 
conditions: C8 column (125 x 4 mm, 120 Å pore diameters, 5 µm particle size), 20–55%  acetonitrile (0.1% TFA) in 
15 min followed by a gradient of 55–95% acetonitrile (0.1% TFA) for 7 min, flow rate of 1 ml/min. 
The obtained data proved that aromatic sulfur groups are highly prone to chemical 
modifications in [C2mim][OAc]. The finding that C2 (diphenyl disulfide) reacts faster than C1
(thiophenol) supports the idea that thiol groups are first oxidized to the disulfide before they 
react with in situ formed NHCs. 
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a) 1H-NMR in D2O b) 13C-NMR in D2O
c) ESI-MS of compound C3 
Figure 5.46: a) 1H-NMR and b) 13C-NMR spectra of product C3 in D2O, c) ESI mass spectrum and isotopic pattern of 
compound C3.
Product C3: 1H-NMR (300 MHz, D2O) δ = 7.7 (d, J = 2.2 Hz, 1-H), 7.6 (d, J = 2.2 Hz, 1-H), 
7.4 (m, 3-H, Ar), 7.3 (m, 2-H, Ar), 4.3 (q, J = 7.3 Hz, 2-H), 3.8 (s, 3-H), 1.3 (t, J = 7.3 Hz,  
3-H) ppm. 13C NMR (D2O) δ = 130.3, 130.0, 129.2, 128.6, 123.6, 123.5, 45.17, 36.1, 14.3 
ppm. 
a) 1H-NMR in D2O b) 13C-NMR in D2O
Figure 5.47: a) 1H-NMR and b) 13C-NMR spectra of product C4 in cyclohexane-d12.
Product C4: 1H-NMR (500 MHz, cyclohexane-d12) δ = 7.88-7.80 (m, 4-H, Ar), 7.70-7.67  
(m, 1-H, Ar), 3.04 (s, 3-H) ppm. 13C-NMR (cyclohexane-d12) δ =139.8, 129.0, 127.5, 125.3, 
16.1 ppm. 
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5.2.6.  Reaction of benzyl mercaptan and dibenzyl disulfide in [C2mim][OAc] 
To investigate chemical reactions of thiols which are not directly bound on aromatic systems, 
benzyl mercaptan (BzlSH) C5 and dibenzyl disulfide (BzlSSBzl) C6 were analyzed in neat 
[C2mim][OAc] by RP-HPLC, thin-layer chromatography (TLC), ESI-MS and NMR 
spectroscopy. Again, both substances were completely soluble in the ionic liquid. Shortly after 
dissolution, benzyl mercaptan C5 was immediately oxidized to dibenzyl disulfide C6 which 
was much faster than the oxidation of thiophenol C1 to diphenyl disulfide C2 in previous 
experiments. After oxidation of C5 to C6, new reaction products C7, C8 and C9 occurred in 
the chromatograms (figure 5.49). This observation was further evidence that thiols were first 
oxidized to disulfides before they are modified by in situ generated imidazole-carbenes in 
[C2mim][OAc]. 
At the beginning of the reaction, product C8 (5.31 min) was generated by the reaction of 
dibenzyl disulfide C6 and the imidazole-carbene. In contrast to previous experiments, reaction 
product C8 was not stable in [C2mim][OAc] and further converted to reaction products C7
(2.82 min) and C9 (18.44 min). According to the results of the RP-HPLC, dibenzyl disulfide 
(C6) was completely converted after 2 h at room temperature. Collection and analysis of 
products C7, C8 and C9 revealed the structures highlighted in figure 5.48. 
Equilibrium 
oxidation-reduction
Equilibrium 
deprotonation-
protonation
Product 
found 
Products 
found 
Figure 5.48: NHC formation and modification of benzyl mercaptan C5 and dibenzyl disulfide C6 in neat 
[C2mim][OAc].
The instability of C8 in the ionic liquid can be explained by the additional methylene group 
between the sulfur atom and the aromatic aryl system. Considering the existence of reaction 
products C7 and C9 it is supposed that the methylene group in product C8 can be attacked by 
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the nucleophile benzyl mercaptan anion which leads directly to the formation of C7 and C9. 
For an unambiguous identification, reaction products C7, C8 and C9 were collected by 
column chromatography following the procedure in 8.1.1 and analysed via NMR spectroscopy 
and ESI-MS. The isolated and purified product C7 was a dark orange liquid which was easily 
soluble in water. Product C8 was obtained as a highly viscous liquid which could be 
concentrated under reduced pressure. 
In order to verify these results, dibenzyl disulfide (C6) was directly dissolved in the neat 
[C2mim][OAc] and analysed in the same manner as benzyl mercaptan. The dissolution and 
analysis of dibenzyl disulfide C6 in the ionic liquid led to the same products as the dissolution 
of benzyl mercaptan (C5). However, formation of C7, C8 and C9 was faster starting with 
dibenzyl disulfide (C6). Similar to the observation made by the dissolution of thiophenol (C1) 
and diphenyl disulfide (C2), the direct use of the disulfide C6 resulted in a faster product 
formation for its reduced form C5. In the case of C6 as a starting compound, the main product 
C7 was already detectable after 5 min reaction time (figure 5.49). 
a) BzlSH in neat [C2mim][OAc] b) BzlSSBzl in neat [C2mim][OAc]
Figure 5.49: Analytical RP-HPLC of C5 benzyl mercaptan and C6 dibenzyl disulfide in neat [C2mim][OAc] at 240 nm 
using a C8 column (125 x 4 mm, 120 Å pore diameters, 5 µm particle size). HPLC conditions: 20–55% acetonitrile 
(0.1% TFA) in 15 min followed by a gradient of 55–95% acetonitrile (0.1% TFA) for 7 min using a flow rate of  
1 ml/min. 
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a) 1H-NMR in D2O b) 13C-NMR in D2O
c) ESI-MS of compound C8
Figure 5.50: a) 1H-NMR and b) 13C-NMR spectra of product C8 in D2O, c) ESI mass spectrum and isotopic pattern of 
compound C8.
Product C8: 1H-NMR (300 MHz, D2O) δ = 7.5 (d, J = 2.1 Hz, 1-H), 7.5 (d, J = 2.2 Hz, 1-H), 
7.3-7.2 (m, 3-H), 7.1-7.0 (m, 2-H), 4.1 (s, 2-H), 4.0 (q, J = 7.3 Hz, 2-H), 3.6 (s, 3-H), 1.2 (t, 
J = 7.4 Hz, 3-H) ppm. 13C-NMR (D2O) δ = 136.0, 129.2, 128.7, 128.5, 125.2, 123.0, 44.6, 
39.8, 35.5, 14.2 ppm. 
a) 1H-NMR in D2O b) 13C-NMR in D2O
Figure 5.51: a) 1H NMR and b) 13C NMR spectra of product C7 in D2O.
Product C7: 1H-NMR (300 MHz, D2O) δ = 7.0 (d, J = 2.3 Hz, 1-H), 4.0 (q, J = 7.3 Hz, 2_H), 
3.5 (s, 3-H), 1.2 (t, J = 7.3 Hz, 3-H) ppm.13C-NMR (D2O) δ = 119.8, 117.8, 43.0, 34.7, 13.6 
ppm. 
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5.2.7.  Reaction of [Cys22]BM2(22-35) in [C2mim][OAc] 
In the further course of this work possible modifications of cysteine-containing peptides by 
neat [C2mim][OAc] were examined with respect to the identified chemical modifications of 
the model organic compounds C1/C2 and C5/C6. As a model peptide for this experiment, the  
N-terminal cysteine peptide P1 [Cys22]BM2(22-35) was applied. After dissolution of P1 in 
neat [C2mim][OAc] reaction progress was monitored by analytical RP-HPLC according to 
instruction 8.1.2. All new occurring peaks in the chromatograms were collected and analysed 
by ESI-MS. The experimental isotopic pattern and the calculated mass spectrum of P1
[Cys22]BM2(22-35) in [C2mim][OAc] resulted in the expected reaction products and allowed 
the identification of several unexpected side products. 
After dissolution of P1 in neat [C2mim][OAc] two peaks at 9.67 min and 16.53 min were 
detected in the chromatogram. The peak at 9.67 min could be assigned to starting peptide P1
by a reference chromatogram of P1 in water (0.1% TFA). ESI-MS analysis of the newly 
formed product P1e at 16.53 min showed the monoisotopic mass of the disulfide of peptide 
P1 (Figure 5.54c). Similar to the rapid oxidation of the organic thiols C1 and C5 in 
[C2mim][OAc] model peptide P1 was immediately oxidized to disulfide P1e shortly after 
dissolution in the ionic liquid. After 30 min, two new products P1a at 7.99 min and P1b at 
9.24 min appeared in the chromatogram. The isotopic pattern of product P1a was in perfect 
agreement with the proposed structure (figure 5.52). 
[Cys22]BM2(22-35) in [C2mim][OAc] No. Proposed structures
P1 IGRKIQNLHGITWC
P1a, a 
P1b, b 
P1c, c 
P1d, d 
P1e, e 
IGRKIQNLHGITWCCWTIGHLNQ
IKRGI 
Figure 5.52: Left: RP-HPLC experiment of P1 [Cys22]BM2(22-35) in neat [C2mim][OAc] over 24 h. Right: Numbers 
and presumed structures of the products identified by LC-MS.
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After 1 h, the peak area of the peptide disulfide P1e clearly decreased indicating that the 
disulfide bond was not stable in the reaction mixture. At a retention time of 10.72 min a new 
product P1c occurred which continually increased over 24 h. The mass spectrum of P1c was 
in line with the chemical structure highlighted in figure 5.52. After 4 h, a new peak P1d was 
detected at a retention time of 12.34 min. Surprisingly, this product showed the mass of the 
desulfurated peptide P1 as a result of the conversion of Cys22 to Ala22.  
a) Experimental spectra of P1a b) Experimental spectra of P1b
Theoretical monoisotopic mass Theoretical monoisotopic mass
C79H129N26O17S C73H120N24O19S
[M+H]2+ = 873.49 m/z [M+2H]2+ = 835.45 m/z
Figure 5.53: a) MS of reaction product P1a which is formed between the imidazolium-carbene and peptide P1. b)
MS of the oxidized product P1b at a retention time of 10.72 min. 
a) Experimental spectra P1c b) Experimental spectra P1d c) Experimental spectra P1e
Theoretical monoisotopic mass Theoretical average masses Theoretical monoisotopic mass
C79H129N26O19S C73H120N24O17 C146H238N48O34S2
[M+H]2+ = 889.48 m/z [M+2H]2+ = 803.47 m/z [M+3H]3+ = 1091.60 m/z
Figure 5.54: a) MS of reaction product P1c at a retention time of 10.72 min. b) MS of the desulfurization product 
P1d collected at 12.34 min. c) MS of the oxidized product P1e at 16.53 min. 
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The collected data from RP-HPLC, LC-MS and NMR analysis confirmed the suspected 
formation of N-heterocyclic carbenes (NHCs) in the neat ionic liquid [C2mim][OAc] which is 
proposed by numerous sources in the literature.[154-155, 216] All identified reaction products and 
modifications of organic model compounds C1, C2, C5, C6 and peptide P1
[Cys22]BM2(22-35) can be explained by the existence of NHCs in the neat ionic liquid. The 
proposed reaction scheme for the NHC formation is highlighted below (figure 5.55).[1]
Figure 5.55: Possible formation of N-heterocyclic carbenes (NHC) in the neat ionic liquid [C2mim][OAc]. These in situ
formed carbenes can react with sulfur-containing compounds and cysteine side chains in proteins.[1]
In the proposed mechanism, carbene formation is the result of an equilibrium between the 
protonated (1) and deprotonated (2) imidazolium cation. The reaction is initiated through 
the deprotonation of the C(2) atom at the imidazolium cation.[1] Amyes et al. as well as Cheng 
et al. were able to calculate the pKa value of the 1-ethyl-3-methylimidazolium cation to 22.1 
which is similar to that of fluorene derivatives which are widely used in organic chemistry and 
well known for their ability to give off protons under basic conditions.[217]
These results support the presumption of a possible C(2) deprotonation by the acetate anion 
confirming the results of previous studies by L. Nyulaszi and colleagues.[157] In the further 
course of the reaction, the formed imidazolium carbene (2) reacts with disulfides to form an 
imidazolium-thio intermediate (3) which further decays to 1-ethyl-3-methylimidazole-2-
thione (4) and the corresponding thioether (5). 
In the further course of this work 1‑ethyl-3-methyl-imidazolium acetate ([C2mim][OAc]) was 
investigated as potential ligation media for hydrophobic peptides. Therefore, the addition of 
polar protic solvents such as water was tested to supress NHC formation. The following 
chapter summarizes and discusses these studies (5.2.8). 
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5.2.8.  Effect of water to NHC-induced modifications  
Considering the mechanism of NHC formation in figure 5.55, proton donating co-solvents 
such as water should reduce the carbene formation in [C2mim][OAc] and decrease 
unexpected peptide modifications. To test this theory model peptide P1 [Cys22]BM2(22-35) 
was dissolved and analyzed in different mixtures of [C2mim][OAc] and water from 10 to 30% 
(v/v). Indeed, RP-HPLC analysis, according to instruction 8.1.2, showed that the reaction rate 
of the peptide modification slowed down with rising concentrations of water. 
a) 10% water (v/v) b) 20% water (v/v) c) 30% water (v/v)
Figure 5.56: Reaction progress of model peptide P1 [Cys22]BM2(22-35) in mixture of [C2mim][OAc] with a) 10% 
water, b) 20% water and c) 30% water. HPLC conditions: 20 - 30% acetonitrile in 20 min, flow rate 1 ml/min.
The presence of 10% water in the reaction solution showed a minor influence on the 
formation of the side products P1a-P1d. However, the generation of these side products was 
distinctively slower compared to the formation in the neat ionic liquid. After 30 min, only a 
small amount of product P1a was detectable in the chromatogram. Although the formation of 
side products was not fully suppressed by the addition of 10% water, the influence of the 
increased water content was clearly visible compared to the neat ionic liquid (chapter 5.2.7). 
Similar to the reaction in neat [C2mim][OAc], the peak of the dimerized peptide P1e
disappeared over a time period of 24 h indicating that the oxidized form of peptide P1 was 
the most reactive. The addition of 20% water further decreased the reaction rate of the side 
product formation. After 24 h, only a very small amount of product P1a appeared in the 
chromatogram. However, the oxidized reaction products P1b and P1c were still detectable 
after 1 h. In contrast to the experiment with 10% of water, the peptide disulfide P1e was still 
detectable after 24 h at 20% water content. At a water percentage of 30%, no NHC-induced 
side reactions were detectable in the chromatogram. Only the disulfide P1e was detectable at 
17.06 min which was left as a single peak after 4 h. The results proved that a water content of 
at least 30% is necessary to supress the NHC-induced modifications. In the further course of 
this work [C2mim][OAc]/water mixtures were investigated as possible ligation media for 
hydrophobic Hmp-peptides. 
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5.2.9.  Evaluation of optimal water content for NCL 
The first study investigated the optimal water content for the IL-mediated native chemical 
ligation. Therefore, ligation buffers D1-D6 were prepared with rising amounts of water 
according to instruction 10.1.4. In each ligation experiment the water content was increased 
by 10% as highlighted in table 5.28. As model reaction for these experiments cysteine peptide 
P1 [Cys22]BM2(22-35) (3.62 min) and Hmp-peptide P7 [Leu21]BM2(17-21)-Hmp
(7.57/8.33 min) were ligated to product P22 [Leu21]BM2(17-35) (21.57 min). The only 
observable side reaction was Hmp hydrolysis at 5.13 min (figure 5.57). 
a) D1 (IL/water, 100:0) b) D2 (IL/water, 90:10) c) D3 (IL/water, 80:20)
d) D4 (IL/water, 70:30) e) D5 (IL/water, 60:40) f) D6 (IL/water, 50:50)
Figure 5.57: Ligation experiments in buffer D1-D6 with P1 [Cys22]BM2(22-35) and P7 ALHFL-Hmp. HPLC was 
performed with a C8 column (125 x 4 mm, 120 Å pore diameters, 5 µm particle size). Gradient: 25 - 35% acetonitrile 
in 30 min, flow rate 1 ml/min. PhSH (thiophenol), P7-OH (hydrolysis product of P7).  
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The high solubility potential of the IL-based buffers allowed much higher peptide 
concentrations for peptides P1 [Cys22]BM2(22-35) and P7 [Leu21]BM2(17-21)-Hmp
compared to aqueous ligation buffers usually applied for NCL. In contrast to conventional 
ligation buffers denaturing agents such as urea or guanidinium chloride were not necessary 
for the preparation of buffers D. Also, the addition of buffer salts like disodium phosphate was 
unnecessary. Except for [C2mim][OAc] and water only TCEP HCl and thiophenol were added 
to the ligation solution. The pH of the solution was highly dependent on water content and 
was ideal for buffers D5 and D6. However, the highest solubility potential for hydrophobic 
peptides was found in buffers D1-D3.  
Table 5.28: Composition, pH values and ligation yields in buffers D1–D6. 
Buffer [C2mim][OAc] [%] Water [%] Measured pH Ligation yield [%]
D1 100 0 11.4 0
D2 90 10 10.5 0
D3 80 20 9.5 10.1
D4 70 30 8.7 40.8
D5 60 40 7.6 71.7
D6 50 50 6.8 55.6
In buffers D1 and D2 no ligation product was observable. Already at the start of the reaction  
Hmp-peptide P7 [Leu21]BM2(17-21)-Hmp was entirely hydrolysed to side product P7-OH. 
The high pH value seemed to destroy peptide P1 whose peak area decreased constantly over a 
time period of 6 h. In buffer D3 ligation yields of 10% were achieved (figure 5.58). A 
significant improvement could be observed in buffer D4 with a ligation yield of 41%. After 
6 h, the best ligation yields for product P22 [Leu21]BM2(17-35) were achieved in buffer D5
with a water content of 40 % and a pH of 7.6 while ligation in buffer D6 resulted in peptide 
precipitation. In the following course of this work, buffer D5 was further used as a ligation 
media for the long and hydrophobic BM2 fragments.  
Figure 5.58: Relative peak area of ligation product P22 [Leu21]BM2(17-35) against the reaction time.[218]
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5.2.10. Ionic liquid-mediated NCL of [Leu10]BM2(1-51) 
In order to test ligation buffer D5 for the synthesis of transmembrane peptides, product P27
[Leu10]BM2(1-51) was produced by ligation of the N-terminal cysteine peptide  
P3 [Cys11]BM2(11-51) and the hydrophobic Hmp-peptide diastereomer P16a or P16b 
[Leu10]BM2(1-10)-Hmp. The ligation was performed according to instruction 10.1.5 and 
monitored via analytical RP-HPLC over 24 h (figure 5.59). The high water content (40 %) 
and the presence of TCEP prevented modifications of the peptide chain. As single side 
reaction, hydrolysis product P16-OH appeared at 14.80 min. However, the amount of Hmp 
hydrolysis was slightly higher than for ligations in the HFIP-based buffer C (figure 5.41). 
Already at the start of the reaction ligation product P27 was detectable at 21.49 min. After 
24 h, ligation yields of 76% for P16a and 73% for P16b were obtained. The final ligation 
product could be separated from ligation buffer D5 by preparative RP-HPLC following 
protocol 8.1.7. Analysis via ESI-MS revealed the expected molecular mass and isotopic pattern 
of formula C270H442N76O66S3 which was identical to the ligation product P27 obtained in the 
HFIP-based ligation buffer C (figure 5.60). 
Table 5.29: Results for ligation experiments of P16a and P16b in buffer D5. 
Ligation Dia. Product Buffer Time Hydrolysis Yield
a) 1 [Leu10]BM2(1-51) D5 24 h 24% 76%
b) 2 [Leu10]BM2(1-51) D5 24 h 27% 73%
Amino acid sequence of P27: MLEPFQILSLCSFILSALHFLCWTIGHLNQIKRGINMKIRIKGPNKETINR
Figure 5.59: Stacked chromatograms of NCL of P3 + P16a and P3 + P16b. HPLC was performed with a C18 column 
(150 x 4 mm, 100 Å pore diameter, 3 µm particle size). Gradient: 10% acetonitrile for 3 min followed by 99% 
acetonitrile in 30 min, flow rate 1 ml/min. P16-MPAA- BM2(1-10)-MPAA, P16-OH- BM2(1-21)-COOH. 
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In conclusion, the ionic liquid based ligation buffer D5 is an excellent ligation media for 
hydrophobic transmembrane peptides. The NCL of [Leu10]BM2(1-51) in the ionic liquid-based 
buffer D5 was successful. 
RP-HPLC analysis of the purified ligation product P27 [Leu10]BM2(1-51) showed one single 
peak at a retention time of 19.91 min and no further impurities. The experimental 
monoisotopic mass and isotopic pattern of ligation product P27 was in excellent agreement 
with the simulated isotopic pattern.  
a) Analytical RP-HPLC of [Leu10]BM2(1-51)
b) ESI-MS of P27 [Leu10]BM2(1-51) c) Isotopic pattern of P27
Theoretical average masses Theoretical monoisotopic mass
[M+6H]6+ = 985.187 m/z [M+4H]4+ = 1477.277 m/z C270H442N76O66S3
[M+5H]5+ = 1182.023 m/z [M+3H]3+ = 1969.367 m/z [M+4H]4+ = 1476.325 m/z
Figure 5.60: a) Analytical RP-HPLC chromatogram of ligation product P27. HPLC was performed with a C4 column 
(MultoHigh U C4, 100 x 4 mm). Gradient: 40 – 70% acetonitrile in 30 min, flow rate 1 ml/min, b) experimental  
ESI-MS and c) isotopic pattern of peptide P27. 
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5.3. Development of novel follow-up protocols: desulfurization and Acm-group 
deprotection 
5.3.1.  HFIP-mediated desulfurization 
Since cysteine is a rather rare amino acid in most native peptide sequences, other amino acid 
residues were investigated for decades as possible ligation sites. The combination of the native 
chemical ligation followed by conversion of cysteine to alanine is the most utilized ligation 
strategy for peptides without native cysteine residues at the ligation site. One of the fastest 
and most efficient methods is the free-radical-based desulfurization in the presence of VA-044 
and TCEP (chapter 3.6.1). Ingeniously, TCEP can also be used in the NCL as a reducing agent 
that prevents unintended oxidation of thiol groups. The similar compositions of ligation and 
desulfurization buffers provide the opportunity to combine both methods. This one-pot 
ligation and desulfurization strategy was first published by Yan and Dawson and was used 
numerous times as a successful pathway for the synthesis of various peptides.[164] However, 
most publications describe the desulfurization of well water soluble peptides. The 
desulfurization of highly hydrophobic and poorly water soluble peptides and proteins is rarely 
presented in the literature. Especially, hydrophobic transmembrane peptides such as  
BM2(1-51) are usually not soluble in standard desulfurization buffers.  
A further aim of this thesis is the development of an appropriate desulfurization buffer for 
poorly-soluble peptides. Therefore, peptide P23 [Cys(Acm)11][Leu21][Cys22]BM2(1-51) was 
converted to desulfurization product P25 [Cys(Acm)11][Leu21]BM2(1-51). In a first study, 
peptide P23 was tried to desulfurize using a conventional, water-based desulfurization buffer 
(instruction 11.1.1). However, as expected, the hydrophobic peptide P23 was not soluble in 
aqueous buffer solutions resulting in peptide precipitation. Encouraged by the good solubility 
in ligation buffer C, an HFIP-based desulfurization buffer was tested for the synthesis of P25
[Cys(Acm)11][Leu21]BM2(1-51) (instruction 11.1.2). Both experiments are compared below. 
a) b)
Figure 5.61: a) Desulfurization of peptide P23 in commonly used aqueous desulfurization buffer. b) Desulfurization 
of peptide P23 in HFIP-based buffer. HPLC conditions: C4 column, gradient: 45–70% ACN in 30 min, 1 ml/min. 
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Due to the poor solubility of P23 [Cys(Acm)11][Leu21][Cys22]BM2(1-51) in the aqueous buffer 
solution, almost no conversion to product P25 [Cys(Acm)11][Leu21]BM2(1-51) was detectable 
in the chromatogram (figure 5.61a). The addition of HFIP led to the formation of two 
separated phases: an upper phase, which contained well water soluble compounds like 
sodium phosphate, TCEP and guanidinium chloride, and a lower HFIP containing phase which 
included the peptide (figure 5.62a). The binary system imminently formed an emulsion by 
agitation. The suspension was able to convert peptide P23 to product P25 within 6 h  
(figure 5.61b). Both phases were easily separable by short centrifugation. Product P25 was 
obtained with a nearly quantitative yield and purified by preparative RP-HPLC of the 
separated lower HFIP phase following instructions 11.1.2. 
a)
b)
Figure 5.62: a) Comparison of the upper water containing phase and the lower HFIP phase. After centrifugation, 
the lower HFIP phase contains almost the entire product, b) RP-HPLC, ESI-MS and isotopic pattern ([M+5H]5+) of the 
purified peptide P25. RP-HPLC conditions: C4 column (MultoHigh U C4, 100 x 4 mm), gradient 45 – 70% acetonitrile 
in 30 min, flow rate of 1 ml/min. 
 94                                                                                                                                                                                      Results
5.3.2. Acm deprotection using conventional procedures 
One of the most utilized protecting groups for thiols is the acetaminomethyl (Acm) group. 
Acm is not cleavable under basic or acidic conditions and remains at cysteine during peptide 
cleavage from the solid support. This protecting group is also stable under radical conditions 
like described for the metal-free desulfurisation (chapter 5.3.1). However, Acm is an 
unpopular protecting group due to its difficulties in removal. Over the time, many different 
methods were published with the aim of remove Acm efficiently from cysteine residues. 
Nevertheless, most of these methods require toxic chemicals such as heavy metal salts like 
mercury acetate. Alternative, elemental iodine can also be applied for Acm deprotection, 
however, with the risk of peptide oxidation. Acm deprotection by iodine is especially useful 
for peptides with multiple Acm protecting groups. Thereby, peptides with disulfide bonds are 
formed which are less sensitive to oxidation. However, for deprotection of a single Acm group 
within the peptide chain, heavy metal ions were described as more efficient  
(chapter 3.6.2). Today, the use of silver salts is the most common way to remove Acm from 
cysteine. Interestingly, not all silver salts show the same efficiency for Acm deprotection. The 
anion of the silver salt seems to play an equally important role for an efficient cleavage. Silver 
trifluoromethanesulfonate (AgOTf) was found to be the most potent salt in previous 
studies.[187] However, silver ions sometimes create strong complexes with membrane peptides 
making AgOTf difficult for Acm deprotection.[219] Some studies even describe the usage of 
elemental iodine as the most efficient alternative to heavy metal ions without any oxidation 
observed by RP-HPLC and ESI-MS.[182a] In order to investigate the best method for Acm 
deprotection from peptide P25 [Cys(Acm)11][Leu21]BM2(1-51) elemental iodine and AgOTf 
were tested and compared according to instructions 12.1.1 and 12.1.2 (figure 5.63). As 
product P26 [Leu21]BM2(1-51) was acquired. 
a) b)
Figure 5.63: a) Acm deprotection of peptide P25 with elemental iodine in concentrated acetic acid. b) Acm 
deprotection of peptide P25 with AgOTf. HPLC conditions: C4 column (MultoHigh U C4, 100 x 4 mm), gradient  
45–70% acetonitrile in 30 min, flow rate of 1 ml/min. 
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The Acm deprotection by elemental iodine resulted in several products with similar retention 
times of around 13.3 min. A further single product with a retention time of 19.9 min was 
already detected at the beginning of the reaction. The reaction was completed after 10 min 
since no traces of starting peptide P25 [Cys(Acm)11][Leu21]BM2(1-51) were detectable by  
RP-HPLC. 
ESI-MS analysis of all products revealed that the peaks at approximately 13.3 min were 
oxidized side products of product P26 [Leu21][BM2(1-51). The main signal in ESI-MS could 
be assigned to the two-fold oxidized side product P26-O2. The product with the retention time 
of 19.9 min showed the exact mass and the correct isotopic pattern of final peptide product 
P26 [Leu21][BM2(1-51). According to RP-HPLC analysis Acm deprotection with elemental 
iodine reached a yield of 20%. The results of the ESI-MS analysis are depicted in figure 5.64. 
a) Isotopic pattern P26-O2 b) ESI-MS of P26 c) Isotopic pattern P26
Theoretical monoisotopic mass Theoretical average masses Theoretical monoisotopic mass
C270H442N76O68S3 C270H442N76O66S3 C270H442N76O66S3
[M+5H]5+ = 1187.660 m/z [M+5H]5+ = 1182.023 m/z [M+4H]4+ = 1476.325 m/z
Figure 5.64: a) Isotopic pattern of product P26-O2 that was monitored in RP-HPLC at 13.3 min, b) Entire ESI-MS 
spectrum of product P26 collected at a retention time of 19.9 min, c) isotopic pattern of peptide P26. 
A further deprotection experiment tested silver trifluoromethanesulfonate (AgOTf) for 
cleavaging Acm from P25. Deprotection was carried out in concentrated TFA containing 0.2 
M AgOTf following instruction 12.1.1. According to RP-HPLC analysis, 50% of the starting 
peptide P25 [Cys(Acm)11][Leu21]BM2(1-51) was deprotected after 10 min. Product P26
[Leu21]BM2(1-51) occurred at a retention time of 19.8 min similar to the deprotection 
product acquired by the oxidative deprotection with elemental iodine. The reaction was 
completed after 120 min. In table 5.30 the yields of the Acm deprotection by iodine and 
AgOTf are compared. 
Table 5.30: Acquired yields of peptide P26 by Acm deprotection using elemental iodine or AgOTf. 
Peptide Solution for Acm deprotection Yield [%]
[Leu21]BM2(1-51) 0.2 M AgOTf in TFA 66a
[Leu21]BM2(1-51) 0.2 M I2 in AcOH 20b
a Calculated by real obtained mass.
b Calculated by relative peak area analysis by RP-HPLC.
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After successful Acm deprotection using AgOTf, product P26 was purified by preparative  
RP-HPLC following procedure 8.1.7. The final peptide P26 [Leu21]BM2(1-51) was analyzed 
by analytical RP-HPLC and ESI-MS. In figures 5.65 the reinjection of the purified peptide P26
and the results of the mass spectrometry are illustrated. 
a)
b) ESI-MS of P26 [Leu21]BM2(1-51) c) Isotopic pattern P26
Theoretical average masses Theoretical monoisotopic mass
[M+6H]6+ = 985.187 m/z [M+4H]4+ = 1477.277 m/z C270H442N76O66S3
[M+5H]5+ = 1182.023 m/z [M+3H]3+ = 1969.367 m/z [M+5H]5+ = 1181.262 m/z
Figure 5.65: a) Reinjection of the purified product P26. The RP-HPLC experiment was performed with a C4 column 
(MultoHigh U C4, 100 x 4 mm) using water as eluent A and acetonitrile as eluent B containing 0.1% TFA. Gradient: 
45–70% acetonitrile in 30 min, with a flow rate of 1 ml/min, b) ESI-MS spectra of purified product P26 obtained by 
Acm deprotection using AgOTf, c) Isotopic pattern of the [M+5H]5+ signal of P26. 
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5.4. Predominate fold analysis of BM2 peptides by CD spectroscopy 
After cleavage from the solid support, freeze drying and purification, most chemically 
synthesized peptides were obtained as an unstructured “random coil”. Under physiological 
conditions and in the presence of folding inducing additives, defined secondary structures 
with the lowest energetic ground state are preferred. Fluorine containing solvents such as TFE 
possess folding promoting properties and facilitate the formation of secondary structures 
(chapter 3.5.2).[126a, 126b] A simple method to determine the percentage of α-helices,  
β-turns and unstructured regions within a peptide chain is circular dichroism (CD) 
spectroscopy. This method relies on differential absorption of right- and left-handed circularly 
polarized light through chiral, optically active molecules such as peptides and proteins.  
Right-handed α-helical peptides provide a CD spectrum with a characteristic negative CD band 
at 209 nm and 222 nm.[220] The helical content of the synthesized BM2 fragments P2
[Cys22]BM2(22-51) and P17 BM2(1-21)-NH2 and final target peptides P26 [Leu21]BM2(1-51) 
and P27 [Leu10]BM2(1-51) were determined by CD spectroscopy according to instruction 
8.1.9. Previous NMR studies already provided some structural information on the BM2 
channel sequence which is highlighted in figure 5.66.[195] However, the structure between 
residues 36-44 is not fully clarified yet.  
1 10 20 30 40 50
MLEPFQILSICSFILSALHFLCWTIGHLNQIKRGINMKIRIKGPNKETINR
rndm. helical rndm. unknown helical 
Figure 5.66: Available structural information of BM2(1-51) obtained from solution NMR and CD studies.[4, 195]
In order to gain more structural information’s about the BM2(1-51) channel domain, CD 
spectroscopy of the BM2 fragments P2 and P17 and of the ligation products P25, P26 and 
P27 were performed. These measurements were carried out in a phosphate buffer, TFE or 
POPC lipid bilayers according to instructions 8.1.9 and 8.1.10. 
Circular dichroism in phosphate buffer and TFE 
a) CD spectra of BM2 fragments in buffer or TFE b) CD spectra of final ligation products in TFE
Figure 5.67: Far UV CD spectra between 190–260 nm, a) BM2(1-21) P17 in TFE (blue), [Cys22]BM2(22-51) P2 in TFE 
(purple), [Cys22]BM2(22-51) P2 in 0.2 M Na2HPO4 buffer (red), b) [Cys(Acm)
11][Leu21]BM2(1-51) P25 (red), 
[Leu21]BM2(1-51) P26 (black) and [Leu10]BM2(1-51) P27 (blue).  
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CD spectroscopy of P2 [Cys22]BM2(1-51) in phosphate buffer showed a typical CD band for a 
random coil with an undefined secondary structure and a minimum at approximately 200 nm. 
The helical percentage of peptide P2 in phosphate buffer was lower than 20%. This result 
confirmed that phosphate buffers, without addition of helix promoting additives, are not cable 
of inducing peptide folding efficiently. However, analysis of P2 [Cys22]BM2(1-51) and P17
BM2(1-21)-NH2 in TFE displayed characteristic spectra for an α-helix. Surprisingly, analysis of 
P2 in TFE showed an unexpectedly high helical content of over 76.5% which was slightly 
higher than the α-helical content of peptide P17 (72.7%) that carries the half of the proton 
conducting channel domain of BM2(1-51). 
Deconvolution of CD spectra of P25 [Cys(Acm)11][Leu21]BM2(1-51), P26 [Leu21]BM2(1-51) 
and P27 [Leu10]BM2(1-51) showed α-helical contents between 59-66% (table 5.31). The 
additional Acm group at peptide P25 had only a minor but rather helix promoting effect in 
TFE. The results of the final deprotected ligation products P26 [Leu21]BM2(1-51) and  
P27 [Leu10]BM2(1-51) were almost equal and reached α-helical contents of around 60%. 
Table 5.31: Results of the deconvoluted CD spectra at a wavelength of 190-260 nm in TFE. 
Peptide P2a P2 P17 P25 P26 P27
Helical 18.10 % 76.50 % 72.70 % 66.30 % 63.30 % 59.1 %
Antiparallel 55.30% 0.40% 0.20% 0.60% 0.50% 0.7%
Parallel 10.00% 2.20% 3.90% 3.50% 4.80% 5.1%
Beta-Turn 22.30 % 11.00 % 10.10 % 12.00 % 11.60 % 12.4 %
Rndm. Coil 29.40 % 6.70 % 17.60 % 13.00 % 21.10 % 22.1 %
Total Sum 135.10 % 96.70 % 104.50 % 95.50 % 101.30 % 99.4 %
a 0.2 M Na2HPO4  buffer
Circular dichroism in POPC liposomes 
a) CD spectrum of P26 in POPC liposomes b) CD spectrum of P27 in POPC liposomes
Figure 5.68: Far UV CD spectra between 190–260 nm of the final BM2 peptides in 0.65 mM POPC, Na2HPO4 buffer 
at a pH of 7.5. a) P26 [Leu21]BM2(1-51), b) P27 [Leu10]BM2(1-51). 
Biological cell membranes are mainly composed of phospholipid bilayers in which 
transmembrane proteins are embedded. Commercially available phospholipids like  
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) are often applied to simulate the 
conditions in biological cell membranes due to their ability to form micelles or liposomes in 
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aqueous phosphate buffers. The lipophilic tails of phospholipids create a cell membrane 
similar liposome in which helical protein segments start to fold spontaneously.[221] In order to 
evaluate the secondary structure of the final peptides P26 [Leu21]BM2(1-51) and P27 
[Leu10]BM2(1-51), in a cell membrane-like environment, CD spectroscopy was recorded in 
unilamellar POPC liposomes with low polydispersity. The liposomal suspension was prepared 
by extrusion using a membrane with a pore size of 1 μm according to instructions 8.1.9 and 
8.1.10. Figure 5.68 displays the CD spectra of P26 [Leu21]BM2(1-51) and P27  
[Leu10]BM2(1-51) with the typical double minima at 211 nm and 228 nm.  
The data confirmed that the final BM2 peptides P26 [Leu21]BM2(1-51) and P27 
[Leu10]BM2(1-51) predominantly possess the characteristic folding of an α-helical structure in 
both POPC liposomes and TFE. Deconvolution of CD spectra revealed a predominant helical 
content of over 60% in POPC bilayers (table 5.32) which is in line with CD spectra in TFE 
(table 5.31).
Table 5.32: Results of the deconvoluted CD curves of peptides P26 and P27 at 200-260 nm in POPC/Na2HPO4 buffer. 
Peptide P26 [Leu21]BM2(1-51) P27 [Leu10]BM2(1-51)
Helical 65.4 % 64.3 %
Antiparallel 2.40% 2.50%
Parallel 4.30% 4.60%
Beta-Turn 10.8 % 10.9 %
Rndm. Coil 24.4 % 25.5 %
Total Sum 107.3 % 107.7 %
Previous NMR studies demonstrated that the region of BM2(6–28) forms an α-helical 
structure while the rest of the peptide sequence was predicted to be structurally disordered.[4]
In 2019, new NMR studies performed by Mei Hong et al. revealed that residues 1-5 and 29-35 
display chemical shifts that belong to random coil or β-sheet conformation.[195] The CD studies 
in TFE and POPC, which were performed during this work, indicate that the region between 
residues 36-44 might also contain an α-helical section which concurs with recently published 
NMR studies.[195]
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6. Conclusion 
Advantages and disadvantages of Hmp-peptides 
During this work, the Hmp group turned out to be highly useful for the preparation of peptide 
thioesters. Hmp-peptides provide several advantages over alternative thioester peptides such 
as a simple and fast synthesis and compatibility with Fmoc-based SPPS. Moreover, Hmp 
carries three functional groups which allow the attachment of C-terminal solubilizing tags or 
other functional groups. So far, the only alternative method which combines Fmoc-based 
SPPS with temporary bound solubilizing tags is the Dbz/MeDbz strategy developed by 
Dawson and co-workers.[40] However, in contrast to Dbz/MeDbz-peptides, Hmp-peptides are 
not prone to capping steps or over-acetylation and need no additional activation step by toxic 
chemicals such as 4-nitrophenyl chloroformate.[40a] During Fmoc-SPPS, Hmp is protected 
which reduces the risk of unexpected side reactions. Moreover, the thiol group of Hmp can be 
protected with different orthogonal protecting groups that enable one-pot ligations with 
multiple peptide segments. The only by-product that is formed during native chemical ligation 
is from hydrolysis of the Hmp-group under neutral or slightly basic conditions. This can 
decrease the ligation yield and needs to be kept into account while choosing  
Hmp-peptides.  
However, all ligation methods investigated during this work were performed with reasonable 
ligation yields of approximately 90%. Although previous reports described the advantages of 
Hmp, this building block is not commercially available so far. Indeed, Hmp could be 
efficiently synthesized in two steps during this work starting from cheap and easily available 
precursors (chapter 5.1.1).  
Synthesis of Hmp-peptides 
At the beginning of this thesis the production and properties of Hmp-peptides were intensively 
studied. The Mitsunobu reaction was found to be a decisive coupling step which was most 
efficient if performed as double coupling with a maximum coupling time of 2 h. Experiments 
with longer coupling times displayed no enhanced resin loadings. Racemisation of the Hmp 
coupled amino acid, induced by the Mitsunobu reaction, could be excluded as demonstrated 
by the synthesis and analysis of Phe-(L-Leu)-Hmp and Phe-(D-Leu)-Hmp (chapter 5.1.2). 
However, the very different retention times in the chromatogram of the investigated dipeptide 
diastereomers were a surprising finding during these studies. 
Model Hmp-peptides P4-P12 could be easily synthesized by manual Fmoc-SPPS. Peptides P4
[Ile21]BM2(17-21)-Hmp, P5 [Ile21]BM2(17-21)-Hmp-ADO and P6 [Ile21]BM2(17-21)-Hmp-
ADO2 were synthesized with isoleucine at the ligation site while P7 [Leu21]BM2(17-21)-Hmp, 
P8 [Leu21]BM2(17-21)-Hmp-ADO and P9 [Leu21]BM2(17-21)-Hmp-ADO2 were produced as 
leucine counterparts. Especially important was the production of model peptides P10
[Leu21]BM2(17-21)-Hmp-Lys5, P11 [Leu21]BM2(17-21)-Hmp-ADO-Lys5 and P12
[Leu21]BM2(17-21)-Hmp-ADO2-Lys5 which were assembled with C-terminal pentalysine tags. 
Thereby it was discovered that introduction of an ADO unit was necessary for a successful 
synthesis of Hmp-peptides with pentalysine tags. Peptide P10 [Leu21]BM2(17-21)-Hmp-Lys5
without an additional spacer unit could not be obtained by Fmoc-SPPS. However, after 
preparative RP-HPLC, P11 and P12 were obtained with yields of 1.1% and 1.7%, respectively. 
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Model peptides P13-P15 with C-terminal polyarginine tags could not be synthesized by  
Fmoc-SPPS even if ADO units were incorporated as spacer units. Synthesis of long  
Hmp-peptides P16-P20 succeeded by automated, microwave-assisted Fmoc-SPPS. In order to 
prevent peptide cleavage from the solid support, 2-methylpiperidine was necessary for Fmoc 
deprotection steps. After purification, peptide P16 [Leu10]BM2(1-10)-Hmp was acquired with 
a yield of 2.9%. Peptides P18 [Leu21]BM2(1-21)-Hmp and P19 [Leu21]BM2(1-21)-Hmp-ADO2
were obtained with 1.7% and 3.6% yield. Ingeniously, the synthesis of the long peptide P20
[Leu21]BM2(1-21)-Hmp-ADO-Lys5 also succeeded and reached a yield of 0.56% after 
purification by preparative RP-HPLC. In conclusion all planned peptides could be synthesized 
successfully by manual or automated Fmoc-SPPS except for the arginine carrying model 
peptides P13-P15. 
Solubilizing tag-assisted NCL
In a first set of ligation studies the influence of different solubilizing tags on ligation yields 
was studied. Therefore, model peptides P4, P7-P9, P11-P12 were ligated using a conventional 
(aqueous) buffer solution (chapter 5.1.9). P22 [Leu21]BM2(17-35) was acquired as product.  
Initial ligation studies with P4 [Ile21]BM2(17-21)-Hmp and P7 [Leu21]BM2(17-21)-Hmp 
revealed ligation yields of only 3% for the isoleucine carrying peptide P4 and 87% yield for 
the leucine counterpart P7. These results confirmed previous findings by Liu and  
co-workers.[60] Next, the influence of C-terminal ADO tags was tested by the ligation of P8
[Leu21]BM2(17-21)-Hmp-ADO and P9 [Leu21]BM2(17-21)-Hmp-ADO2 which both reached 
yields of approximately 85%. These results showed that C-terminal ADO units possess only a 
small steric hindrance which could not reduce ligation efficiency. Especially interesting were 
ligation experiments with peptides with C-terminal pentalysine tags. These ligation 
experiments were also performed in aqueous ligation buffer A. The successful ligations of 
model peptides P11 [Leu21]BM2(17-21)-Hmp-ADO-Lys5 and P12 [Leu
21]BM2(17-21)-Hmp-
ADO2-Lys5 proved the feasibility of the method. According to RP-HPLC analysis both ligations 
reached yields over 80% indicating only a small negative effect of the C-terminal pentalysine 
tag to the ligation yield. 
A powerful demonstration of the solubilizing tag-assisted NCL was made by the successful 
ligation of P23 [Cys(Acm)11][Cys22][Leu21]BM2(1-51) in aqueous phosphate buffer A. This 
ligation could be achieved with a yield of 71%. Since organic co-solvents as additives were not 
necessary in buffer A, the solubilizing tag-assisted native chemical ligation strategy represents 
an environmentally friendly method for the production of hydrophobic peptides.  
Investigation of the HFIP/TFE-assisted NCL 
The usage of fluorinated alcohols as co-solvents for aqueous ligation buffers turned out to be 
another efficient method to ligate hydrophobic Hmp-peptides. However, TFE as an additive 
led to the formation of an unexpected side product SP2 which was not capable of reacting 
during the ligation. ESI-MS revealed a mass increase of 26 Da which could be explained by 
carbamylation of the N-terminal cysteine residue of peptide P2 [Cys22]BM2(22-51). Possible 
peptide carbamylation is well described in the literature in the presence of cyanate. Different 
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studies investigated an equilibrium between urea and cyanate as well as cyclic modifications 
of cysteine side chains by cyanate.[213-214] However, this side reaction has never been described 
in the literature using TFE as a co-solvent for ligation buffers. Considering these results TFE 
was suspected to promote cyanate formation by deamination of urea. Successful ligation 
studies of the AM2 proton channel,[131] using TFE as a co-solvent, were performed in 
guanidinium chloride based buffers which tend not to in situ cyanate formation. In 
conclusion, it was found that TFE and urea cannot be used together for peptide buffers 
without the risk of unintended modifications. As a consequence HFIP was further investigated 
as a possible co-solvent for urea-based phosphate buffers. In the course of this work HFIP 
turned out to be an ideal co-solvent for Hmp-peptides. In contrast to TFE no peptide 
modifications were detectable in analytical RP-HPLC or ESI-MS using HFIP as co-solvent. All 
hydrophobic peptides P16 [Leu10]BM2(1-10)-Hmp, P18 [Leu21]BM2(1-21)-Hmp and P19
[Leu21]BM2(1-21)-Hmp-ADO2 were entirely soluble in the HFIP buffer C and could be 
efficiently ligated. Moreover, the presence of HFIP seemed to reduce the formation of the 
hydrolysis product. As a result, ligation products P23 [Cys(Acm)11][Cys22][Leu21]BM2(1-51) 
and P27 [Leu10]BM2(1-51) were acquired with yields of 82-96%. 
Investigation of N-heterocyclic carbenes (NHCs) in [C2mim][OAc]
The detailed study of [C2mim][OAc] during this thesis confirmed that imidazolium-based 
ionic liquids are able to chemically react with sulfur containing compounds and cysteine 
residues in peptides. For the first time reaction products of [C2mim][OAc] and organic model 
compounds could be isolated and unambiguously identified by TLC, ESI-MS and solution 
NMR. All sulfur containing compounds (PhSH, PhSSPh, BzlSH and BzlSSBZl) were tested as 
thiols and disulfides. Surprisingly, both forms (disulfides and thiols) were always detectable 
right after dissolution in the ionic liquid independent of which form was used as starting 
compound. This observation suggests that reducing and oxidizing conditions exist 
simultaneously in [C2mim][OAc]. The obtained RP-HPLC data confirmed the assumption that 
the in situ generated N-heterocyclic carbenes (NHCs) react primarily with disulfides (chapter 
5.2.5 and 5.2.6). This finding supports the hypothesis that thiols are oxidized first in 
[C2mim][OAc] before they undergo chemical modifications by imidazolium carbenes. 
Furthermore, it was found that the presence of an adjacent methyl group at the sulfur 
containing compound led to cleavage of sulfur. However, in absence of an adjacent methyl 
group as in the case of diphenyl disulfide, the reaction stops after reaction of the imidazolium 
cation with sulfur.  
In the further course of this work the cysteine containing peptide P1 [Cys22]BM2(22-35) was 
dissolved and analyzed in the neat ionic liquid [C2mim][OAc]. It could be demonstrated that 
peptide P1 was modified in a similar way as observed for the organic model compounds 
(PhSH, PhSSPh, BzlSH and BzlSSBZl). In neat [C2mim][OAc] peptide P1 was first oxidized to 
the disulfide before it was attacked by the imidazolium cation. Additionally, further oxidation 
of the cysteine residue was found by ESI-MS. An interesting side reaction was observed by 
desulfurization of cysteine to the corresponding alanine residue which provides a possible 
alterative way for a one-pot ligation-desulfurization strategy. However, this observed side 
reaction must first be investigated and improved in further studies before it can be used as an 
alternative synthetic pathway for hydrophobic peptides.
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Ligation experiments in [C2mim][OAc] 
The native chemical ligation in the ionic liquid based buffers succeeded for short model  
Hmp-peptides as well as for long and hydrophobic BM2 fragments. The discovery that a water 
content of at least 30% was sufficient to prevent NHCs-induced modifications of peptide  
P1 [Cys22]BM2(22-35) was the fundament of the IL-based buffer solution (chapter 5.2.8). The 
ideal water content for the native chemical ligation of Hmp-peptides was discovered by a 
series of ligation experiments using rising amounts of water from 0-50% (v/v). P7
[Leu21]BM2(17-21)-Hmp and P1 [Cys22]BM2(22-35) were applied as model peptides for these 
ligation studies (chapter 5.2.9).  
The IL-based ligation buffers D1 (0% water, pH 11.4) and D2 (10% water, pH 10.5) showed 
no product formation. These results were explained by the high pH values of the solutions 
which primarily hydrolysed the Hmp group. Buffer D3 (20% water, pH 9.45) showed product 
formation, however, with a yield of only 10%. In buffer D4 (30% water, pH 8.70) a ligation 
yield of 40.8% was achieved. Buffer D5 (40% water, pH 7.5) turned out as most efficient 
ligation media. This buffer solution was composed of 60% [C2mim][OAc] and 40% water 
containing 150 mM TCEP HCl and 150 mM thiophenol. In buffer D5 ligation product P22
[Leu21]BM2(17-35) was obtained with a yield of 72%. Although buffer D6 (50% water,  
pH 6.8) showed ligation yields of approximately 56%, a dramatic loss of peptide solubility 
began. In the further course of this work buffer D5 was investigated for the ligation of long 
hydrophobic BM2 segments. The power of the this buffer solution was impressively 
demonstrated by the successful ligation of the final product P27 [Leu10]BM2(1-51) with yields 
between 73-76% (chapter 5.2.10). 
Desulfurization and Acm deprotection 
The radical-based desulfurization of peptide P23 [Cys(Acm)11][Leu21][Cys22]BM2(1-51) to 
product P25 [Cys(Acm)11][Leu21]BM2(1-51) was not possible in the commonly applied 6 M 
guanidinium chloride based (aqueous) desulfurization buffer which is usually described in 
literature. The poor solubility of peptide P23 led to precipitation and poor cysteine conversion 
as shown in the desulfurization experiment using the standard, aqueous buffer solution 
(chapter 5.3.1). Since HFIP was successfully applied in ligation experiments (chapter 5.2.3), 
desulfurization buffers on the base of HFIP were tested. As result an HFIP/buffer based 
emulsion was discovered, which could be successfully applied for the desulfurization of 
peptide P23 with a yield of 99%. The newly developed emulsion showed further advantages 
in comparison with “classical” buffer solutions. One major benefit was the significantly 
simplified product separation by centrifugation. After centrifugation almost all the peptide 
was left in the lower HFIP phase as shown in figure 5.62. By separation of the upper aqueous 
phase all good water soluble impurities were removed immediately. The remaining lower 
HFIP phase could then be subjected to preparative RP-HPLC for purification of product P25. 
Acm deprotection of peptide P25 [Cys(Acm)11][Leu21]BM2(1-51) to the product P26
[Leu21]BM2(1-51) succeeded in two different ways. In a first experiment deprotection of Acm 
was possible by treatment with elementary iodine reaching 20% yield. However, massive 
amounts of oxidized side products were detected by ESI-MS and analytical RP-HPLC. Finally, 
the deprotection of Acm was achieved with a yield of 66% using silver 
trifluoromethanesulfonate (AgOTf). 
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Predominant fold analysis of the final target peptides by CD spectroscopy 
Structural analysis of P26 [Leu21]BM2(1-51) and P27 [Leu10]BM2(1-51) displayed a 
characteristic spectra of an α-helix with double-minima at 209/223 nm in TFE and 211/228 
nm in the POPC emulsion. The deconvolution of the CD spectra in TFE or POPC liposomes 
gave similar results. It was found that P26 and P27 exist predominantly in an α-helical form, 
containing around 60% α-helix which is in line with recent NMR studies.[195] These finding 
might indicate some ordered helical regions between the BM2 residues 36-44 which were 
predicted to be structurally disordered in former solution NMR studies of the BM2 channel.[4]
Comparison of the final target peptides with the native BM2(1-51) sequence 
During this thesis the first total chemical synthesis of the two hydrophobic membrane peptide 
sequences P26 [Leu21]BM2(1-51) and P27 [Leu10]BM2(1-51) was achieved. Substitution of 
Ile10 or Ile21 by leucine was necessary for synthesis via NCL since isoleucine neighbouring 
ligation sites resulted in exceptionally low ligation yields (chapter 5.1.9). These results 
confirmed previous studies with Hmp-peptides by F. Liu and co-workers.[60] According to the 
current state of knowledge, both mutation sites Leu21 and Leu10 are located outside of the 
channel pore, directed to the lipid bilayer membrane (figure 3.8).[4] For this reason, it is 
reasonable to suppose that the mutations should not dramatically change the function and the 
proton flux rate compared to the native BM2(1-51) sequence. 
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7. Chemicals and Materials 
7.1. Reagents and solvents for analytic methods 
All reagents and solvents for analytical purposes were purchased from commercial sources 
and stored according to manufacturer recommendations. 
Liquid chemicals for analytic: Acetonitrile HPLC grade (Sigma-Aldrich), water HPLC grade 
(VWR chemicals), trifluoroacetic acid for HPLC (Carl Roth), demethylsolfoxid-d6 (DMSO-d6) 
(Sigma Aldrich), chloroform-d1 (CDCl3) (Deutero), deuterium oxide (D2O) (Deutero), 
cyclohexane-d12 (Deutero), 1,1,1,3,3,3-hexaflorpropan-2-ol (Carbolution Chemicals),  
2,2,2-trifluorethanol (Carbolution Chemicals). 
Solid chemicals for analytic: Sinapinic acid (Fluka analytical), cyano-4-hydroxycinnamic 
acid (Sigma-Aldrich), 5,5-dithiobis-2-nitrobenzoic acid (Ellman-reagent) (VWR Chemicals),  
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) (Avanti). 
7.2. Reagents and solvents for synthetic methods 
All purchased reagents and building blocks for the Fmoc-solid phase peptide synthesis  
(Fmoc-SPPS) were used without pre-purification and stored as recommended by the 
manufacturer. The Hmp(Trt) building block was synthesized according to procedure 9.1 and 
used without further purification steps.  
Solvents and liquid reagents for synthesis: Anisole (Sigma-Aldrich), dichloromethane  
(Carl Roth), diethyl ether (Carl Roth), diisopopylcarbodiimide (Iris Biotech),  
N,N-dimethylformamide (Merck Millipore), hydrochloric acid (VWR Chemicals),  
N,N-diisopropylethylamine (Sigma-Aldrich), N-methyl-2-pyrrolidone (Carl Roth), piperidine 
(Carl Roth), tetrahydrofuran anhydrous (VWR Chemicals), trifluoroacetic acid (Carl Roth), 
triisoprpylsilane (Sigma-Aldrich),  (Sigma-Aldrich), N,N-diisopropylethylamine (Carl Roth), 
acetic acid (Carl Roth), acetic acid anhydride (Carl Roth), 1,2-diemethoxyethane (Sigma-
Aldrich), 1,1,1,3,3,3-hexaflorpropan-2-ol (Carbolution Chemicals), 2,2,2-trifluorethanol 
(Carbolution Chemicals), 2-methylpiperidine (Alfa Aesar), 3-chloro-1,2-propanediol (Sigma-
Aldrich), hexane (Sigma-Aldrich), 1-ethyl-3-methylimidazolium acetate [C2mim][AcO] 
(Iolitec), thiophenol (Sigma-Aldrich), benzyl mercaptan (Alfa Aesar), diphenyl sulfide (Sigma-
Aldrich), diethyl azodicaboxylate solution in 40% toluene (Sigma-Aldrich), N,N,N,N-
tetramethylethylenediamine (Sigma-Aldrich), nitric acid 68% (Carl Roth). 
Solid reagents for synthesis: Guanidinium chloride (Carl Roth), O-(7-Azabenzotriazol-1-yl)-
N,N,N′,N′-tetramethyluronium-hexafluorphosphat (HATU) (Carbolution Chemicals), 
monosodium phosphate (Carl Roth), sodium hydroxide (Carl Roth), tris-(2-carboxyethyl)-
phosphine hydrochloride (TCEP ·HCl) (Iris Biotech), 4-mercatophenylacetic acid (Sigma-
Aldrich), urea (Carl Roth), disodium phosphate (Carl Roth), glutathione (Sigma Aldrich),  
2,2-dithiobis(5-nitropyridine) (Sigma Aldrich), 2,2-azobis[2-(2-imidazolin-2-yl)propane 
dihydrochloride (VA044) (TCI), sodium hydride 60% dispersion in mineral oil (Sigma-
Aldrich).  
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Table 7.1: Solid supports for the Fmoc-solid phase peptide synthesis (Fmoc-SPPS). 
Name Loading [mmol/g] Commercial source
AmphiSpheres 40 RAM 0.33 / 0.27 Agilent Technologies
TentaGel R RAM 0.18 RAPP Polymere
Rink Amide MBHA resin 0.40 Novabiochem
Table 7.2: Used Fmoc protected building blocks for the solid phase peptide synthesis (SPPS). 
Building blocks for Fmoc-SPPS  Molecular weight [g/mol] Commercial source 
Fmoc-L-Ala-OH 311.3 Carbolution Chemicals
Fmoc-L-Arg(Pbf)-OH 648.8 Carbolution Chemicals
Fmoc-L-Asn(Trt)-OH 596.7 Carbolution Chemicals
Fmoc-L-Asp(OtBu)-OH 411.5 Carbolution Chemicals
Fmoc-L-Cys(Trt)-OH 585.7 Carbolution Chemicals
Fmoc-L-Gln(Trt)-OH 610.7 Carbolution Chemicals
Fmoc-L-Glu(OtBu)-OH 425.5 Carbolution Chemicals
Fmoc-L-Gly-OH 297.3 Carbolution Chemicals
Fmoc-L-His(Trt)-OH 619.7 Carbolution Chemicals
Fmoc-L-Ile-OH 353.4 Carbolution Chemicals
Fmoc-L-Leu-OH 353.4 Carbolution Chemicals
Fmoc-L-Lys(Boc)-OH 468.6 Carbolution Chemicals
Fmoc-L-Met-OH 371.5 Carbolution Chemicals
Fmoc-L-Phe-OH 387.4 Carbolution Chemicals
Fmoc-L-Pro-OH 337.3 Carbolution Chemicals
Fmoc-L-Ser(tBu)-OH 383.4 Carbolution Chemicals
Fmoc-L-Thr(tBu)-OH 397.5 Carbolution Chemicals
Fmoc-L-Trp(Boc)-OH 526.6 Carbolution Chemicals
Fmoc-L-Tyr(tBu)-OH 459.5 Carbolution Chemicals
Fmoc-L-Val-OH 339.4 Carbolution Chemicals
Fmoc-8-amino-3,6-dioxaoctanoiic 
acid (Fmoc-ADO-OH) 385.42 Ires Biotech 
Hmp(Trt)-OH 332.0 Comm. not available
Fmoc-Cys(Acm)-OH 378.0 Ires Biotech
Fmoc-D-Leu-OH 353.4 Carbolution Chemicals
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7.3. Laboratory equipment 
Table 7.3: Instruments for analytical or synthetic methods used during this work.  
Analytical/Synthetic method Instrument Type Manufacturer 
Preparative RP-HPLC 
996 Photodiode Array Detector (PAD)
600-MS system controller 
600 Pump 
Waters 
Analytical RP-HPLC 2998 Photodiode Array Detector 2695 Separation Module Waters 
MALDI-TOF-MS Autoflex speed TOF/TOF Bruker Daltonik
Electrospray ionization (ESI) 
mass spectrometry Impact II Bruker Daltonik
LC-MS HPLC 1200/Impact II Agilent/Bruker 
UV/Vis spectroscopy UV-1600PC VWR 
pH measurement 716 DMS Titrino Five Easy F20
Metrohm 
Mettler Toledo
Peptide synthesis Liberty CEM 
Circular dichroism (CD) 
spectroscopy J-810 spectropolarimeter Jasco 
Nuclear Magnetic Resonance 
(NMR) spectroscopy 
300 MHz Avance III 
500 MHz DRX 500 Bruker BioSpin 
Table 7.4: Analytical columns for reverse phase high-performance liquid chromatography (RP-HPLC). 
Solid phase Column specification 
C4 MultoHigh Bio 300-5-C4, 125 x 4 mm, 300 Å pore diameter, 5 μm particle size 
C4 MultoHigh U C4, 100 x 4 mm, 100 Å pore diameter, 5 μm particle size 
C8 Prontosil 120-5 C8 SH, 125 x 4 mm, 120 Å pore diameters, 5 μm particle size
C18 MultoHigh 100 RP18 3μ, 150 x 4 mm, 100 Å pore diameter, 3 μm particle size
Table 7.5: Preparative columns for reverse phase high-performance liquid chromatography (RP-HPLC). 
Solid phase Column specification 
C4 MultoHigh Bio300-5, 250 x 20 mm, 300 Å pore diameter, 5.0 μm particle size 
C18 MultoKrom 100-5, 250 x 20 mm, 100 Å pore diameter, 5.0 μm particle size 
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8. Analytical Methods  
8.1. Analytic methods 
8.1.1.  Analysis of thiols and disulfides in [C2mim][OAc]  
Reactions of sulfur-containing compounds in 1‑ethyl-3-methyl-imidazolium acetate were 
studied by dissolving thiophenol (19.8 mg, 1.83 μl), diphenyl disulfide (39.3 mg), benzyl 
mercaptan (22.3 mg, 2.11 μl) and dibenzyl disulfide (44.4 mg) in 1.5 ml neat [C2mim][OAc]. 
The mixtures were agitated at room temperature until reactions were completed according to 
RP-HPLC analysis. For reaction monitoring by RP-HPLC aliquots of the solutions (5 μl) were 
dissolved in 250 μl acetonitrile (0.1% TFA) and analyzed after 0, 1, 2, 4, 8, 12, 24, 48 and 
72 h. Reaction products were purified by column chromatography using a mixture of 
acetonitrile/water (9:1) as an eluent. Product containing fractions were combined and 
evaporated under reduced pressure. For clear identification, all products were analyzed by 
TLC, ESI-MS and NMR spectroscopy.  
8.1.2.  Analysis of [Cys22]BM2(22-35) in [C2mim][OAc]  
Model peptide [Cys22]BM2(23-35) (0.825 mg, 12 mM) was dissolved in 43 μl neat 
[C2mim][OAc] (molar ratio 1:500) and agitated at room temperature until no further reaction 
progress was detectable by RP-HPLC. The effect of the water content to possible peptide 
modifications was investigated by increasing the water content (10, 20, 30% (v/v). For 
sample preparation, aliquots of the reaction mixture (4 μl) were dissolved in 60 μl 
acetonitrile/water (0.4% TFA) and analyzed after 0, 0.5, 1, 2, 4, 8 and 24 h. All found 
products in the chromatogram were separated and analyzed by ESI-MS. 
8.1.3.  Thin-layer chromatography (TLC) 
Thin-layer chromatography (TLC) was carried out on silica gel 60 F 254 coated glass plates. 
For hydrophobic samples pure n-hexane or a mixture of n-hexane/ethyl acetate (59:1, v/v) 
was prepared. For hydrophilic or ionic substances, a solvent system containing 
acetonitrile/water (9:1, v/v) was applied. All plates were analysed by UV irradiation with 
254  nm and 366 nm. The results and retardation factors (RF) of the TLC measurements are 
shown in the appendix (chapter 15.2.2). 
8.1.4.  Nuclear magnetic resonance (NMR) spectroscopy 
NMR spectroscopy was performed using a Bruker Avance III spectrometer with a frequency of 
300 MHz for 1H-NMR and 75 MHz for 13C-NMR. Ionic liquids and hydrophilic compounds 
were dissolved in deuterium oxide (D2O) or dimethyl sulfoxide-d6 (DMSO-d6). For 
hydrophobic compounds chloroform-d1 (Cl3CD) or cyclohexane-d12 was used. Hydrophobic 
and volatile substances which could not be isolated from ionic liquids by column 
chromatography were directly extracted by cyclohexane-d12 and measured. All results were 
evaluated using MestReNova 11.0 software from Mestrelab Research.  
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8.1.5. Mass spectrometry LC-MS, ESI-MS and MALDI-TOF-MS 
MALDI-TOF mass spectrometry was performed using an Autoflex speed TOF/TOF
spectrometer from Bruker Daltonics. Sinapinic acid (SA) or α-cyano-4-hydroxycinnamic acid 
(HCCA) were applied as a matrix for the preparation of peptide samples. The samples were 
dissolved in a mixture of acetonitrile and water (80/20%, v/v) containing 0.1% TFA and 
mixed with a concentrated matrix solution (1:1). For sample preparation, 0.2 μl of the 
mixture was pipetted onto a MALDI-TOF target plate and dried at room temperature. 
Liquid chromatography mass spectrometry (LC-MS) was carried out with an Impact II mass 
spectrometer from Bruker Daltonics. As ionization method, electrospray ionization (ESI) was 
applied. Good water soluble samples were dissolved in 0.1% TFA or in a mixture of 
acetonitrile and 0.1% TFA (1:1). Hydrophobic samples, especially hydrophobic peptides, were 
dissolved in a mixture of 70% TFE and 30% water containing 0.1% TFA. 
8.1.6.  Reverse-phase high performance liquid chromatography  
Analytical reverse-phase high performance liquid chromatography (RP-HPLC) was carried out 
on a Waters HPLC System (2695 Separation Module, 2998 PAD). As eluent A, water  
(0.1% TFA) and as eluent B, acetonitrile (0.1% TFA) were applied. Analysis of short model 
peptides were performed on a C18 column (MultoHigh 100 RP18 3μ, 150 x 4 mm, 100 Å pore 
diameter, 3 μm particle size). Long, hydrophobic peptides were measured on one of two  
C4 columns (MultoHigh Bio 300-5-C4, 125 x 4 mm, 300 Å pore diameter, 5 μm particle size 
or MultoHigh U C4, 100 x 4 mm). HPLC studies with ionic liquids were performed with a C8 
column (Prontosil 120-5 C8 SH, 125 x 4 mm, 120 Å pore diameters, 5 μm particle size). 
Strong hydrophobic and poorly soluble peptides were pre-dissolved with TFE or HFIP and 
diluted with a 0.2% TFA. The used columns, the gradient and the exact method of each 
measurement are described in the caption of each chromatogram. 
8.1.7. Purification by preparative RP-HPLC 
Short model peptides were purified by preparative RP-HPLC using a C18 column (MultoKrom 
100-5, 250 x 20 mm, 100 Å pore diameter, 5.0 μm particle size) with water (0.1% TFA) and 
acetonitrile (0.1% TFA) as eluents. Longer, more hydrophobic peptides were purified with a 
C4 column (MultoHigh Bio300-5, 250 x 20 mm, 300 Å pore diameter, 5.0 μm particle size). 
Good soluble peptides were dissolved in the smallest possible amount of water/acetonitrile 
(0.2% TFA) (2:1). Hydrophobic peptides were pre-dissolved in TFE or HFIP and carefully 
diluted (without precipitation) using a mixture of water/acetonitrile (0.2% TFA) (1:1). 
Peptides obtained by ligation, desulfurization or Acm deprotection were directly separated 
from the reaction buffer. Therefore, the buffers were diluted with TFE/water (0.2% TFA) 
(1:1) and injected in the preparative HPLC. After purification, the separated fractions were 
frozen and lyophilized. The purified products were characterized by mass spectrometry 
(8.1.5) and analytical RP-HPLC (8.1.6).  
 110                                                                                                                                                                Analytical Methods
8.1.8.  UV/Vis spectroscopy 
UV/Vis spectroscopy was primarily used to determine the number of Fmoc-groups on the resin 
support. To calculate the resin loading the method of Eissler and Samson was applied.[222]
Fmoc cleavage was achieved by 20% piperidine in DMF. The piperidine solution was agitated 
with the resin twice (5 min, 15 min) and transferred into a 50 ml volumetric flask. 
Subsequently, the volumetric flask was filled up to 50 ml with 20% piperidine/DMF solution. 
The concentrated Fmoc deprotection solution from the flask was diluted  
(1:100, v/v) with 20% piperidine/DMF and transferred in a cuvette with 1 cm path length. 
The absorption of the diluted Fmoc deprotection solution was analysed at 289.8 nm. As 
reference (blank) sample served 20% piperidine solution in DMF. The calculation of the resin 
loading was carried out with formula 1. 
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Figure 8.1 Absorption spectrum of the Fmoc deprotection product N-(9H-Fluoren-9-ylmethyl)-piperidine in 20% 
piperidine/DMF. The absorption maximum at 298.8 nm shows a broader signal compared to 301 nm which led to a 
more accurate calculation of the resin loading using formula 1.[222]
8.1.9.  Circular dichroism (CD)-spectroscopy 
Circular dichroism (CD) was recorded with a Jasco J-810 spectropolarimeter using a 
wavelength range between 190 – 260 nm at 20 °C (0.1 cm path-length cuvette). CD 
spectroscopy in TFE or in phosphate buffer (0.2 M Na2HPO4, pH 7.0) was performed at a 
peptide concentration of 0.1 mg/ml. Peptides which were measured in 1-palmitoyl-2-oleoyl-
sn-glycero-3-phosphocholine (POPC) liposomes were prepared as follows: 1 mM  
(1.0 equiv.) of the peptide and 15 mM (15.0 equiv.) POPC were dissolved in the smallest 
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possible amount of TFE. Subsequently, TFE was removed from the sample with nitrogen gas 
and the remaining residue was dried in vacuum for 24 h. The dried residue was suspended in 
degassed Na2HPO4 buffer (10 mM, pH 7.5) under argon atmosphere for 2 h at room 
temperature. The amount of degassed Na2HPO4 buffer was calculated to a final POPC 
concentration of 0.5  mg/ml. Finally, the sample was subjected to three freeze/thaw cycles 
and extruded 20 times through a polycarbonate membrane following instruction 8.1.10. All 
data were acquired in [mdeg] and converted into molar ellipticity [deg x cm2 x dmol-1]. The 
obtained data were deconvoluted using the software CDNN. 
Table 8.1: Amounts and peptides investigated by CD spectroscopy. 
Entry Type Peptide [mg] Buffer / Solvent
P2
Fragments
[Cys22]BM2(22-51) 0.02 phosphate buffer
P2 [Cys22]BM2(22-51) 0.02 TFE
P17 BM2(1-21)-NH2 0.02 TFE
P25
Ligation 
products 
[Cys(Acm)11][Leu21]BM2(1-51) 0.02 TFE
P26 [Leu21]BM2(1-51) 0.02 TFE
P27 [Leu10]BM2(1-51) 0.02 TFE
P26 Ligation
products 
[Leu21]BM2(1-51) 0.02 POPC buffer
P27 [Leu10]BM2(1-51) 0.02 POPC buffer
Phosphate buffer: 0.2 M Na2HPO4 buffer, pH 7.0
POPC buffer: 0.65 mM POPC in 10 mM Na2HPO4, pH 7.5
UV -Range Vol. [ml] Conc. [mg/ml] Cuvette length Temp.
190 – 260 nm 0.2 0.1 0.1 cm 20 °C
8.1.10. Reconstitution of membrane peptides into lipid POPC vehicles 
Liposomal POPC suspensions for CD spectroscopy were prepared by extrusion using a mini 
extruder with a polycarbonate membrane. The extrusion was performed over the transition 
temperature of POPC (Tm = -2 °C) at room temperature. The assembly of the mini extruder is 
illustrated in the three-dimensional exploded view drawing below.  
Figure 8.2: Assembly of the Extruder, 1) Polycarbonate Membrane, 2) Filter Supports, 3) O-Rings, 4) Membrane 
Supports, 5) Teflon Ring, 6) Retainer Nut, 7) Outer Casting.
Once the sample was subjected to three freeze-thaw cycles the solution was carefully loaded 
in a gas-tight syringe which was placed into the hole of retainer nut 6. An empty second 
syringe was placed in the hole at the end of the outer casting 7. The samples were extruded 
by transferring the solution through the polycarbonate membrane 1 (pore size: 1 μm) from 
the syringe at position 6 into the syringe at position 7. This step was repeated 20 times to 
obtain unilamellar vesicles. 
 112                                                                                                                                                                 Synthetic Methods
8.1.11.  SDS-polyacrylamide gel electrophoresis (PAGE) 
Preparation of the buffers and gels were performed as described in the literature.[223] Peptide 
samples were prepared in 20 μl of sample buffer by heating to 95 °C for 10 minutes. The 
electrophoresis was performed with an initial voltage of 30 V until the sample completely 
entered the stacking gel. Finally, the voltage was increased to 200 V until the run was over. 
Gels were stained after gel electrophoresis with 0.02% Coomassie stain solution and then 
destained by a fixing solution for 6 h at room temperature. Protein sizes were compared to a 
color-coded low range Protein Marker (1.7-42 kDa) as a reference.  
9. Synthetic Methods 
9.1. Synthesis of Hmp(Trt) 
9.1.1.  3-Chloro-2-hydroxypropanoic acid 
3-chloro-1, 2-propanediole (1 equiv., 10.0 g, 90.5 mmol) was carefully added to 30 ml conc. 
nitric acid and slowly heated to 80 °C until the release of brown nitrogen oxides started. The 
temperature was kept at 80 °C for 20 min and carefully increased to 100 °C for further 
20 min. Afterwards, the reaction solution was cooled to room temperature and partially 
neutralized by slowly adding 7 g NaHCO3. The product was extracted with diethyl ether  
(6 x 100 ml), the organic layer dried over Na2SO4 and the solvent removed under reduced 
pressure. At the end of the evaporation the temperature was carefully increased to 60 °C to 
remove any remaining nitric acid. In order to precipitate the product, the viscous residue was 
cooled to 5 °C and treated with ultrasonic. Finally, the crude product was washed three times 
with cold chloroform and filtered to obtain 7.4 g (66%) 3-chloro-2-hydroxypropanoic acid. 
9.1.2.  2-Hydroxy-3-(triphenylmethyl)thio-propanoic acid (Hmp(Trt)) 
3-chloro-2-hydroxypropanoic acid (1 equiv., 5.92 g, 47.5 mmol) was dissolved in 50 ml  
dry-DME and cooled to 0 °C. Sodium hydride (60% oil dispersion) (1 equiv., 1.9 g,  
47.5 mmol) was slowly added to the stirred solution in small portions. A second solution of 
triphenylmethyl thiol (1.05 equiv., 13.11 g, 49.8 mmol) and sodium hydride (1 equiv., 1.9 g, 
47.5 mmol) was added dropwise within 30 min under stirring. After 4 h of stirring, the 
solvent was removed under reduced pressure. The remaining residue was dissolved in a 
mixture of 400 ml diethyl ether/water (1:1). Afterwards the aqueous phase was separated, 
washed with diethyl ether (2 x 100 ml) and acidified to a final pH of 3 using 1 M hydrochloric 
acid. The product was extracted with ethyl acetate (3 x 100 ml) and the organic layer dried 
over Na2SO4. Finally, the solvent was removed under reduced pressure until a highly viscous 
liquid was left. The viscous liquid was solidified in the refrigerator and the rest of the solvent 
was removed under reduced pressure at room temperature. The dry and yellow powder was 
directly used for Fmoc-SPPS. Yield: 11.08 g (98%). 
Synthetic Methods   113
9.2. Manual synthesis of model Hmp-peptides 
Manual Fmoc-SPPS of Hmp-peptides was performed in a syringe with a filter inlet. The exact 
amounts of amino acids, activator and activator base as well as the coupling/deprotection 
conditions are presented for each peptide in the tables below. Peptides with a C-terminal 
solubilizing tag (Lys5, ADO2) were preloaded manually following a standard Fmoc-SPPS 
protocol using the respective amino acid building block (4 equiv., 0.2 M) with  
1-[bis(dimethylamin)methylen]-1H-1,2,3-triazol[4,5-b]pyridinium-3-oxid-hexafluorophosphat 
(HATU, 0.2 M, 3.95 equiv.) as an activator and N,N-diisopropylethylamin (DIEA, 0.4 M, 8.00 
equiv.) as an activator base. All coupling steps were performed twice at room temperature for 
30 min. Fmoc cleavage was achieved by treating the resin for 5 min and 15 min with 20% 
piperidine/DMF solution at room temperature. Loading determination was performed using 
the method of Eissler and Samson according to instruction 8.1.8.[222] All coupling and 
deprotection steps were followed by intense washing steps with DMF and DCM.  
For the coupling of the Hmp rearrangement unit Hmp(Trt) (4.0 equiv., 0.2 M), HATU  
(3.95 equiv., 0.2 M) and DIEA (8.0 equiv., 0.4 M) were dissolved in DMF and agitated with 
the resin for 60 min at room temperature (double coupling). The first amino acid  
(Leu or Ile) at Hmp(Trt) was coupled by the Mitsunobu reaction. According to this procedure, 
amino acid coupling was achieved by agitating the solid support in a solution of the respective 
amino acid (0.2 M, 4 equiv.), triphenylphosphane (PPh3, 0.2 M, 3.9 equiv.) and diethyl 
azodicarboxylate (DEAD, 40 wt% in toluene, 3.9 equiv.) in dry-THF (2 h, double coupling).  
Peptide cleavage from the resin was achieved in a mixture of 90% TFA, 5% water, 2.5% TIPS 
and 2.5% anisole for 3 h at room temperature. For 100 mg of resin, 1 ml of cleavage solution 
was applied. The crude peptides were precipitated in cold diethyl ether, centrifuged, and 
washed with three times with cold diethyl ether. 
Table 9.1: Types, amounts and loading capacities of resin supports for manual Fmoc-SPPS of Hmp-peptides.  
Entry Peptide Resin Amount [g] Loading [mmol/g]
P4 [Ile21]BM2(17-21)-Hmp 0.30a 0.33
P5 [Ile21]BM2(17-21)-Hmp-ADO 0.125b 0.18
P6 [Ile21]BM2(17-21)-Hmp-ADO2 0.125b 0.18
P7 [Leu21]BM2(17-21)-Hmp 0.5a 0.33
P8 [Leu21]BM2(17-21)-Hmp-ADO 0.25a 0.33
P9 [Leu21]BM2(17-21)-Hmp-ADO2 0.25a 0.33
P10 [Leu21]BM2(17-21)-Hmp-Lys5 0.25a 0.33
P11 [Leu21]BM2(17-21)-Hmp-ADO-Lys5 0.25a 0.33
P12 [Leu21]BM2(17-21)-Hmp-ADO2-Lys5 0.25a 0.33
P13 [Leu21]BM2(17-21)-Hmp-Arg5 0.25a 0.33
P14 [Leu21]BM2(17-21)-Hmp-ADO-Arg5 0.25a 0.33
P15 [Leu21]BM2(17-21)-Hmp-ADO2-Arg5 0.25a 0.33
a AmphiSpheres RAM 40 resin
b Tentagel resin
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Synthesis of P4: [Ile21]BM2(17-21)-Hmp 
Table 9.2: Amino acids and coupling conditions for the manual Fmoc-SPPS of peptide P4. 
Building 
block 
Amount
[mg] 
DMF 
[ml] 
Activator/Base and 
coupling conditions 
Deprotection Base and 
conditions 
Hmp 145 2 
HATU/DIEA,
30 min (double coupling)
No deprotection 
Ile 140 
2.5
dry-THF 
DEAD/PPh3, 2 h
(double coupling)
20% piperidine, double 
deprotection  
(5 min, 15 min)
Phe 155 2
HATU/DIEA, 
30 min (double coupling)
His 248 2
Leu 140 2
Ala 130 2
Coupling with HATU/DIEA 149 mg HATU/138 μl DIEA
Wash after coupling 1 min , 5 ml (3 times DMF)
Fmoc-deprotection 5 ml (20% piperidine/DMF)
Wash after Fmoc-deprotection 1 min, 5 ml (3 times DMF, 3 times DCM, 3 times DMF)
Wash before Mitsunobu reaction 1 min , 5 ml (3 times DMF, 4 times dry-THF)
Coupling with DEAD/PPh3 225 μl DEAD (100%)/130 mg PPh3
Wash after Mitsunobu reaction 1 min , 5 ml (5 times DMF)
Synthesis of P5: [Ile21]BM2(17-21)-Hmp-ADO 
Table 9.3: Amino acids and coupling conditions for the manual Fmoc-SPPS of peptide P5.
Building 
block 
Amount
[mg] 
DMF 
[ml] 
Activator/Base and 
coupling conditions 
Deprotection Base and 
conditions 
ADO 70 2.0 HATU/DIEA,  
30 min (double coupling)
20% piperidine, double 
deprotection  
(5 min, 15 min) 
Hmp 82 2.0 No deprotection
Ile 160 
2.3
dry-THF 
DEAD/PPh3, 2 h 
(double coupling) 
20% piperidine, double 
deprotection  
(5 min, 15 min)
Phe 70 2.0
HATU/DIEA,  
30 min (double coupling)
His 112 2.0
Leu 64 2.0
Ala 60 2.0
Coupling with HATU/DIEA 67 mg HATU/63 μl DIEA 
Wash after coupling 1 min , 3 ml (3 times DMF)
Fmoc-deprotection 3 ml (20% piperidine/DMF)
Wash after Fmoc-deprotection 1 min, 3 ml (3 times DMF, 3 times DCM, 3 times DMF)
Wash before Mitsunobu reaction 1 min , 3 ml (3 times DMF, 4 times dry-THF)
Coupling with DEAD/PPh3 70 μl DEAD (100%)/118 mg PPh3
Wash after Mitsunobu reaction 1 min , 3 ml (5 times DMF)
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Synthesis of P6: [Ile21]BM2(17-21)-Hmp-ADO2
Table 9.4: Amino acids and coupling conditions for the manual Fmoc-SPPS of peptide P6. 
Building 
block 
Amount
[mg] 
DMF 
[ml] 
Activator/Base and 
coupling conditions 
Deprotection Base and 
conditions 
ADO 70 2.0
HATU/DIEA,  
30 min (double coupling)
20% piperidine, double 
deprotection  
(5 min, 15 min) 
ADO 70 2.0 
Hmp 82 2.0 No deprotection
Ile 160 
2.3
dry-THF 
DEAD/PPh3, 2 h 
(double coupling) 
20% piperidine, double 
deprotection  
(5 min, 15 min)
Phe 70 2.0
HATU/DIEA,  
30 min (double coupling)
His 112 2.0
Leu 64 2.0
Ala 60 2.0
Coupling with HATU/DIEA 67 mg HATU/63 μl DIEA 
Wash after coupling 1 min , 3 ml (3 times DMF)
Fmoc-deprotection 3 ml (20% piperidine/DMF)
Wash after Fmoc-deprotection 1 min, 3 ml (3 times DMF, 3 times DCM, 3 times DMF)
Wash before Mitsunobu reaction 1 min , 3 ml (3 times DMF, 4 times dry-THF)
Coupling with DEAD/PPh3 70 μl DEAD (100%)/118 mg PPh3
Wash after Mitsunobu reaction 1 min , 3 ml (5 times DMF)
Synthesis of P7: [Leu21]BM2(17-21)-Hmp 
Table 9.5: Amino acids and coupling conditions for the manual Fmoc-SPPS of peptide P7. 
Building 
block 
Amount
[mg] 
DMF 
[ml] 
Activator/Base and 
coupling conditions 
Deprotection Base and 
conditions 
Hmp 240 3.3 
HATU/DIEA,
30 min (double coupling)
No deprotection 
Leu 292 
4.2
dry-THF 
DEAD/PPh3, 2 h
(double coupling)
20% piperidine, double 
deprotection  
(5 min, 15 min)
Phe 256 3.3
HATU/DIEA, 
30 min (double coupling)
His 409 3.3
Leu 234 3.3
Ala 218 3.3
Coupling with HATU/DIEA 248 mg HATU/230 μl DIEA 
Wash after coupling 1 min , 5 ml (3 times DMF)
Fmoc-deprotection 5 ml (20% piperidine/DMF)
Wash after Fmoc-deprotection 1 min, 5 ml (3 times DMF, 3 times DCM, 3 times DMF)
Wash before Mitsunobu reaction 1 min , 5 ml (3 times DMF, 4 times dry-THF)
Coupling with DEAD/PPh3 375 μl DEAD (40% in toluene)/216 mg PPh3
Wash after Mitsunobu reaction 1 min , 5 ml (5 times DMF)
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Synthesis of P8: [Leu21]BM2(17-21)-Hmp-ADO 
Table 9.6: Amino acids and coupling conditions for the manual Fmoc-SPPS of peptide P8. 
Building 
block 
Amount
[mg] 
DMF 
[ml] 
Activator/Base and 
coupling conditions 
Deprotection Base and 
conditions 
ADO 64 1 HATU/DIEA,  
30 min (double coupling)
20% piperidine, double 
deprotection  
(5 min, 15 min) 
Hmp 120 2 No deprotection
Leu 146 
2
dry-THF 
DEAD/PPh3, 2 h 
(double coupling) 
20% piperidine, double 
deprotection  
(5 min, 15 min)
Phe 128 2
HATU/DIEA,  
30 min (double coupling)
His 205 2
Leu 117 2
Ala 109 2
Coupling with HATU/DIEA 124 mg HATU/115 μl DIEA 
Wash after coupling 1 min , 5 ml (3 times DMF)
Fmoc-deprotection 5 ml (20% piperidine/DMF)
Wash after Fmoc-deprotection 1 min, 5 ml (3 times DMF, 3 times DCM, 3 times DMF)
Wash before Mitsunobu reaction 1 min , 5 ml (3 times DMF, 4 times dry-THF)
Coupling with DEAD/PPh3 187 μl DEAD (40% in toluene)/109 mg PPh3
Wash after Mitsunobu reaction 1 min , 5 ml (5 times DMF)
Synthesis of P9: [Leu21]BM2(17-21)-Hmp-ADO2
Table 9.7: Amino acids and coupling conditions for the manual Fmoc-SPPS of peptide P9. 
Building 
block 
Amount
[mg] 
DMF 
[ml] 
Activator/Base and 
coupling conditions 
Deprotection Base and 
conditions 
ADO 64 1
HATU/DIEA,  
30 min (double coupling)
20% piperidine, double 
deprotection  
(5 min, 15 min) 
ADO 64 1 
Hmp 120 2 No deprotection
Leu 146 
2
dry-THF 
DEAD/PPh3, 2 h 
(double coupling) 
20% piperidine, double 
deprotection  
(5 min, 15 min)
Phe 128 2
HATU/DIEA,  
30 min (double coupling)
His 205 2
Leu 117 2
Ala 109 2
Coupling with HATU/DIEA 124 mg HATU/115 μl DIEA 
Wash after coupling 1 min , 5 ml (3 times DMF)
Fmoc-deprotection 5 ml (20% piperidine/DMF)
Wash after Fmoc-deprotection 1 min, 5 ml (3 times DMF, 3 times DCM, 3 times DMF)
Wash before Mitsunobu reaction 1 min , 5 ml (3 times DMF, 4 times dry-THF)
Coupling with DEAD/PPh3 187 μl DEAD (40% in toluene)/109 mg PPh3
Wash after Mitsunobu reaction 1 min , 5 ml (5 times DMF)
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Synthesis of P10: [Leu21]BM2(17-21)-Hmp-Lys5
Table 9.8: Amino acids and coupling conditions for the manual Fmoc-SPPS of peptide P10. 
Building 
block 
Amount
[mg] 
DMF 
[ml] 
Activator/Base and 
coupling conditions 
Deprotection Base and 
conditions 
Lys* 155 2 HATU/DIEA,  
30 min (double coupling)
20% piperidine, double 
deprotection  
(5 min, 15 min) 
Hmp 120 2 No deprotection
Leu 146 
2
dry-THF 
DEAD/PPh3, 2 h 
(double coupling) 
20% piperidine, double 
deprotection  
(5 min, 15 min)
Phe 128 2
HATU/DIEA,  
30 min (double coupling)
His 205 2
Leu 117 2
Ala 109 2
Coupling with HATU/DIEA 124 mg HATU/115 μl DIEA 
Wash after coupling 1 min , 4 ml (3 times DMF)
Fmoc-deprotection 4 ml (20% piperidine/DMF)
Wash after Fmoc-deprotection 1 min, 4 ml (3 times DMF, 3 times DCM, 3 times DMF)
Wash before Mitsunobu reaction 1 min , 4 ml (3 times DMF, 4 times dry-THF)
Coupling with DEAD/PPh3 187 μl DEAD (40% in toluene)/109 mg PPh3
Wash after Mitsunobu reaction 1 min , 4 ml (5 times DMF)
* Repeated five times (synthesis of Lys5 tag).
Synthesis of P11: [Leu21]BM2(17-21)-Hmp-ADO-Lys5
Table 9.9: Amino acids and coupling conditions for the manual Fmoc-SPPS of peptide P11. 
Building 
block 
Amount
[mg] 
DMF 
[ml] 
Activator/Base and 
coupling conditions 
Deprotection Base and 
conditions 
Lys* 155 2
HATU/DIEA,  
30 min (double coupling)
20% piperidine, double 
deprotection  
(5 min, 15 min) 
ADO 64 2 
Hmp 120 2 No deprotection
Leu 146 
2
dry-THF 
DEAD/PPh3, 2 h 
(double coupling) 
20% piperidine, double 
deprotection  
(5 min, 15 min)
Phe 128 2
HATU/DIEA,  
30 min (double coupling)
His 205 2
Leu 117 2
Ala 109 2
Coupling with HATU/DIEA 124 mg HATU/115 μl DIEA 
Wash after coupling 1 min , 4 ml (3 times DMF)
Fmoc-deprotection 4 ml (20% piperidine/DMF)
Wash after Fmoc-deprotection 1 min, 4 ml (3 times DMF, 3 times DCM, 3 times DMF)
Wash before Mitsunobu reaction 1 min , 4 ml (3 times DMF, 4 times dry-THF)
Coupling with DEAD/PPh3 187 μl DEAD (40% in toluene)/109 mg PPh3
Wash after Mitsunobu reaction 1 min , 4 ml (5 times DMF)
* Repeated five times (synthesis of Lys5 tag).
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Synthesis of P12: [Leu21]BM2(17-21)-Hmp-ADO2-Lys5
Table 9.10: Amino acids and coupling conditions for the manual Fmoc-SPPS of peptide P12. 
Building 
block 
Amount
[mg] 
DMF 
[ml] 
Activator/Base and 
coupling conditions 
Deprotection Base and 
conditions 
Lys* 155 2
HATU/DIEA,  
30 min (double coupling)
20% piperidine, double 
deprotection  
(5 min, 15 min) 
ADO 64 2
ADO 64 2
Hmp 120 2 No deprotection
Leu 146 
2
dry-THF 
DEAD/PPh3, 2 h 
(double coupling) 
20% piperidine, double 
deprotection  
(5 min, 15 min)
Phe 128 2
HATU/DIEA,  
30 min (double coupling)
His 205 2
Leu 117 2
Ala 109 2
Coupling with HATU/DIEA 124 mg HATU/115 μl DIEA 
Wash after coupling 1 min , 4 ml (3 times DMF)
Fmoc-deprotection 4 ml (20% piperidine/DMF)
Wash after Fmoc-deprotection 1 min, 4 ml (3 times DMF, 3 times DCM, 3 times DMF)
Wash before Mitsunobu reaction 1 min , 4 ml (3 times DMF, 4 times dry-THF)
Coupling with DEAD/PPh3 187 μl DEAD (40% in toluene)/109 mg PPh3
Wash after Mitsunobu reaction 1 min , 4 ml (5 times DMF)
* Repeated five times (synthesis of Lys5 tag).
Synthesis of P13: [Leu21]BM2(17-21)-Hmp-Arg5
Table 9.11: Amino acids and coupling conditions for the manual Fmoc-SPPS of peptide P13. 
Building 
block 
Amount
[mg] 
DMF 
[ml] 
Activator/Base and 
coupling conditions 
Deprotection Base and 
conditions 
Arg* 215 2 HATU/DIEA,  
30 min (double coupling)
20% piperidine, double 
deprotection  
(5 min, 15 min) 
Hmp 120 2 No deprotection
Leu 146 
2
dry-THF 
DEAD/PPh3, 2 h 
(double coupling) 
20% piperidine, double 
deprotection  
(5 min, 15 min)
Phe 128 2
HATU/DIEA,  
30 min (double coupling)
His 205 2
Leu 117 2
Ala 109 2
Coupling with HATU/DIEA 124 mg HATU/115 μl DIEA 
Wash after coupling 1 min , 4 ml (3 times DMF)
Fmoc-deprotection 4 ml (20% piperidine/DMF)
Wash after Fmoc-deprotection 1 min, 4 ml (3 times DMF, 3 times DCM, 3 times DMF)
Wash before Mitsunobu reaction 1 min , 4 ml (3 times DMF, 4 times dry-THF)
Coupling with DEAD/PPh3 187 μl DEAD (40% in toluene)/109 mg PPh3
Wash after Mitsunobu reaction 1 min , 4 ml (5 times DMF)
* Repeated five times (synthesis of Arg5 tag).
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Synthesis of P14: [Leu21]BM2(17-21)-Hmp-ADO-Arg5
Table 9.12: Amino acids and coupling conditions for the manual Fmoc-SPPS of peptide P14. 
Building 
block 
Amount
[mg] 
DMF 
[ml] 
Activator/Base and 
coupling conditions 
Deprotection Base and 
conditions 
Arg* 215 2
HATU/DIEA,  
30 min (double coupling)
20% piperidine, double 
deprotection  
(5 min, 15 min) 
ADO 64 2 
Hmp 120 2 No deprotection
Leu 146 
2
dry-THF 
DEAD/PPh3, 2 h 
(double coupling) 
20% piperidine, double 
deprotection  
(5 min, 15 min)
Phe 128 2
HATU/DIEA,  
30 min (double coupling)
His 205 2
Leu 117 2
Ala 109 2
Coupling with HATU/DIEA 124 mg HATU/115 μl DIEA 
Wash after coupling 1 min , 4 ml (3 times DMF)
Fmoc-deprotection 4 ml (20% piperidine/DMF)
Wash after Fmoc-deprotection 1 min, 4 ml (3 times DMF, 3 times DCM, 3 times DMF)
Wash before Mitsunobu reaction 1 min , 4 ml (3 times DMF, 4 times dry-THF)
Coupling with DEAD/PPh3 187 μl DEAD (40% in toluene)/109 mg PPh3
Wash after Mitsunobu reaction 1 min , 4 ml (5 times DMF)
* Repeated five times (synthesis of Arg5 tag).
Synthesis of P15: [Leu21]BM2(17-21)-Hmp-ADO2-Arg5
Table 9.13: Amino acids and coupling conditions for the manual Fmoc-SPPS of peptide P15. 
Building 
block 
Amount
[mg] 
DMF 
[ml] 
Activator/Base and 
coupling conditions 
Deprotection Base and 
conditions 
Arg* 215 2
HATU/DIEA,  
30 min (double coupling)
20% piperidine, double 
deprotection  
(5 min, 15 min) 
ADO 64 2
ADO 64 2
Hmp 120 2 No deprotection
Leu 146 
2
dry-THF 
DEAD/PPh3, 2 h 
(double coupling) 
20% piperidine, double 
deprotection  
(5 min, 15 min)
Phe 128 2
HATU/DIEA,  
30 min (double coupling)
His 205 2
Leu 117 2
Ala 109 2
Coupling with HATU/DIEA 124 mg HATU/115 μl DIEA 
Wash after coupling 1 min , 4 ml (3 times DMF)
Fmoc-deprotection 4 ml (20% piperidine/DMF)
Wash after Fmoc-deprotection 1 min, 4 ml (3 times DMF, 3 times DCM, 3 times DMF)
Wash before Mitsunobu reaction 1 min , 4 ml (3 times DMF, 4 times dry-THF)
Coupling with DEAD/PPh3 187 μl DEAD (40% in toluene)/109 mg PPh3
Wash after Mitsunobu reaction 1 min , 4 ml (5 times DMF)
* Repeated five times (synthesis of Arg5 tag).
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9.3. Automated microwave-assisted Fmoc-SPPS 
Automated microwave-assisted Fmoc-SPPS was carried out on a Liberty peptide synthesizer 
(CEM) using a standard Fmoc protocol. Peptide sequences as well as the resin types, amounts 
and loading capacities are depicted in table 9.14. The amount of the activator, activator base 
and amino acids for each peptide are presented in the following tables below. The coupling 
cycles for the automated Fmoc-SPPS are shown in the appendix (chapter 15.1.4). The resins 
for the synthesis of Hmp-peptides P16, P18, P19 and P20 were manually preloaded with the 
solubilizing tag (Lys5, ADO2), spacer (ADO), Hmp and the first two amino acids following 
instruction 9.2.  
Coupling reactions (double coupling, 15min) were performed with Fmoc-amino acids (0.2 M, 
4 equiv.), activated with 1-[bis(Dimethylamin)methylen]-1H-1,2,3-triazol[4,5-b]pyridinium-
3-oxid-hexafluorophosphat (HATU, 0.2 M, 3.95 equiv.) and N,N-diisopropylethylamin (DIEA, 
0.4 M, 8.00 equiv.) in N,N-Dimethylformamide (DMF) under microwave irradiation.[2] Fmoc 
deprotection from peptides P1, P2, P3 and P17 was achieved with 20% piperidine in DMF. 
Fmoc cleavage from Hmp-peptides P16, P18, P19 and P20 was performed with 20%  
2-methylpiperidin in DMF.[60] All deprotection and coupling steps were followed by intensive 
washing steps with DMF and DCM according to the protocols in the appendix  
(chapter 15.1.4).  
Peptide cleavage from the resin was accomplished in a mixture of 90% TFA, 5% water, 2.5% 
TIPS and 2.5% anisole for 3 h at room temperature. For 100 mg of resin, 1 ml of cleavage 
solution was applied. The crude peptides were precipitated in cold diethyl ether, centrifuged, 
and washed three times with diethyl ether. 
Table 9.14: Types, amounts and loading capacities of the resin supports used for the automated microwave-assisted 
Fmoc-SPPS of long BM2 peptides. 
Entry Peptide sequence 
Resin 
Amount [g]
Loading 
[mmol/g]
P1 CWTIGHLNQIKRGI 0.5b 0.40 
P2 CWTIGHLNQIKRGINMKIRIKGPNKETINR 0.68a 0.27 
P3 CSFILSALHFLAWTIGHLNQIKRGINMKIRIKGPNKETINR 0.75a 0.33 
P16 MLEPFQILSL-Hmp 0.76a 0.33 
P17 MLEPFQILSICSFILSALHFL 0.27a 0.33 
P18 MLEPFQILSIC(Acm)SFILSALHFL-Hmp 0.68a 0.33 
P19 MLEPFQILSIC(Acm)SFILSALHFL-Hmp-ADO-ADO 0.27a 0.33 
P20 MLEPFQILSIC(Acm)SFILSALHFL-Hmp-ADO-KKKKK 0.68a 0.33 
a AmphiSpheres RAM 40 resin.
b Rink Amide MBHA resin.
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Fmoc-SPPS of P1: [Cys22]BM2(22-35)  
Table 9.15: Amino acids and coupling conditions for the automated, microwave-assisted Fmoc-SPPS of peptide P1. 
Amino acid Weight [g] DMF [ml] Coupling Conditions Fmoc-Deprotection
Ala 0.7 11
Double coupling 
50 °C, 40 W, 12 min
Double deprotection 
50 °C, 40 W, 320 sec
Arg 2.7 21
Asn 2.5 21
Cys 2.5 21
Gln 1.35 11
Gly 1.25 21
His 1.37 11
Ile 2.27 32
Leu 0.78 11
Lys 2.0 21
Thr 0.9 11
Trp 1.16 11
Activator: 15.2 g HATU dissolved in 80 ml DMF
Base: 14 ml DIEA diluted to 40 ml with NMP
Deprotection: 42 ml piperidine and 168 ml DMF
DMF: 560 ml
Fmoc-SPPS of P2: [Cys22]BM2(22-51) 
Table 9.16: Amino acids and coupling conditions for the automated, microwave-assisted Fmoc-SPPS of peptide P2. 
Amino acid Weight [g] DMF [ml] Coupling Conditions Fmoc-Deprotection
Arg 5.1 39
Double coupling 
50°C , 35 W, 14 min
Double deprotection 
30°C, 35 W, 40 sec 
50°C, 35 W, 3min
Asn 6 50
Cys 1.9 16
Gln 2 16
Glu 1.4 16
Gly 2.3 39
His 2 16
Ile 5.16 73
Leu 1.13 16
Lys 4.7 50
Met 1.2 16
Pro 1.1 16
Thr 2.5 27
Trp 1.7 16
Activator: 26.6 g HATU dissolved in 140 ml DMF
Base: 25 ml DIEA diluted to 71 ml with NMP
Deprotection: 136 ml piperidine and 544 ml DMF
DMF: 6000 ml
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Fmoc-SPPS of P3: [Cys11]BM2(11-51) 
Table 9.17: Amino acids and coupling conditions for the automated, microwave-assisted Fmoc-SPPS of peptide P3. 
Amino acid Weight [g] DMF [ml] Coupling Conditions Fmoc-Deprotection
Ala 1.62 26
Double coupling 
60 °C, 33 W, 12 min
Double deprotection 
50 °C, 40 W, 120 sec
Arg 4.93 38
Asn 5.85 49
Cys 1.73 15
Gln 1.84 15
Glu 1.28 15
Gly 2.26 38
His 3.22 26
Ile 6.71 95
Leu 2.68 38
Lys 4.59 49
Met 1.11 15
Phe 2.01 26
Pro 1.01 15
Ser 1.99 26
Thr 2.07 26
Trp 1.58 26
Activator: 35.15 g HATU dissolved in 185 ml DMF
Base: 44.4 ml DIEA diluted to 40 ml with NMP
Deprotection: 190 ml piperidine and 570 ml DMF
DMF: 7300 ml
Fmoc-SPPS of P16: [Leu10]BM2(1-10)-Hmp 
Table 9.18: Amino acids and coupling conditions for the automated, microwave-assisted Fmoc-SPPS of peptide P16. 
Amino acid Weight [g] DMF [ml] Coupling Conditions Fmoc-Deprotection
Gln 1.84 15
Double coupling 
60 °C, 33 W, 12 min
Double deprotection 
50 °C, 40 W, 200 sec
Glu 1.28 15
Ile 1.06 15
Leu 1.84 26
Met 1.11 15
Phe 1.16 15
Pro 1.01 15
Activator: 7.6 g HATU dissolved in 40 ml DMF
Base: 9.25 ml DIEA diluted to 25 ml with NMP
Deprotection: 40 ml 2-methylpiperidine and 160 ml DMF
DMF: 1400 ml
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Fmoc-SPPS of P17: [Ile21]BM2(1-21) 
Table 9.19: Amino acids and coupling conditions for the automated, microwave-assisted Fmoc-SPPS of peptide P17. 
Amino acid Weight [g] DMF [ml] Coupling Conditions Fmoc-Deprotection
Ala 0.7 11
Double coupling 
50 °C, 33 W, 12 min
Double deprotection 
35 °C, 40 W, 60 sec 
50 °C, 40 W, 360 sec
Cys 1.3 11
Gln 1.35 11
Glu 1.0 11
His 1.4 11
Ile 2.0 28
Leu 2.0 28
Met 0.82 11
Phe 1.8 23
Pro 0.75 11
Ser 1.8 23
Activator: 9.5 g HATU dissolved in 50 ml DMF
Base: 10.5 ml DIEA diluted to 30 ml with NMP
Deprotection: 70 ml piperidine and 280 ml DMF
DMF: 3500 ml
Fmoc-SPPS of P18: [Leu21]BM2(1-21)-Hmp 
Table 9.20: Amino acids and coupling conditions for the automated, microwave-assisted Fmoc-SPPS of peptide P18. 
Amino acid Weight [g] DMF [ml] Coupling Conditions Fmoc-Deprotection
Ala 1.1 17
Double coupling 
50 °C, 30 W, 14 min
Double deprotection 
35 °C, 40 W, 60 sec 
50 °C, 40 W, 3 min
Gln 2.1 17
Glu 1.5 17
His 2.1 17
Ile 2.8 40
Leu 3.6 51
Met 1.3 17
Phe 2.2 28
Pro 1.15 17
Ser 3.1 40
Manual coupling of Fmoc-Cys(Acm)-OH
3.13 mg Fmoc-Cys(Acm), 282 mg HATU, 263 μl 
DIEA in 3.7 ml DMF (60 min, double coupling) 
Activator: 16.2 g HATU dissolved in 85 ml DMF
Base: 15.7 ml DIEA diluted to 45 ml with NMP
Deprotection: 70 ml 2-methylpiperidine and 280 ml DMF
DMF: 3500 ml
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Fmoc-SPPS of P19: [Leu21]BM2(1-21)-Hmp-ADO2
Table 9.21: Amino acids and coupling conditions for the automated, microwave-assisted Fmoc-SPPS of peptide P19. 
Amino acid Weight [g] DMF [ml] Coupling Conditions Fmoc-Deprotection
Ala 0.7 11
Double coupling 
50 °C, 30 W, 14 min
Double deprotection 
35 °C, 40 W, 60 sec 
50 °C, 40 W, 3 min
Gln 1.34 11
Glu 0.95 11
His 1.4 11
Ile 1.63 23
Leu 2.0 28
Met 0.82 11
Phe 1.32 17
Pro 0.75 11
Ser 1.76 23
Manual coupling of Fmoc-Cys(Acm)-OH
1.56 mg Fmoc-Cys(Acm), 141 mg HATU, 132 μl 
DIEA in 2.0 ml DMF (60 min, double coupling)
Activator: 9.5 g HATU dissolved in 50 ml DMF
Base: 10.50 ml DIEA diluted to 30 ml with NMP
Deprotection: 60 ml 2-methylpiperidine and 240 ml DMF
DMF: 3000 ml
Fmoc-SPPS of P20: [Leu21]BM2(1-21)-Hmp-ADO-Lys5
Table 9.22: Amino acids and coupling conditions for the automated, microwave-assisted Fmoc-SPPS of peptide P20. 
Amino acid Weight [g] DMF [ml] Coupling Conditions Fmoc-Deprotection
Ala 1.1 17
Double coupling 
50 °C, 30 W, 14 min
Double deprotection 
35 °C, 40 W, 60 sec 
50 °C, 40 W, 3 min
Gln 2.1 17
Glu 1.5 17
His 2.1 17
Ile 2.8 40
Leu 3.6 51
Met 1.3 17
Phe 2.2 28
Pro 1.15 17
Ser 3.1 40
Manual coupling of Fmoc-Cys(Acm)-OH
3.13 mg Fmoc-Cys(Acm), 282 mg HATU, 263 μl 
DIEA in 3.7 ml DMF (60 min, double coupling) 
Activator: 16.2 g HATU dissolved in 85 ml DMF
Base: 15.7 ml DIEA diluted to 45 ml with NMP
Deprotection: 70 ml 2-methylpiperidine and 280 ml DMF
DMF: 3500 ml
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10. Development of Ligation Protocols 
10.1. Summary of ligation experiments 
Ligation yields, hydrolysis amounts and possible side reactions were investigated by detailed 
ligation studies using the model Hmp-peptides P4, P7-P12. These results were applied to 
optimise conditions for ligation experiments with long BM2 peptides. For the synthesis of the 
proton channel sequences P26 [Leu21]BM2(1-51) and P27 [Leu10]BM2(1-51), the  
Hmp-peptides P16, P18, P19 and P20 were ligated with the N-terminal cysteine peptides P2
or P3. Dependent on the type of the C-terminal solubilizing tag four different ligation buffers 
A, B, C or D were tested. The compositions of these buffers are listed in table 10.2. The good 
soluble Hmp-peptide P20 was ligated in the water based standard buffer A. More hydrophobic 
peptides P18 and P19 were ligated in buffer B or C. For ligation experiments in the ionic 
liquid based buffers D1-D6 model Hmp-peptide P7 was applied. The ligation of the final 
product P27 [Leu10]BM2(1-51) was performed in the optimized ionic-liquid based buffer D5. 
Table 10.1: Ligation experiments in ligation buffers A, B, C and D. 
Entry Ligation product Cys-peptide Hmp-peptide Buffer
P21 [Ile21]BM2(17-35) P1 P4 A
P22
[Leu21]BM2(17-35) P1 P7 A
[Leu21]BM2(17-35) P1 P7 D1-D6
[Leu21]BM2(17-35) P1 P8 A
[Leu21]BM2(17-35) P1 P9 A
[Leu21]BM2(17-35) P1 P11 A
[Leu21]BM2(17-35) P1 P12 A
P23
[Cys11(Acm)][Leu21]BM2(1-51) P2 P18a B, C
[Cys11(Acm)][Leu21]BM2(1-51) P2 P18b C
[Cys11(Acm)][Leu21]BM2(1-51) P2 P19a C
[Cys11(Acm)][Leu21]BM2(1-51) P2 P19b C
[Cys11(Acm)][Leu21]BM2(1-51) P2 P20 A,C
P27 [Leu10]BM2(1-51) P3 P16a C
P27 [Leu10]BM2(1-51) P3 P16b C
P27 [Leu10]BM2(1-51) P3 P16a D5
P27 [Leu10]BM2(1-51) P3 P16b D5
a Hmp peptide diastereomer 1.
b Hmp peptide diastereomer 2.
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Table 10.2: Compositions of the tested ligation buffers A, B, C and D. 
Abbre. Ligation conditions
Buffer A 8 M Urea + 0.2 M Na2HPO4 + 150 mM MPAA + 100 mM TCEP, pH 7.00
Buffer B Buffer A / trifluoroethanol (TFE) (2:1), pH 7.00
Buffer C Buffer A / hexafluoro-2-propanol (HFIP) (2:1), pH 7.50
Buffer D1 [C2mim][OAc], 150 mM thiophenol, 150 mM TCEP
Buffer D2 [C2mim][OAc]/water (90:10, v/v), 150 mM thiophenol, 150 mM TCEP
Buffer D3 [C2mim][OAc]/water (80:20, v/v), 150 mM thiophenol, 150 mM TCEP
Buffer D4 [C2mim][OAc]/water (70:30, v/v), 150 mM thiophenol, 150 mM TCEP
Buffer D5 [C2mim][OAc]/water (60:40, v/v), 150 mM thiophenol, 150 mM TCEP
Buffer D6 [C2mim][OAc]/water (50:50, v/v), 150 mM thiophenol, 150 mM TCEP
10.1.1. Native chemical ligation in buffer A 
Ligation experiments in buffer A were performed in 500 μl of 8 M urea solution containing 
14.14 mg (200 mM) disodium phosphate, 7.17 mg (50 mM, 50 equiv.)  
tris(2-carboxyethyl)phosphine hydrochloride (TCEP HCl) and 12.6 mg (150 mM, 150 equiv.) 
4-mercaptophenylacetic acid (MPAA) as a catalyst. To dissolve MPAA, 10 M sodium hydroxide 
solution was added until a final pH of 6.0 was reached. In order to dissolve the peptides,  
1.5 equiv. of the N-terminal cysteine peptide and 1.0 equiv. of the C-terminal Hmp-peptide 
were agitated in ligation buffer A for 5 min at room temperature. The reaction was started by 
adjusting the pH to 7.0 using a 2.5 M sodium hydroxide solution. Finally, the reaction mixture 
was agitated under a nitrogen atmosphere. 
Reaction progress was monitored by RP-HPLC after 0 h, 0.5 h, 1 h and 2 h for short model  
Hmp-peptides P1, P2, P4, P7-P12 and 0 h, 1 h, 2 h, 4 h, 8 h and 24 h for the long  
Hmp-peptide P20. Samples preparation: 5 μl of the ligation buffer was diluted with 60 μl 
acetonitrile/water (0.1% TFA) (1:1, v/v). 
Table 10.3: Equivalents and amounts of cysteine and Hmp-peptides for 500 µl ligation buffer A. 
Entry Peptide Mw [g/mol] Equiv. Amount [mg]
P1 [Cys22]BM2(22-35) 1637.95 1.5 1.06
P2 [Cys22]BM2(22-51) 3532.20 1.5 1.1a
P4 [Ile21]BM2(17-35)-Hmp 702.86 1.0 0.35
P7 [Leu21]BM2(17-35)-Hmp 702.86 1.0 0.35
P8 [Leu21]BM2(17-35)-Hmp-ADO 848.02 1.0 0.43
P9 [Leu21]BM2(17-35)-Hmp-ADO2 993.18 1.0 0.50
P11 [Leu21]BM2(17-35)-Hmp-ADO-Lys5 1489.89 1.0 0.75
P12 [Leu21]BM2(17-35)-Hmp-ADO2-Lys5 1635.02 1.0 0.82
P20 [Leu21]BM2(1-21)-Hmp-ADO-Lys5 3383.19 1.0 0.68a
a Buffer volume 200 µl.
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10.1.2. Native chemical ligation in buffer B 
Ligation experiments in buffer B were performed in 200 μl of a mixture containing ligation 
buffer A and TFE (2:1, v/v) at a pH of 7.00. For dissolution of hydrophobic peptides  
1.0 equiv. Hmp-peptide and 1.5 equiv. of cysteine peptide were pre-dissolved in 66 μl TFE. 
The reaction was started by adding 134 μl of ligation buffer A and agitated for 24 h under a 
nitrogen atmosphere.  
Reaction progress was monitored by RP-HPLC after 0 h, 1 h, 2 h, 4 h, 8 h and 24 h. Therefore, 
aliquots of 2.5 μl ligation buffer were mixed with 7 μl of TFE and dissolved in 30 μl water 
(0.1% TFA). 
Table 10.4: Equivalents and amounts of cysteine and Hmp-peptides for 200 µl ligation buffer B. 
Entry Peptide Mw [g/mol] Equiv. Amount [mg]
P2 [Cys22]BM2(22-51) 3532.20 1.5 1.1
P18a [Leu21]BM2(1-21)-Hmp 2597.17 1.0 0.53
10.1.3. Native chemical ligation in buffer C 
Ligation experiments in buffer C were performed in 200 μl of a mixture containing ligation 
buffer A and HFIP (2:1, v/v) at a pH of 7.50. For dissolution of hydrophobic peptides, 
1.0 equiv. of the Hmp-peptide and 1.5 equiv. of the cysteine peptide were pre-dissolved in 
66 μl HFIP. The reaction was started by adding 134 μl of ligation buffer A. If necessary small 
amounts of pure water were added to obtain a single phase. Finally, the reaction mixture was 
agitated for 24 h under a nitrogen atmosphere. 
Reaction progress was monitored by RP-HPLC after 0 h, 1 h, 2 h, 4 h, 8 h and 24 h. Therefore 
aliquots of 2.5 μl sample solution were diluted with 7 μl HFIP and dissolved in 30 μl water 
(0.1% TFA). Subsequently the reaction product was purified by preparative RP-HPLC 
following procedure 8.1.7.  
Table 10.5: Equivalents and amounts of cysteine and Hmp-peptides for 200 µl ligation buffer C. 
Entry Peptide Mw [g/mol] Equiv. Amount [mg]
P2 [Cys22]BM2(22-51) 3532.20 1.5 1.1
P3 [Cys22]BM2(11-51) 4732.64 1.1 1.136
P16a [Leu21]BM2(1-10)-Hmp 1293.59 1.0 0.278
P16b [Leu10]BM2(1-10)-Hmp 1293.59 1.0 0.278
P18a [Leu21]BM2(1-21)-Hmp  Dia.1 2597.17 1.0 0.53
P18b [Leu21]BM2(1-21)-Hmp  Dia. 2 2597.17 1.0 0.53
P19a [Leu21]BM2(1-21)-Hmp-ADO2 Dia. 1 2887.48 1.0 0.61
P19b [Leu21]BM2(1-21)-Hmp-ADO2 Dia. 2 2887.48 1.0 0.61
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10.1.4. Native chemical ligation in buffer D (D1-D6) 
For the preparation of the ionic liquid based buffers D1-D6,  8.55 mg (0.03 mmol, 150 mM 
TCEP HCl and 3.09 μl (0.03 mmol, 150 mM) thiophenol were dissolved in 200 μl 
[C2mim][OAc] containing increasing amounts of water according to table 10.6. The ligation 
of model peptides P1 and P7 was started by dissolving 0.36 mg (11 mM, 1.1 equiv.) of 
cysteine peptide [Cys22]BM2(22-35) and 0.14 mg (10 mM, 1.0 equiv.) of ALHFL-Hmp in 20 μl 
ligation buffer D. The reaction mixture was agitated at room temperature under argon for 6 h.  
For analytical RP-HPLC 2 μl of the reaction mixture were dissolved in 30 μl acetonitrile/water 
(60:40, v/v) with 0.8% TFA. The reaction progress was monitored after 0 min, 10 min, 
30 min, 1 h, 2 h, 4 h and 6 h.   
Table 10.6: Compositions of ligation buffers D1-D6. 
Buffer [C2mim][OAc] [%] Water content [%]
D1 100 0
D2 90 10
D3 80 20
D4 70 30
D5 60 40
D6 50 50
10.1.5. Native chemical ligation of P27 in buffer D5 
For the preparation of ligation buffer D5, 8.55 mg (0.03 mmol, 150 mM) TCEP HCl and 3.09 
μl (0.03 mmol, 150 mM) thiophenol were dissolved in a mixture of 200 μl [C2mim][OAc] and 
water (60:40, v/v). In order to start the reaction 0.139 mg (1.1 x 10-4 mmol, 2.15 mM, 1.0 
equiv.) of [Leu10]BM2(1-10)-Hmp and 0.568 mg (1.2 x 10-4 mmol, 2.4 mM, 1.1 equiv.) of 
[Cys11]BM2(11-51) were dissolved in 50 μl of the ligation solution. The final ligation solution 
was agitated for 24 h at room temperature under argon atmosphere.   
Reaction progress was monitored by analytical RP-HPLC with acetonitrile (0.1% TFA) and 
water (0.1% TFA) as liquid phase. Therefore, 4 μl from the ligation solution was diluted with 
40 μl acetonitrile/water (60:40, v/v) with 0.8 % TFA. The ligation product was purified and 
separated from the ligation solution by preparative RP-HPLC following the procedure 
described in section 8.1.7. 
Table 10.7: Equivalents and amounts of cysteine and Hmp-peptides for 50 µl ligation buffer D. 
Entry Peptide Mw [g/mol] Equiv. Amount [mg]
P3 [Cys11]BM2(11-51) 4732.64 1.1 0.568
P16a/P16b [Leu10]BM2(1-10)-Hmp 1293.59 1.0 0.139
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11. Desulfurization Protocols 
11.1. Conventional and HFIP-based desulfurization of BM2 peptides 
11.1.1. Metal-free desulfurization in conventional buffer   
The desulfurization experiment of the hydrophobic peptide P23 (0.6 mg, 0.01 μmol) was 
carried out in 200 μl of 6 M guanidinium chloride (GdnHCl)/0.2 M disodium phosphate 
buffer containing 0.5 M TCEP HCl. After dissolution of TCEP HCl, the pH of the mixture was 
adjusted to 6.5 using a 5 M sodium hydroxide solution. In order to start the reaction 12.5 μl 
of 160 mM glutathione and 20 μl of 300 mM 2,2-azobis[2-(2-imidazolin-2-yl)propane 
dihydrochloride (VA044) solution were added. The reaction mixture was agitated (1000 rpm) 
under inert conditions (Ar, N2) at room temperature. After complete conversion of the 
reactant by analytical HPLC, the reaction was stopped by adding aliquots of concentrated TFA 
until a final pH of 2 was reached. Reaction progress was followed by analytical RP-HPLC at 
220 nm. For HPLC sample preparation, 10 μl of the reaction mixture was dissolved in 30 μl of 
water (0.1% TFA).  
Table 11.1: Molecular weight and amount of peptide P23 for desulfurization in conventional buffer. 
Entry Peptide Mw [g/mol] Equiv. Amount [mg]
P23 [Cys(Acm)11][Cys22]BM2(1-51) 6008.22 1.0 0.60
11.1.2. Metal-free desulfurization in HFIP containing buffer   
Peptide P23 (0.6 mg, 0.01 mmol) was dissolved in 320 μl of desulfurization emulsion 
containing one part HFIP (80 μl) and three parts (240 μl) 6 M guanidinium chloride 
(GdnHCl)/0.2 M disodium phosphate buffer with 0.5 M tris(2-carboxyethyl)phosphine 
hydrochloride (TCEP HCl) at a pH of 6.5. For pH adjustment, a 5 M sodium hydroxide 
solution was added. The reaction was started by adding 12.5 μl of 160 mM glutathione (GSH) 
and 20 μl of 300 mM 2,2-azobis[2-(2-imidazolin-2-yl)propane dihydrochloride (VA044) to the 
reaction mixture. The solution was agitated under argon at room temperature. After complete 
conversion of the reactant by RP-HPLC, concentrated TFA was added until a final pH of 2 was 
reached. In order to observe the reaction progress aliquots of 10 μl of the reaction mixture 
were dissolved in 30 μl water (0.1% TFA) and analyzed by RP-HPLC at 220 nm. After 
desulfurization product P25 was purified by preparative RP-HPLC according to instruction 
8.1.7. 
Table 11.2: Molecular weight and amount of peptide P23 for desulfurization in the HFIP-based buffer. 
Entry Peptide Mw [g/mol] Equiv. Amount [mg]
P23 [Cys(Acm)11][Cys22]BM2(1-51) 6008.22 1.0 0.60
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12. Acetaminomethyl (Acm) deprotection 
12.1. Comparison between silver salts and elemental iodine 
12.1.1. Acm deprotection using silver trifluoromethanesulfonate 
The deprotection of the acetaminomethyl (Acm) group with silver ions was carried out by 
treating 0.6 mg of P25 (0.1 μM, 1.0 equiv.) in 1 ml of concentrated trifluoroacetic acid (TFA) 
containing of 7.7 mg (30 mM, 300 equiv.) silver trifluoromethanesulfonate (AgOTf) and 1.6 
μl (15 mM, 150 equiv.) anisole. During the Acm deprotection, the reaction was kept at 4 °C 
and agitated under an argon atmosphere (1000 rpm). In order to protect the silver ions from 
light, the deprotection was performed in a black, opaque reaction vessel. The reaction 
progress was monitored by analytical HPLC after 0, 10, 60 and 120 min. For analysis via
RP-HPLC, 10 μl of the reaction solution was diluted with 40 μl of 6 M DTT solution in acetic 
acid/water (1:1, v/v). According to RP-HPLC analysis, the deprotection of Acm was finished 
after 120 min. In order to stop the reaction a two-fold excess (2 ml) of 6 M DTT solution in 
acetic acid/water (1:1, v/v) was added and the mixture was agitated (2000 rpm) for 2 h at 
room temperature. Finally, product P26 was purified by preparative RP-HPLC following 
procedure 8.1.7. 
Table 12.1: Amounts and equivalents of peptide P25, AgOTf and anisole in 1 ml concentrated TFA. 
Substance Molecular weight Equivalents Amount [µmol] Amount[mg]
P25 5976.16 g/mol 1.0 0.1 0.60
AgOTf 256.94 g/mol 300 30 7.70
Anisole 108.14 g/mol 150 15 1.59
12.1.2. Acm deprotection using elemental iodine 
For the deprotection of the acetaminomethyl (Acm) group by elementary iodine, 0.6 mg  
(0,02 mM, 1.0 equiv.) of peptide P25 was dissolved in 5 ml concentrated acetic acid 
containing 15.18 mg (12 mM, 600 equiv.) elemental iodine and 4.44 μl 37 % aqueous HCl 
solution. The solution was flushed with argon and agitated at room temperature for 60 min. 
Analytical HPLC was applied after 0, 10, 30 and 60 min by diluting 10 μl of the reaction 
solution with 50 μl of 0.1 M sodium ascorbate solution in TFE/water (1:1, v/v). After 
disappearance of the starting peptide by HPLC, the excess iodine was destroyed by the 
addition of 1 ml of 1 M sodium thiosulfate (Na2S2O3) solution. In order to reduce disulfide 
bonds, 2 ml of 6 M DTT solution was mixed with the reaction solution and agitated at room 
temperature for 1 h.   
Table 12.2: Amounts and equivalents of peptide P25 and iodine in 5 ml concentrated acetic acid. 
Substance Molecular weight Equivalents Amount [µmol] Amount[mg]
P25 6005.28 g/mol 1.0 0.1 0.60
Iodine 253.8 g/mol 600 60 15.2
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13. List of Abbreviations 
Abbreviation Name 
Aβ Amyloid beta peptides 
ACN Acetonitrile 
ACP Acyl carrier protein 
Acm Acetaminomethyl 
ADO 8-(9-Fluorenylmethyloxycarbonyl-amino)-3,6-dioxaoctanoic acid 
AgBF4 Silver tetrafluoroborate 
AgOAc Silver acetate 
AgOTf silver trifluoromethanesulfonate 
AIBN Azobisisobutyronitrile 
AM2 Influenza A virus matrix 2 protein 
AMP 2-Amino-2-methylpropane-1-thiol 
APS Ammonium persulfate 
BM2 Influenza B virus matrix 2 protein  
BMIM-PF6 1-Butyl-3-methylimidazolium hexafluorophosphate 
Boc tert-Butyloxycarbonyl 
BPTI Bovine pancreatic trypsin inhibitor 
Bzl Benzyl mercaptan 
C1q Complement component 1q protein complex 
Cbz Carbobenzoxy 
CD Circular dichroism 
[C2mim][OAc] 1-Ethyl-3-methylimidazolium acetate 
CPB Carboxypeptidase B 
GPCR G protein-coupled receptor 
CP10 Chemotactic protein 10 kDa 
3D Three-Dimensional 
DAGK Escherichia coli diacylglycerol kinase 
DBU 1,8-Diazabicyclo[5.4.0]undec-7ene 
DCC N,N'-Dicyclohexylcarbodiimide 
DCM Dichloromethane 
Ddae 4,4-dimethyl-2,6-dioxocyclohexylidene-3-[2-(2-aminoethoxy) ethoxyl]-propan-1-ol 
DEN2C Dengue virus capsid protein 2 
DGK Diacylglycerol kinase 
Dia. Diastereomer 
DIC N,N'-Diisopropylcarbodiimide 
DIEA N,N-Diisopropylethylamine 
DMAP 4-Dimethylaminopyridine 
DMF Dimethylformamide 
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Dmmb 2-Mercapto-4,5-dimethoxybenzyl 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DPC Dodecylphosphocholine 
DSC N,N-Disuccinimidyl carbonate 
DTNP 2,2′-Dithiobis(5-nitropyridine) 
DTT Dithiothreitol 
EPO Hormone erythropoietin 
ESI Electrospray ionization 
EtOH Ethanol 
Fmoc Fluorenylmethyloxycarbonyl 
GnHCl Guanidinium chloride 
GroES E. coli cochaperonin 
GST Glutathione-S-transferase 
H4 Histone H4 
HATU O-(7-Azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium-hexafluorphosphat 
HBTU 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 
HCCA α-Cyano-4-hydroxycinnamic acid 
HCV p7 Hepatitis C virus ion channel p7 
hEPO Human erythropoietin 
HPLC High performance liquid chromatography 
HF Hydrofluoric acid 
HFIP Hexafluoroisopropanol 
Histone H2B Human histone protein of chromatin 
Hiv Human immunodeficiency viruses 
4-Hmb 4-Hydroxymethyl benzoic acid 
Hmp 2-hydroxy-3-mercaptopropanamide 
HMSP 2-hydroxy-2-methyl-3-sulfanylpropanoic acid 
HMPA Hexamethylphosphoramide 
HMPB resin 4-(4-Hydroxymethyl-3-methoxyphenoxy)-butanoyl amide resin 
HOAt 1-Hydroxy-7-azabenzotriazol 
HOBt 1-Hydroxybenzotriazole 
IFITM3 Interferon-induced transmembrane protein 3 
IGF1 Insulin-like growth factor 1 
INT Intermediate 
KAHA ligation α-Ketoacid-hydroxylamine ligation 
KCL Kinetically controlled ligation 
KcsA potassium channel of streptomyces A 
Kir5.1 Potassium Voltage-Gated Channel Subfamily J Member 16 
LC3-II Autophagosomal Marker Protein 
Abbreviations   133
LCMS Liquid chromatography mass spectroscopy 
M1 Matrix protein 1 
MALDI Matrix-assisted laser desorption/ionization 
MCoTI-II Momordica cochinchinensis trypsin inhibitor-II 
MeBzl Methylbenzyl 
MeNbz Ortho-(N-methyl)aminoanilide 
MeOH Methanol 
mKC CXC chemokine from murine 
MMPA 1-Mercapto-3-methoxypropan-2-yl acetate 
Mmsb 2-methoxy-4-methylsulfinylbenzyl alcohol 
MS Mass spectroscopy 
MO 1-Monooleoyl-rac-glycerol 
3-MPA 3-Mercaptopropionic acid 
MPAA 4-Mercatophenylacetic acid 
MSP 1-methoxy-3-sulfanylpropan-2-ol 
Nbz N-acyl-benzimidazolinone 
NCL Native chemical ligation 
NHC N‐heterocyclic carbenes 
Nmbu 4-(N-methylamino)butanoyl 
NMR Nuclear magnetic resonance 
Nmec N-methyl-N-[2-(methylamino)ethyl]carbamoyl 
NMP N-Methyl-2-pyrrolidone 
Ntl N-terminal linker (2-[(2-Aminoethyl)sulfonyl]ethanol) 
NY-ESO-1 New York esophageal squamous cell carcinoma-1 
OG Octylglycoside 
oNb-OEG3 Ortho-nitrobenzyl-(oligoethylene glycol)3
ORL1 Opioid receptor like 1 
PEGA Mono-2-acrylamidoprop-1-yl[2-aminoprop-1-yl] polyethylene glycol cross-linked with bis 2-acrylamidoprop-1-yl polyethyleneglycol 
Phacm phenylactamidomethyl 
PBS Phosphate-buffered saline 
PEG Polyethylene glycol 
POPC 1-Palmitoyl-2-oleoylphosphatidylcholine 
POPG 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol 
PPh3 Triphenylphosphine 
PSh Thiophenol 
PPO Polyethylene glycol-polyamide 
PPO2 (Polyethylene glycol-polyamide)2
PYY Peptide tyrosine tyrosine 
Q11 Amino acid sequence: Ac-Gln-Gln-Lys-Phe-Gln-Phe-Gln-Phe-Glu-Gln-Gln
RBM Removable backbone modification 
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RNA Ribonucleic acid 
Rndm. Random 
RNP Ribonucleoprotein 
RP Reverse phase 
SA Sinapinic acid 
SDS Sodium dodecyl sulfate 
SDS PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEA Bis(2-sulfanylethyl)amido 
SNUT Solubility enhancing ubiquitous tags 
SPPS Solid phase peptide synthesis 
SUMO-2 Small ubiquitin-related modifier 2 
TBS t-Butyldimethylsilyl 
TCEP  Tris(2-carboxyethyl)phosphine 
TEMED Tetramethylethylendiamine 
TEGBz 4-(3,6,9-Trioxadecyl)oxybenzyl alcohol 
TEV cleavage site Tobacco etch virus cleavage site 
TLC Thin-layer chromatography 
TM Trans membrane 
TMD Trans membrane domain 
TMP Trans membrane peptide 
TMS-CHN2 Trimethylsilyldiazomethane 
TFA Trifluoroacetic acid 
TFE Trifluoroethanol 
THF Tetrahydrofuran 
Thz Thiazolidine 
TIS Triisopropylsilane 
TIPS Triisopropylsilane 
Tris Tris(hydroxymethyl)aminomethane 
TS Transition state 
UV/Vis Ultraviolet / visible 
VA-044 2,2'-Azobis[2-(2-imidazolin-2-yl)propane] dihydrochloride 
Vpu Viral Protein U (HIV virus) 
vRNPs Viral ribonucleoproteins 
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15. Appendix 
15.1. Supporting information for internal modifications 
15.1.1. Synthesis of model Hmp-peptides (chapter 5.1.5) 
ESI-MS of P4 [Ile21]BM2(17-21)-Hmp 
Figure 15.1: Experimental and simulated isotopic pattern of model peptide P4. 
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ESI-MS of P5 [Ile21]BM2(17-21)-Hmp-ADO 
Figure 15.2: Experimental and simulated isotopic pattern of model peptide P5. 
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ESI-MS of P6 [Ile21]BM2(17-21)-Hmp-ADO2
Figure 15.3: Experimental and simulated isotopic pattern of model peptide P6. 
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ESI-MS of P7 [Leu21]BM2(17-21)-Hmp 
Figure 15.4: Experimental and simulated isotopic pattern of model peptide P7. 
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ESI-MS of P8 [Leu21]BM2(17-21)-Hmp-ADO 
Figure 15.5: Experimental and simulated isotopic pattern of model peptide P8. 
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ESI-MS of P9 [Leu21]BM2(17-21)-Hmp-ADO2
Figure 15.6: Experimental and simulated isotopic pattern of model peptide P9. 
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15.1.2. Test cleavage after ADO, Hmp and Leu coupling 
Table 15.1: Found molecular masses and possible products after test cleavage. 
Entry Test cleavage Found [m/z] Found product
a) ADO-Lys5 803.66
1+ ADO-Lys5
b) Hmp-ADO-Lys5 907.67
1+ Hmp-ADO-Lys5
c) Leu-Hmp-ADO-Lys5 1132.81
1+ (Leu)2-Hmp-ADO-Lys5
a)         ADO-Lys5 b)      Hmp-ADO-Lys5 c)  (Leu)2-Hmp-ADO-Lys5
Figure 15.7: Spectra for table 16.1. Test cleavage of peptide P11 [Leu21]BM2(17-21)-Hmp-ADO-Lys5. This experiment 
proved that the main side product (Leu)2-Hmp-ADO-Lys5 was the result of the Mitsunobu reaction. 
15.1.3.Solubility test of the penta-lysine tag 
P18: [Leu21]BM2(1-21)-Hmp 
MLEPFQILSIC(Acm)SFILSALHFL-Hmp 
P20: [Leu21]BM2(1-21)-Hmp-ADO-Lys5
MLEPFQILSIC(Acm)SFILSALHFL-Hmp-ADO-KKKKK
Figure 15.8: Comparison of the solubility of peptide P18 [Leu21]BM2(1-21)-Hmp without a C-terminal solubilizing 
tag (left, 0.5 mg/ml) and peptide P20 [Leu21]BM2(1-21)-Hmp-ADO-Lys5 with a penta-lysine tag (right, 0.5 mg/ml) in 
water containing 0.1% TFA.
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15.1.4. Synthesis of complete BM2 peptides (chapter 5.1.6) 
Coupling cycles for N-terminal cysteine peptides 
Table 15.2: Standard coupling cycle for the synthesis of the N-terminal cysteine peptides P1 [Cys22]BM2(22-35) and 
P2 [Cys22]BM2(22-51) using automated microwave assisted Fmoc-SPPS with a scale of 0.25 mmol. 
Operation Solvent Volume [ml]
Swell Resin DMF 10.0
Operation Solvent Volume [ml]
Wash-Top DMF 10.0
Fmoc-Deprotection 20 % Piperidine/DMF 10.0
Fmoc-Deprotection 20 % Piperidine/DMF 10.0
Wash-Top DMF 10.0
Wash-Bottom DMF 10.0
Wash-Top DMF 10.0
Wash-Top DMF 10.0
Add Amino Acid 0.2 M DMF 5.0
Add Activator 0.5 M DMF 2.0
Add Activator Base 2.0 M NMP 1.0
Microwave Method - -
Add Amino Acid 0.2 M DMF 5.0
Add Activator 0.5 M DMF 2.0
Add Activator Base 2.0 M NMP 1.0
Microwave Method - -
Wash-Top DMF 10.0
Wash-Bottom DMF 10.0
Wash-Top DMF 10.0
Operation Solvent Volume [ml]
No final deprotection - -
Wash-Top DMF 10.0
Wash-Top DMF 10.0
Wash-Top DMF 10.0
Figure 15.9: UV Report of N-terminal cysteine peptide P2 [Cys22]BM2(22-51). 
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Table 15.3: Coupling cycle with additional washing steps for the synthesis of the N-terminal cysteine peptides P3
[Cys11]BM2(11-51) using automated microwave assisted Fmoc-SPPS with a scale of 0.25 mmol.[207]
Operation Solvent Volume [ml]
Swell Resin DMF 10.0
Operation Solvent Volume [ml]
Wash-Top DMF 10.0
Fmoc-Deprotection 20 % Piperidine/DMF 10.0
Wash-Top DMF
Fmoc-Deprotection 20 % Piperidine/DMF 10.0
Wash-Top DMF 10.0
Wash-Bottom DCM 10.0
Wash-Top DCM 10.0
Wash-Top DMF 10.0
Wash-Top DMF 10.0
Add Amino Acid 0.2 M DMF 5.0
Add Activator 0.5 M DMF 2.0
Add Activator Base 2.0 M NMP 1.0
Microwave Method - -
Add Amino Acid 0.2 M DMF 5.0
Add Activator 0.5 M DMF 2.0
Add Activator Base 2.0 M NMP 1.0
Microwave Method - -
Wash-Top DMF 10.0
Wash-Bottom DCM 10.0
Wash-Top DMF 10.0
Operation Solvent Volume [ml]
No final deprotection - -
Wash-Top DCM 10.0
Wash-Top DCM 10.0
Figure 15.10: UV Report of N-terminal cysteine peptide P3 [Cys11]BM2(11-51) using an improved coupling cycle.[207]
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Coupling cycle for C-terminal Hmp-peptides 
Table 15.4: Coupling cycle for Hmp-peptides using automated, microwave-assisted Fmoc-SPPS for a scale of 0.25 
mmol. 
Operation Solvent Volume [ml]
Swell Resin DMF 10.0
Operation Solvent Volume [ml]
Wash-Top DMF 10.0
Fmoc-Deprotection 20 % 2-Methylpiperidine/DMF 10.0
Wash-Top DMF
Fmoc-Deprotection 20 % 2-Methylpiperidine/DMF 10.0
Wash-Top DMF 10.0
Wash-Bottom DCM 10.0
Wash-Top DCM 10.0
Wash-Top DMF 10.0
Wash-Top DMF 10.0
Add Amino Acid 0.2 M DMF 5.0
Add Activator 0.5 M DMF 2.0
Add Activator Base 2.0 M NMP 1.0
Microwave Method - -
Add Amino Acid 0.2 M DMF 5.0
Add Activator 0.5 M DMF 2.0
Add Activator Base 2.0 M NMP 1.0
Microwave Method - -
Wash-Top DMF 10.0
Wash-Bottom DCM 10.0
Wash-Top DMF 10.0
Operation Solvent Volume [ml]
No final deprotection - -
Wash-Top DCM 10.0
Wash-Top DCM 10.0
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15.1.5. Analytical RP-HPLC of P22 [Leu21]BM2(17-35) (chapter 5.1.9) 
Figure 15.11: Reinjection of P22. HPLC conditions: C18 column (150 x 4 mm, 100 Å pore diameter, 3 µm particle 
size). Gradient: 15 – 45% acetonitrile in 30 min, flow rate of 1 ml/min. 
Figure 15.12: ESI-MS of ligation product P22 [Leu21]BM2(17-35) synthesized in conventional ligation buffer A. 
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15.2. Supporting information for external conditions 
15.2.1. HFIP-assisted NCL: ESI-MS of ligation product P23 (chapter 5.2.3) 
Figure 15.13: ESI-MS of ligation product P23 synthesised in the HFIP-based buffer C. 
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15.2.2. TLCs of sulfur compounds in [C2mim][OAc] (chapter 5.2.5 and 5.2.6) 
a) b)
n-hexane acetonitrile/water (9:1)
Figure 15.14: TLC of diphenyl disulfide in [C2mim][OAc] with a) n-hexane as eluent and b) acetonitrile/water (9:1). 
a) b)
n-hexane/EtOAc (1:59) acetonitrile/water (9:1)
Figure 15.15: TLC of dibenzyl disulfide in [C2mim][OAc] with a) n-hexane/EtOAc (1:59) as eluent and b)
acetonitrile/water (9:1). 
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15.2.3. Ionic liquid-mediated NCL: ESI-MS P22 (chapter 5.2.9) 
Figure 15.16: ESI-MS of ligation product P22 [Leu21]BM2(17-35) synthesised in the ionic liquid based buffer D5. 
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15.2.4. Ionic liquid-mediated NCL: ESI-MS of P27 (chapter 5.2.10)  
Figure 15.17: ESI-MS of ligation product P27 [Leu10]BM2(1-51) synthesised in the ionic liquid based buffer D5. 
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15.3. Supporting information for follow-up protocols 
15.3.1. Desulfurization: ESI-MS of product P25 (chapter 5.3.1) 
Figure 15.18: Experimental and simulated ESI mass spectrum of P25. 
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15.3.2. Acm deprotection: ESI-MS of product P26 (chapter 5.3.2) 
Figure 15.19: Experimental and simulated ESI mass spectrum of P26. 
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15.4. Circular dichroism spectroscopy 
15.4.1. CD spectroscopy in TFE and phosphate buffer (chapter 5.4) 
Table 15.5: Results of the deconvoluted CD curve of peptide P17 analyzed in TFE.  
Wavelength 190 - 260 nm 195 – 260 nm 200 – 260 nm 205 – 260 nm 210 – 260 nm
Helix 72.70 % 74.20 % 74.60 % 69.60 % 72.60 %
Antiparallel 0.20 % 0.70 % 1.90 % 2.90 % 2.30 %
Parallel 3.90 % 3.10 % 2.90 % 2.90 % 3.10 %
Beta-Turn 10.10 % 10.20 % 10.30 % 11.70 % 11.00 %
Rndm. Coil 17.60 % 17.50 % 15.30 % 14.60 % 13.80 %
Total Sum 104.50 % 105.60 % 104.90 % 101.70 % 102.90 %
Table 15.6: Results of the deconvoluted CD curve of peptide P2 analyzed in TFE. 
Wavelength 190 - 260 nm 195 – 260 nm 200 – 260 nm 205 – 260 nm 210 – 260 nm
Helix 76.50 % 75.10 % 73.70 % 78.90 % 74.70 %
Antiparallel 0.40 % 1.20 % 2.40 % 2.20 % 2.20 %
Parallel 2.20 % 2.20 % 2.30 % 2.00 % 2.90 %
Beta-Turn 11.00 % 11.00 % 11.40 % 10.60 % 10.80 %
Rndm. Coil 6.70 % 8.30 % 10.00 % 10.30 % 12.90 %
Total Sum 96.70 % 97.70 % 99.80 % 104.00 % 103.50 %
Table 15.7: Results of the deconvoluted CD curve of peptide P2 in 0.2 M Na2HPO4 buffer. 
Wavelength 190 - 260 nm 195 – 260 nm 200 – 260 nm 205 – 260 nm 210 – 260 nm
Helix 18.10 % 16.90 % 16.50 % 20.00 % 17.30 %
Antiparallel 55.30 % 32.50 % 17.90 % 12.10 % 15.20 %
Parallel 10.00 % 12.80 % 14.30 % 14.50 % 14.50 %
Beta-Turn 22.30 % 21.60 % 21.70 % 19.50 % 20.80 %
Rndm. Coil 29.40 % 35.50 % 41.70 % 44.70 % 47.10 %
Total Sum 135.10 % 119.40 % 112.20 % 110.90 % 114.80 %
Table 15.8: Results of the deconvoluted CD curve of peptide P25 in TFE. 
Wavelength 190 - 260 nm 195 – 260 nm 200 – 260 nm 205 – 260 nm 210 – 260 nm
Helix 66.30 % 64.70 % 64.40 % 67.70 % 65.50 %
Antiparallel 0.60 % 1.90 % 3.20 % 3.10 % 3.00 %
Parallel 3.50 % 3.40 % 3.50 % 3.10 % 3.80 %
Beta-Turn 12.00 % 12.20 % 12.40 % 12.10 % 12.10 %
Rndm. Coil 13.00 % 14.50 % 15.30 % 15.00 % 16.70 %
Total Sum 95.50 % 96.70 % 98.70 % 101.10 % 101.10 %
Table 15.9: Results of the deconvoluted CD curve of peptide P26 in TFE. 
Wavelength 190 - 260 nm 195 – 260 nm 200 – 260 nm 205 – 260 nm 210 – 260 nm
Helix 63.30 % 63.50 % 63.00 % 58.90 % 60.50 %
Antiparallel 0.50 % 1.50 % 3.10 % 4.00 % 3.60 %
Parallel 4.80 % 4.20 % 4.10 % 4.20 % 4.40 %
Beta-Turn 11.60 % 11.90 % 12.10 % 13.10 % 12.70 %
Rndm. Coil 21.10 % 21.10 % 19.40 % 19.10 % 18.90 %
Total Sum 101.30 % 102.20 % 101.60 % 99.30 % 100.00 %
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Table 15.10: Results of the deconvoluted CD curve of peptide P27 in TFE. 
Wavelength 190 - 260 nm 195 – 260 nm 200 – 260 nm 205 – 260 nm 210 – 260 nm
Helix 59.1 % 59.6 % 59.2 % 55.9 % 56.6 %
Antiparallel 0.7 % 1.9 % 3.6 % 4.3 % 4.0 %
Parallel 5.1 % 4.6 % 4.5 % 4.6 % 4.8 %
Beta-Turn 12.4 % 12.5 % 12.7 % 13.5 % 13.3 %
Rndm. Coil 22.1 % 21.8 % 20.5 % 20.4 % 20.6 %
Total Sum 99.4 % 100.4 % 100.4 % 98.8 % 99.3 %
15.4.2. CD spectroscopy in POPC liposomes (chapter 5.4) 
Table 15.11: Results of the deconvoluted CD curves of peptide P26 in POPC/Na2HPO4 buffer. 
Wavelength 190 - 260 nm 195 – 260 nm 200 – 260 nm 205 – 260 nm 210 – 260 nm
Helix 59.20 % 61.90 % 65.40 % 57.70 % 66.30 %
Antiparallel 0.30 % 1.10 % 2.40 % 4.00 % 2.90 %
Parallel 6.80 % 5.30 % 4.30 % 4.40 % 3.70 %
Beta-Turn 11.00 % 11.30 % 10.80 % 12.90 % 11.80 %
Rndm. Coil 35.40 % 31.50 % 24.40 % 20.50 % 16.50 %
Total Sum 112.70 % 111.10 % 107.30 % 99.30 % 101.20 %
Table 15.12: Results of the deconvoluted CD curves of peptide P27 in POPC/Na2HPO4 buffer. 
Wavelength 190 - 260 nm 195 – 260 nm 200 – 260 nm 205 – 260 nm 210 – 260 nm
Helix 62.1 % 62.4 % 64.3 % 55.5 % 64.6 %
Antiparallel 0.2 % 1.0 % 2.5 % 4.2 % 3.0 %
Parallel 6.4 % 5.3 % 4.6 % 4.7 % 3.8 %
Beta-Turn 10.5 % 11.2 % 10.9 % 13.1 % 12.1 %
Rndm. Coil 34.4 % 32.3 % 25.5 % 21.5 % 17.2 %
Total Sum 113.6 % 112.2 % 107.7 % 99.0 % 100.8 %
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